{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/swiss/miniconda3/envs/ML/lib/python3.11/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:11: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n",
      "  from tqdm.autonotebook import tqdm, trange\n",
      "/home/swiss/miniconda3/envs/ML/lib/python3.11/site-packages/transformers/tokenization_utils_base.py:1601: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be depracted in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "import chromadb\n",
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "client = chromadb.PersistentClient(path=\"./clinical_trials_chroma\")\n",
    "model = SentenceTransformer(\"malteos/scincl\")\n",
    "collection = client.get_or_create_collection(\"clinical_trials_studies\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "def fix_invalid_json(input_str):\n",
    "    ## add double quotes around elements inside square brackets if not already quoted\n",
    "    fixed_str = re.sub(r'(?<=\\[)([^\\[\\],]+)(?=\\])', lambda x: '\"' + x.group(0).strip() + '\"', input_str)\n",
    "    \n",
    "    ## add double quotes around words in Conditions and Interventions\n",
    "    fixed_str = re.sub(r'(?<=\\[)([^\\\"\\]]+?)(?=\\])', lambda x: '\"' + x.group(0).strip().replace(\", \", '\", \"') + '\"', fixed_str)\n",
    "    \n",
    "    ## fix key-value pairs inside Interventions\n",
    "    fixed_str = re.sub(r'\"([A-Za-z]+): ([A-Za-z0-9\\s]+)\"', r'\"\\1: \\2\"', fixed_str)\n",
    "    \n",
    "    # fix dictionary keys\n",
    "    fixed_str = re.sub(r'(?<!\")(\\b[A-Za-z_]+\\b)(?=\\s*:)', r'\"\\1\"', fixed_str)\n",
    "    \n",
    "    return fixed_str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "INFO 10-25 09:58:45 llm_engine.py:174] Initializing an LLM engine (v0.5.4) with config: model='neuralmagic/Meta-Llama-3.1-8B-Instruct-quantized.w8a16', speculative_config=None, tokenizer='neuralmagic/Meta-Llama-3.1-8B-Instruct-quantized.w8a16', skip_tokenizer_init=False, tokenizer_mode=auto, revision=None, rope_scaling=None, rope_theta=None, tokenizer_revision=None, trust_remote_code=False, dtype=torch.bfloat16, max_seq_len=20000, download_dir=None, load_format=LoadFormat.AUTO, tensor_parallel_size=1, pipeline_parallel_size=1, disable_custom_all_reduce=False, quantization=compressed-tensors, enforce_eager=False, kv_cache_dtype=auto, quantization_param_path=None, device_config=cuda, decoding_config=DecodingConfig(guided_decoding_backend='outlines'), observability_config=ObservabilityConfig(otlp_traces_endpoint=None), seed=0, served_model_name=neuralmagic/Meta-Llama-3.1-8B-Instruct-quantized.w8a16, use_v2_block_manager=False, enable_prefix_caching=False)\n",
      "INFO 10-25 09:58:47 model_runner.py:720] Starting to load model neuralmagic/Meta-Llama-3.1-8B-Instruct-quantized.w8a16...\n",
      "INFO 10-25 09:58:47 weight_utils.py:225] Using model weights format ['*.safetensors']\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b3da153acb8e4a358b9cca8d0ca1ba5a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Loading safetensors checkpoint shards:   0% Completed | 0/2 [00:00<?, ?it/s]\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "INFO 10-25 09:58:50 model_runner.py:732] Loading model weights took 8.4927 GB\n",
      "INFO 10-25 09:58:55 gpu_executor.py:102] # GPU blocks: 4915, # CPU blocks: 2048\n",
      "INFO 10-25 09:58:58 model_runner.py:1024] Capturing the model for CUDA graphs. This may lead to unexpected consequences if the model is not static. To run the model in eager mode, set 'enforce_eager=True' or use '--enforce-eager' in the CLI.\n",
      "INFO 10-25 09:58:58 model_runner.py:1028] CUDA graphs can take additional 1~3 GiB memory per GPU. If you are running out of memory, consider decreasing `gpu_memory_utilization` or enforcing eager mode. You can also reduce the `max_num_seqs` as needed to decrease memory usage.\n",
      "INFO 10-25 09:59:11 model_runner.py:1225] Graph capturing finished in 13 secs.\n"
     ]
    }
   ],
   "source": [
    "from vllm import LLM, SamplingParams\n",
    "from transformers import AutoTokenizer\n",
    "\n",
    "model_id = \"neuralmagic/Meta-Llama-3.1-8B-Instruct-quantized.w8a16\"\n",
    "number_gpus = 1\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_id)\n",
    "\n",
    "llm = LLM(model=model_id, tensor_parallel_size=number_gpus, max_model_len=20000)\n",
    "\n",
    "def pipe(messages):\n",
    "    sampling_params = SamplingParams(temperature=0, top_p=0.9, max_tokens=4096)\n",
    "    prompts = tokenizer.apply_chat_template(messages, add_generation_prompt=True, tokenize=False)\n",
    "    outputs = llm.generate(prompts, sampling_params)\n",
    "    return [i.outputs[0].text for i in outputs]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'ids': [['NCT03032679',\n",
       "   'NCT00686764',\n",
       "   'NCT00130962',\n",
       "   'NCT01632709',\n",
       "   'NCT02283957']],\n",
       " 'distances': [[110.8730239868164,\n",
       "   113.80130004882812,\n",
       "   115.11090087890625,\n",
       "   115.89321899414062,\n",
       "   122.37474060058594]],\n",
       " 'metadatas': [[{'detailedDescription': \"Study Description \\nBrief Summary \\nAfter Institutional Review Board approval, adult patients scheduled for total knee arthroplasty (TKA) will be enrolled into the study after obtaining informed consent over a 24 month period. Interim analyses of cases who have completed the 6 month follow up as on 31st October, 2017 will be analyzed as part of the co- principle investigator's thesis. All consenting patients will be assessed for pain preoperatively, the first 3 post-operative days, at 1, 4 and 6 months from the date of surgery. Pain scores will be assessed using the Numerical Rating Scale during the 3 postoperative days. Pain will be managed by the Acute Pain Service team as per standard protocols.\\n\\nThe Brief pain inventory (BPI) (short form with translations, obtained with permission from MD Anderson), which assesses pain severity and its impact on daily functions will be administered to the patient in a language familiar to them, preoperatively, at 1, 4 and 6 months postoperatively.\\n\\nThe Musculoskeletal Tumour Society Score (MSTS) which evaluates the functional condition (impairment) after completed tumour treatment will be estimated at the end of 6 months from the date of surgery The painDETECT questionnaire (PD-Q) a quick, simple and reliable screening tool to identify the likelihood of a neuropathic pain component in patients and validated in various languages including Hindi and Marathi will be administered preoperatively and at 1, 4 and 6 months after surgery.\\n\\nDetails of postoperative chemotherapy and radiation will also be obtained from patient's notes and the electronic medical record. If the patient cannot follow up at the said intervals, the pain scores would be obtained telephonically and the BPI and PD-Q forms in prepaid envelopes would be given to them at discharge which they would have to duly fill in and post them to the given address at the appropriate intervals if they cannot visit the pain clinic. At the 6th month of follow up, they would be requested to visit the pain clinic for an assessment of MSTS score and completing the BPI and PD-Q.\\n\\nINCLUSION CRITERIA:-\\n\\n* Adult patients above 18 years of age, undergoing TKR\\n* Literate: able to read and write in at least one of the following languages English, Hindi and Marathi\\n* Willing to fill forms and post them and/or answer questions on phone\\n\\nEXCLUSION CRITERIA:-\\n\\n* Refusal of consent\\n* Cognitively impaired\\n* Revision TKRs (including cases with wound wash and nail spacer cementing)\\n\\nDetailed Description \\nINTRODUCTION:- A Total Knee Replacement (TKR) or arthroplasty (TKA) is a complex procedure that requires an Orthopedic Surgeon to make precise measurements and skillfully remove the diseased portions of the bone, in order to shape the remaining bone to accommodate the knee implant. Knee Replacement Surgery is most commonly performed in people with advanced osteoarthritis and should be considered when conservative treatments have been exhausted. Oncologic TKRs are different from the routine TKRs in a way that the former involves a wide local resection of the bone and soft tissues, ranging from 10 to 20 cm, resection of muscles like the head(s) of biceps femoris, the gastrocnemius muscle, the intermuscular septa, the joint capsule, etc. to ensure negative margins along with the complete resection of the tumour, followed by a reconstruction of almost the same length as that resected, to restore function.\\n\\nThe most common indication for doing oncologic TKR is Osteogenic Sarcoma (OGS) of and around the knee joint. The distal femur and proximal tibia are among the most common sites for primary bone tumor. OGS is the most common bone cancer in the world in children and adolescents, and the eighth-most common form of childhood cancer, accounting for 4% of all childhood cancers worldwide. In India, the incidence varies from 4.7% to 11.6%, where this malignancy is associated with significant morbidity and mortality. Additional treatment involves chemotherapy which further delays the healing and recovery of the patient.\\n\\nSurgery is a known risk factor for development of Chronic Post Surgical Pain(CPSP) which as per the definition given by Macrae and Davies, is defined by\\n\\n* Pain developing after a surgical procedure.\\n* Pain of at least 2 months' duration.\\n* Other causes of pain excluded (e.g.- malignancy, infection, etc.).\\n* Pain continuing from a pre-existing pain problem excluded.\\n\\nCPSP is a well known risk factor in many surgeries like (but not exclusive of)-\\n\\n* Mastectomy (Incidence of chronic pain = 11-57%)\\n* Amputation (30-85%)\\n* Inguinal hernia(5-63%)\\n* Cholecystectomy (3-50%)\\n\\nCPSP develops after a surgical procedure or increases in intensity after the surgical procedure. Literature on TKR surgeries indicated for osteoarthritis, report that although many patients report a good outcome after their total knee replacement, at a time when recovery should have been achieved, about 10-34% of patients undergoing TKR for osteoarthritis report moderate to severe CPSP. In around 30% of patients with CPSP, the origin of CPSP might be neuropathic. Neuropathic pain is more severe and adversely affects the quality of life of patients. TKR on its own may cause neuropathic pain postoperatively due to local nerve damage, often to the infrapatellar branch of the saphenous nerve or due to local inflammation. Risk factors associated with the operation include increased duration of surgery and tourniquet time, revision surgery, TKA versus unicompartmental arthroplasty and intraoperative nerve damage. Oncologic TKRs are more extensive and include much morbid excisions, and consequently may be presumed to have a similar if not a greater incidence of CPSP. Some of the risk factors for CPSP include the following (but not exclusive of)-\\n\\n* Pain, moderate to severe, lasting more than 1 month\\n* Repeat surgery\\n* Younger age (adults)\\n* Surgical approach with risk of nerve damage\\n* Neurotoxic chemotherapy\\n\\nPreoperative pain is consistently found to be a predictor for persistent postsurgical pain, which might reflect an independent risk factor but could well be a manifestation of predisposing factors.\\n\\nTata Memorial Hospital, a tertiary cancer institute is a 629 bedded hospital and conducts approximately 6000 surgeries per year out of which approximately 100 TKRs are performed per year. Analgesia peri-operatively is provided by an epidural infusion of a combination of local anaesthetic and an opioid or intravenous opioids with non-steroidal anti-inflammatory analgesics and paracetamol as appropriate. Postoperatively, if inserted, epidural analgesia is continued for up to 3-4 days to help mobilization \\\\& physiotherapy. In the absence of an epidural, around the clock analgesics with or without an opioid administered by means of an Intravenous Patient Controlled Analgesia (IVPCA) device is instituted. These patients are visited by the acute pain service team to address pain issues for the first 3 postoperative days or sometimes longer.\\n\\nSTUDY DESIGN:- Prospective and Observational study\\n\\nMETHODS and MATERIALS:- After Institutional Review Board approval, adult patients scheduled for TKR surgeries will be enrolled into the study after obtaining their informed consent over a 24 month period. However, interim analyses of all cases who have completed the 6 month follow up as on 31st October, 2017 would be analyzed as part of the co- principle investigator's thesis. All consenting patients will be assessed for their pain preoperatively and for the first 3 post-operative days, and at 1, 4 and 6 months from the date of surgery. Pain scores will be assessed using the Numerical Rating Scale during the 3 days after surgery. Pain will be managed by the Acute Pain Service team as per the standard management protocols.\\n\\nThe Brief pain inventory (BPI), (short form with translations, obtained with permission from MD Anderson), which assesses the severity of pain and the impact of pain on daily functions will be administered to the patient in the language familiar to them, preoperatively, at 1, 4 and 6 months postoperatively. The BPI is a useful instrument to assess the severity of pain and impact of pain on daily functions in patients with pain from chronic diseases, conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain. The short form comprises of nine questions related to the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week. It has been widely used and validated in several languages the world over.\\n\\nThe Musculoskeletal Tumour Society Score (MSTS) evaluates the functional condition (impairment) after completed tumour treatment will be estimated at the end of 6 months from the date of surgery. It is calculated on the basis of a standardized physical examination by the physician. This clinical examination assesses six criteria and differs slightly between the upper and lower limb. For the lower limb, the components are pain, function, emotional acceptance of the treatment outcome, need for walking aids, walking and gait. For all criteria, the estimate is made from bad to very good with parallel awarding of points (0 to 5). There is thus a numerical value for each of the six criteria. These six values are added and divided by the maximum possible number of points (30). The percentage value is obtained by multiplying the calculated point value by 100.\\n\\nThe painDETECT questionnaire (PD-Q) is a quick, simple and reliable screening tool to identify the likelihood of a neuropathic pain component in patients with neuropathic pain. This questionnaire had been prepared by professionals and validated in various languages including Hindi and Marathi. Its sensitivity and specificity is higher than other screening questionnaires for neuropathic pain, including the Douleur Neuropathique 4 (DN4), Leeds Assessment of Neuropathic Symptoms and Signs (LANNS), and the Neuropathic Pain Questionnaire (NPQ) (Freynhagen et al 2006). The PD-Q has been used to identify neuropathic pain in patients with knee osteoarthritis (Ohtori et al 2012) and to identify sensory proï¬les in patients with diabetic neuropathy and postherpetic neuralgia (Baron et al 2009).This questionnaire will be administered tot he patients preoperatively , at 1, 4 and 6 months after surgery.\\n\\nDetails of postoperative chemotherapy and radiation will also be obtained from patient's notes and the electronic medical record. If the patient cannot follow up at the said intervals, the pain scores would be obtained telephonically and the BPI and PD-Q forms in prepaid envelopes would be given to them at discharge which they would have to duly fill in and post them to the given address at the appropriate intervals if they cannot visit the pain clinic. At the 6th month of follow up, they would be requested to visit the pain clinic for an assessment of MSTS score and completing the BPI and PD-Q.\\n\\nMEASUREMENTS:-\\n\\n* All demographic, preoperative, intraoperative and postoperative data would be collected by the investigators.\\n* Demographic data includes case no, age, sex, ASA (American Society of Anesthesiologists) grade.\\n* Preoperative variables include pain score, preoperative analgesics, duration of use, and the dose.\\n* Intraoperative variables include duration of surgery, tourniquet time, any nerve or muscle resection and length of bone resected.\\n* Postoperative variables include median average and worst pain score for the first 3 postoperative days , 1, 4 and 6 months after surgery.\\n* Analgesics administered postoperatively, dose \\\\& dosing intervals, impact on daily functions as obtained from the BPI pre-operatively, 1, 4 and 6 months postoperatively.\\n* The painDETECT score to identify the neuropathic component of pain if any, preoperatively and at 1, 4 and 6 months after surgery.\\n* The MSTS score calculated by the physician and obtained from the patient's record at the 6th month after surgery.\\n\\nSTATISTICAL ANALYSIS:- The above mentioned data will be presented as mean (sd), median (range), and frequency (percentage). Categorical data will be analyzed using the Chi-square test or Fisher Exact test (for binary data). Continuous variables will be analyzed using paired t test or Wilcoxon signed rank test as per distribution of data. Repeated measure ANOVA will be used for pain score analysis. Pearson correlation coefficients will be used for association. p-value \\\\<0.05 will be considered statistical significant.\\n\\nIntervention \\n- OTHER : Non interventional study \\n\\t- No intervention\",\n",
       "    'jsonMetadata': '{\"NCT_ID\": \"NCT03032679\", \"Brief_Title\": \"Pain and Impact of Chronic Pain on Function After Total Knee Replacements\", \"Official_title\": \"Postoperative Pain Severity, Incidence Of Chronic Pain And Its Impact On Daily Function Following Total Knee Replacements (TKR) At A Tertiary Cancer Institute\", \"Conditions\": [\"Pain\", \"Postoperative\", \"Pain\", \"Chronic\", \"Osteogenic Sarcoma\", \"Knee Arthropathy\"], \"Interventions\": [\"Other: Non interventional study\"], \"Location_Countries\": [\"India\"], \"Study_Design\": {\"Study_Type\": \"OBSERVATIONAL\"}}',\n",
       "    'nctId': 'NCT03032679',\n",
       "    'officialTitle': 'Postoperative Pain Severity, Incidence Of Chronic Pain And Its Impact On Daily Function Following Total Knee Replacements (TKR) At A Tertiary Cancer Institute'},\n",
       "   {'detailedDescription': \"Study Description \\nBrief Summary \\nBackground: The formation of neuromas, a fusiform swelling of a nerve or nerve ending, is a well documented response to limb amputation. Likewise, Residual Limb Pain (RLP), pain felt from the remaining portion of the amputated limb, is common among amputees. Neuromas are found in more than 90% of lower extremity amputations, of which 30-50% are pain-generating for the patient . And while surgical techniques reveal the commonly held belief that neuroma formation is one of the causal drivers behind RLP, there has been no study to demonstrate that the two events - namely the magnitude of neuroma formation and the magnitude of pain experienced by amputees - are correlated. If this correlation, or lack thereof, were elucidated with the use of ultrasonography, this would provide the preliminary data which could lead to further studies in neuroma minimization and/or proliferation.\\n\\nObjective: This study seeks to use ultrasonography (US) to quantify the degree to which neuroma size and the nature of surrounding tissue correlate with the experience of RLP in trans-femoral amputees.\\n\\nSetting and Subjects: This study will enroll 30 trans-femoral amputees, male and female, who are over the age of 18. The study will take place in the OHSU Orthopaedic Outpatient Clinic, and OHSU Imaging Department.\\n\\nIntervention: None. This is an observational clinical study in which we will characterize the sciatic nerve/neuroma and surrounding tissue using ultrasound.\\n\\nMeasurements: We will use US to measure the cross sectional area of the neuroma at its widest point and compare this to the cross section of the same neuron at the lesser trochanter. Furthermore, we will describe the morphology of the neuroma. To quantify the subject's pain experience we will utilize the Questionnaire for Persons with Transfemoral Amputation (Q-TFA), Trinity Amputation \\\\& Prosthetic Experience Scale (TAPES), Visual Analog Scale (VAS), and the Short Form 36 (SF-36).\\n\\nAnalysis: The statistical analysis will employ a Pearson correlation coefficient and linear regression analysis.\\n\\nIntervention \\n- OTHER : Observational \\n\\t- Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.\\n\\nWe will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36).\",\n",
       "    'jsonMetadata': '{\"NCT_ID\": \"NCT00686764\", \"Brief_Title\": \"Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above-Knee Amputees\", \"Official_title\": \"Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above Knee Amputees\", \"Conditions\": [\"Neuroma Amputation\"], \"Interventions\": [\"Other: Observational\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"OBSERVATIONAL\"}}',\n",
       "    'nctId': 'NCT00686764',\n",
       "    'officialTitle': 'Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above Knee Amputees'},\n",
       "   {'detailedDescription': 'Study Description \\nBrief Summary \\nSubjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.\\n\\nDetailed Description \\nSubjects will have painful primary or post-operative intermetatarsal neuroma. Each subject will be randomly allocated to receive either ALGRX 4975 or placebo in a 1:1 ratio. Study drug or placebo will be injected into the intermetatarsal space containing a painful neuroma. Subjects will complete weekly assessments for the Average Foot Pain Severity, the 7 Interference Items of the BPI, and the number of analgesic units taken. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.\\n\\nPlasma concentrations will be assessed pre-dose and post dose at 5, 10, 15, 20, 30, and 45 min and at 1, 1.5, 2, 2.5, 3 and 4 hours.\\n\\nSafety will be assessed at baseline and during the study with adverse events (all visits), vital signs (Visit 2 pre and post-injection and Visit 3 or at early termination), and laboratory assessments (hematology, chemistry, urinalysis) and ECG (Screening and Visit 3 or at early termination). The injection site will be examined and assessed by a 6-point scale for erythema, edema, and hemorrhage before the injection and at 1, 2 and 4 hours after the injection. A pain on injection NRS will be assessed immediately post- injection at 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after study drug administration. A sensory examination of the foot will be performed before the injection and 4 hours after the injection and at the completion of the study. If a subject has injection pain, the foot may be wrapped in ice for up to 20 minutes, analgesic medication may be provided.\\n\\nIntervention \\n- DRUG : ALGRX 4975 ',\n",
       "    'jsonMetadata': '{\"NCT_ID\": \"NCT00130962\", \"Brief_Title\": \"ALGRX 4975 in the Treatment of Patients With Morton\\'s Neuroma\", \"Official_title\": \"A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma\", \"Conditions\": [\"Neuroma\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE2\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"DOUBLE\"}}',\n",
       "    'nctId': 'NCT00130962',\n",
       "    'officialTitle': 'A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma'},\n",
       "   {'detailedDescription': 'Study Description \\nBrief Summary \\nThe purpose of this study is to see how Post Amputation Pain (PAP) affects the body and brain by using sensory testing (such as pinprick testing), taking pictures of your brain (using a functional magnetic resonance imaging (fMRI) machine) and biomedical interventions (such as an injection of pain medicine). All medicines and the fMRI machine used during this study are FDA approved. The investigators hope that by learning the causes of PAP, the investigators can help future amputees.\\n\\nDetailed Description \\nYour participation in this study will last for 5 weeks and you will be asked to come to a total of 3 visits. The first visit will be during the first week of the study, the second visit during the second week of the study and the third (final) visit will be during the fifth (and final) week of the study. For your first visit you will have a physical examination with some sensory stimulation tests (such as vibration and pinprick tests), some questionnaires about your health and pain history, hot and cold sensory tests, and we will take thermal pictures of your body before and after receiving a quick electrical stimulus. You will also be trained on how to use the finger-span device to rate your pain during the second visit, and how to use an electronic pain diary to record your pain scores three times a day during the five weeks of the study.\\n\\nThe second visit will begin with questionnaires from the first visit and thermal images with a quick electrical stimulus. You will then be brought to an fMRI scanner room at Northwestern University. For an hour and fifteen minutes we will take pictures of your brain and these pictures will help us understand the changes in your brain relating to pain. You will then be put into one of four treatment groups randomly.\\n\\nThe study treatment that you will get will be decided randomly or by chance, like flipping a coin. Injections in this study will use the local anesthetic bupivacaine (a long lasting drug like the numbing agent novocaine used by dentists). This drug causes numbness, blocks pain and other nerve function near the injection site for 6-8 hours. Group 1 will get a sympathetic nerve block of bupivacaine, which changes how your nerves transmit pain, in either the neck or lower back (depending on where the amputation is located), Group 2 will get a placebo injection (no active medicine) in either the neck or lower back (depending on where the amputation is located), Group 3 will get a neuroma injection of bupivacaine (a neuroma is a group of nerves at the end of your residual limb), and Group 4 will get a placebo injection (no active medicine) at the neuroma. Some people get the bupivacaine injection and some people get the placebo injection so that we can compare the groups and see if the bupivacaine brings more, less or the same pain relief as a placebo injection. We scan your brain before the injection so that we can see how your brain responds to pain. We also scan your brain after the injection so that we can see if your brain responds differently to pain after the injection has been done.\\n\\nYou will know the location of your injection before you receive the treatment (neck, lower back or neuroma on your affected limb), but you will not know if you are getting a pain medication injection or placebo injection. Only the study doctors will know this information, and it can be told to you in case of an emergency. After the injection, you will have a second hour of brain scanning. After the scanning, you will be asked to complete some questionnaires, sensory tests, hot and cold temperature testing and we will take thermal pictures of your body before and after a quick electrical stimulus.\\n\\nYour third visit will be four weeks after your second visit. For your third visit you will have the same questionnaires as during the first and second visits, sensory tests, hot and cold temperature testing and we will take thermal pictures of your body before and after a quick electrical stimulus.\\n\\nIntervention \\n- DRUG : Bupivacaine \\n\\t- one injection of 10ml of .25%, - DRUG : Placebo \\n\\t- Dry needling\\n\\t- Dry needling',\n",
       "    'jsonMetadata': '{\"NCT_ID\": \"NCT01632709\", \"Brief_Title\": \"Pathophysiology of Post Amputation Pain\", \"Official_title\": \"Pathophysiology of Post Amputation Pain\", \"Conditions\": [\"Amputation Stumps\", \"Neuroma\"], \"Interventions\": [\"Drug: Bupivacaine\", \"Drug: Placebo\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE4\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"SINGLE\"}}',\n",
       "    'nctId': 'NCT01632709',\n",
       "    'officialTitle': 'Pathophysiology of Post Amputation Pain'},\n",
       "   {'detailedDescription': \"Study Description \\nBrief Summary \\nStudy 4975-MN-202 is a double-blind, placebo-controlled, parallel group, single-injection study in which subjects will be randomized to receive three doses of CNTX-4975 or placebo injected into the intermetatarsal space around a Morton's neuroma. The injection of study medication will be administered by ultrasound-guided needle placement following ankle block anesthesia. The study staff will telephone subjects at Week 1 postinjection and subjects will return to the clinic postinjection at Weeks 2, 4, 8, and 12 for study assessments.\\n\\nIntervention \\n- DRUG : CNTX-4975 , - OTHER : Placebo \",\n",
       "    'jsonMetadata': '{\"NCT_ID\": \"NCT02283957\", \"Brief_Title\": \"A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\", \"Official_title\": \"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\", \"Conditions\": [\"Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\"], \"Interventions\": [\"Drug: CNTX-4975\", \"Other: Placebo\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE2\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"DOUBLE\"}}',\n",
       "    'nctId': 'NCT02283957',\n",
       "    'officialTitle': \"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)\"}]],\n",
       " 'embeddings': None,\n",
       " 'documents': [['{\"metadata\": {\"NCT_ID\": \"NCT03032679\", \"Brief_Title\": \"Pain and Impact of Chronic Pain on Function After Total Knee Replacements\", \"Official_title\": \"Postoperative Pain Severity, Incidence Of Chronic Pain And Its Impact On Daily Function Following Total Knee Replacements (TKR) At A Tertiary Cancer Institute\", \"Conditions\": [\"Pain\", \"Postoperative\", \"Pain\", \"Chronic\", \"Osteogenic Sarcoma\", \"Knee Arthropathy\"], \"Interventions\": [\"Other: Non interventional study\"], \"Location_Countries\": [\"India\"], \"Study_Design\": {\"Study_Type\": \"OBSERVATIONAL\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nAfter Institutional Review Board approval, adult patients scheduled for total knee arthroplasty (TKA) will be enrolled into the study after obtaining informed consent over a 24 month period. Interim analyses of cases who have completed the 6 month follow up as on 31st October, 2017 will be analyzed as part of the co- principle investigator\\'s thesis. All consenting patients will be assessed for pain preoperatively, the first 3 post-operative days, at 1, 4 and 6 months from the date of surgery. Pain scores will be assessed using the Numerical Rating Scale during the 3 postoperative days. Pain will be managed by the Acute Pain Service team as per standard protocols.\\\\n\\\\nThe Brief pain inventory (BPI) (short form with translations, obtained with permission from MD Anderson), which assesses pain severity and its impact on daily functions will be administered to the patient in a language familiar to them, preoperatively, at 1, 4 and 6 months postoperatively.\\\\n\\\\nThe Musculoskeletal Tumour Society Score (MSTS) which evaluates the functional condition (impairment) after completed tumour treatment will be estimated at the end of 6 months from the date of surgery The painDETECT questionnaire (PD-Q) a quick, simple and reliable screening tool to identify the likelihood of a neuropathic pain component in patients and validated in various languages including Hindi and Marathi will be administered preoperatively and at 1, 4 and 6 months after surgery.\\\\n\\\\nDetails of postoperative chemotherapy and radiation will also be obtained from patient\\'s notes and the electronic medical record. If the patient cannot follow up at the said intervals, the pain scores would be obtained telephonically and the BPI and PD-Q forms in prepaid envelopes would be given to them at discharge which they would have to duly fill in and post them to the given address at the appropriate intervals if they cannot visit the pain clinic. At the 6th month of follow up, they would be requested to visit the pain clinic for an assessment of MSTS score and completing the BPI and PD-Q.\\\\n\\\\nINCLUSION CRITERIA:-\\\\n\\\\n* Adult patients above 18 years of age, undergoing TKR\\\\n* Literate: able to read and write in at least one of the following languages English, Hindi and Marathi\\\\n* Willing to fill forms and post them and/or answer questions on phone\\\\n\\\\nEXCLUSION CRITERIA:-\\\\n\\\\n* Refusal of consent\\\\n* Cognitively impaired\\\\n* Revision TKRs (including cases with wound wash and nail spacer cementing)\\\\n\\\\nDetailed Description \\\\nINTRODUCTION:- A Total Knee Replacement (TKR) or arthroplasty (TKA) is a complex procedure that requires an Orthopedic Surgeon to make precise measurements and skillfully remove the diseased portions of the bone, in order to shape the remaining bone to accommodate the knee implant. Knee Replacement Surgery is most commonly performed in people with advanced osteoarthritis and should be considered when conservative treatments have been exhausted. Oncologic TKRs are different from the routine TKRs in a way that the former involves a wide local resection of the bone and soft tissues, ranging from 10 to 20 cm, resection of muscles like the head(s) of biceps femoris, the gastrocnemius muscle, the intermuscular septa, the joint capsule, etc. to ensure negative margins along with the complete resection of the tumour, followed by a reconstruction of almost the same length as that resected, to restore function.\\\\n\\\\nThe most common indication for doing oncologic TKR is Osteogenic Sarcoma (OGS) of and around the knee joint. The distal femur and proximal tibia are among the most common sites for primary bone tumor. OGS is the most common bone cancer in the world in children and adolescents, and the eighth-most common form of childhood cancer, accounting for 4% of all childhood cancers worldwide. In India, the incidence varies from 4.7% to 11.6%, where this malignancy is associated with significant morbidity and mortality. Additional treatment involves chemotherapy which further delays the healing and recovery of the patient.\\\\n\\\\nSurgery is a known risk factor for development of Chronic Post Surgical Pain(CPSP) which as per the definition given by Macrae and Davies, is defined by\\\\n\\\\n* Pain developing after a surgical procedure.\\\\n* Pain of at least 2 months\\' duration.\\\\n* Other causes of pain excluded (e.g.- malignancy, infection, etc.).\\\\n* Pain continuing from a pre-existing pain problem excluded.\\\\n\\\\nCPSP is a well known risk factor in many surgeries like (but not exclusive of)-\\\\n\\\\n* Mastectomy (Incidence of chronic pain = 11-57%)\\\\n* Amputation (30-85%)\\\\n* Inguinal hernia(5-63%)\\\\n* Cholecystectomy (3-50%)\\\\n\\\\nCPSP develops after a surgical procedure or increases in intensity after the surgical procedure. Literature on TKR surgeries indicated for osteoarthritis, report that although many patients report a good outcome after their total knee replacement, at a time when recovery should have been achieved, about 10-34% of patients undergoing TKR for osteoarthritis report moderate to severe CPSP. In around 30% of patients with CPSP, the origin of CPSP might be neuropathic. Neuropathic pain is more severe and adversely affects the quality of life of patients. TKR on its own may cause neuropathic pain postoperatively due to local nerve damage, often to the infrapatellar branch of the saphenous nerve or due to local inflammation. Risk factors associated with the operation include increased duration of surgery and tourniquet time, revision surgery, TKA versus unicompartmental arthroplasty and intraoperative nerve damage. Oncologic TKRs are more extensive and include much morbid excisions, and consequently may be presumed to have a similar if not a greater incidence of CPSP. Some of the risk factors for CPSP include the following (but not exclusive of)-\\\\n\\\\n* Pain, moderate to severe, lasting more than 1 month\\\\n* Repeat surgery\\\\n* Younger age (adults)\\\\n* Surgical approach with risk of nerve damage\\\\n* Neurotoxic chemotherapy\\\\n\\\\nPreoperative pain is consistently found to be a predictor for persistent postsurgical pain, which might reflect an independent risk factor but could well be a manifestation of predisposing factors.\\\\n\\\\nTata Memorial Hospital, a tertiary cancer institute is a 629 bedded hospital and conducts approximately 6000 surgeries per year out of which approximately 100 TKRs are performed per year. Analgesia peri-operatively is provided by an epidural infusion of a combination of local anaesthetic and an opioid or intravenous opioids with non-steroidal anti-inflammatory analgesics and paracetamol as appropriate. Postoperatively, if inserted, epidural analgesia is continued for up to 3-4 days to help mobilization \\\\\\\\& physiotherapy. In the absence of an epidural, around the clock analgesics with or without an opioid administered by means of an Intravenous Patient Controlled Analgesia (IVPCA) device is instituted. These patients are visited by the acute pain service team to address pain issues for the first 3 postoperative days or sometimes longer.\\\\n\\\\nSTUDY DESIGN:- Prospective and Observational study\\\\n\\\\nMETHODS and MATERIALS:- After Institutional Review Board approval, adult patients scheduled for TKR surgeries will be enrolled into the study after obtaining their informed consent over a 24 month period. However, interim analyses of all cases who have completed the 6 month follow up as on 31st October, 2017 would be analyzed as part of the co- principle investigator\\'s thesis. All consenting patients will be assessed for their pain preoperatively and for the first 3 post-operative days, and at 1, 4 and 6 months from the date of surgery. Pain scores will be assessed using the Numerical Rating Scale during the 3 days after surgery. Pain will be managed by the Acute Pain Service team as per the standard management protocols.\\\\n\\\\nThe Brief pain inventory (BPI), (short form with translations, obtained with permission from MD Anderson), which assesses the severity of pain and the impact of pain on daily functions will be administered to the patient in the language familiar to them, preoperatively, at 1, 4 and 6 months postoperatively. The BPI is a useful instrument to assess the severity of pain and impact of pain on daily functions in patients with pain from chronic diseases, conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain. The short form comprises of nine questions related to the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week. It has been widely used and validated in several languages the world over.\\\\n\\\\nThe Musculoskeletal Tumour Society Score (MSTS) evaluates the functional condition (impairment) after completed tumour treatment will be estimated at the end of 6 months from the date of surgery. It is calculated on the basis of a standardized physical examination by the physician. This clinical examination assesses six criteria and differs slightly between the upper and lower limb. For the lower limb, the components are pain, function, emotional acceptance of the treatment outcome, need for walking aids, walking and gait. For all criteria, the estimate is made from bad to very good with parallel awarding of points (0 to 5). There is thus a numerical value for each of the six criteria. These six values are added and divided by the maximum possible number of points (30). The percentage value is obtained by multiplying the calculated point value by 100.\\\\n\\\\nThe painDETECT questionnaire (PD-Q) is a quick, simple and reliable screening tool to identify the likelihood of a neuropathic pain component in patients with neuropathic pain. This questionnaire had been prepared by professionals and validated in various languages including Hindi and Marathi. Its sensitivity and specificity is higher than other screening questionnaires for neuropathic pain, including the Douleur Neuropathique 4 (DN4), Leeds Assessment of Neuropathic Symptoms and Signs (LANNS), and the Neuropathic Pain Questionnaire (NPQ) (Freynhagen et al 2006). The PD-Q has been used to identify neuropathic pain in patients with knee osteoarthritis (Ohtori et al 2012) and to identify sensory pro\\\\ufb01les in patients with diabetic neuropathy and postherpetic neuralgia (Baron et al 2009).This questionnaire will be administered tot he patients preoperatively , at 1, 4 and 6 months after surgery.\\\\n\\\\nDetails of postoperative chemotherapy and radiation will also be obtained from patient\\'s notes and the electronic medical record. If the patient cannot follow up at the said intervals, the pain scores would be obtained telephonically and the BPI and PD-Q forms in prepaid envelopes would be given to them at discharge which they would have to duly fill in and post them to the given address at the appropriate intervals if they cannot visit the pain clinic. At the 6th month of follow up, they would be requested to visit the pain clinic for an assessment of MSTS score and completing the BPI and PD-Q.\\\\n\\\\nMEASUREMENTS:-\\\\n\\\\n* All demographic, preoperative, intraoperative and postoperative data would be collected by the investigators.\\\\n* Demographic data includes case no, age, sex, ASA (American Society of Anesthesiologists) grade.\\\\n* Preoperative variables include pain score, preoperative analgesics, duration of use, and the dose.\\\\n* Intraoperative variables include duration of surgery, tourniquet time, any nerve or muscle resection and length of bone resected.\\\\n* Postoperative variables include median average and worst pain score for the first 3 postoperative days , 1, 4 and 6 months after surgery.\\\\n* Analgesics administered postoperatively, dose \\\\\\\\& dosing intervals, impact on daily functions as obtained from the BPI pre-operatively, 1, 4 and 6 months postoperatively.\\\\n* The painDETECT score to identify the neuropathic component of pain if any, preoperatively and at 1, 4 and 6 months after surgery.\\\\n* The MSTS score calculated by the physician and obtained from the patient\\'s record at the 6th month after surgery.\\\\n\\\\nSTATISTICAL ANALYSIS:- The above mentioned data will be presented as mean (sd), median (range), and frequency (percentage). Categorical data will be analyzed using the Chi-square test or Fisher Exact test (for binary data). Continuous variables will be analyzed using paired t test or Wilcoxon signed rank test as per distribution of data. Repeated measure ANOVA will be used for pain score analysis. Pearson correlation coefficients will be used for association. p-value \\\\\\\\<0.05 will be considered statistical significant.\\\\n\\\\nIntervention \\\\n- OTHER : Non interventional study \\\\n\\\\t- No intervention\", \"criteria\": \"Inclusion Criteria:\\\\n\\\\n* Adult patients above 18 years, undergoing TKR\\\\n* Literate: able to read and write in at least one of the following languages English, Hindi and Marathi\\\\n* Willing to fill forms and post them and/or answer questions on phone\\\\n\\\\nExclusion Criteria:\\\\n\\\\n* Refusal of consent\\\\n* Cognitively impaired\\\\n* Revision knee arthroplasty (including cases with wound wash and nail spacer cementing)\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n- Maximum Age : 99 Years\\\\n\\\\nAccepts Healthy Volunteers: No\\\\n\"}',\n",
       "   '{\"metadata\": {\"NCT_ID\": \"NCT00686764\", \"Brief_Title\": \"Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above-Knee Amputees\", \"Official_title\": \"Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above Knee Amputees\", \"Conditions\": [\"Neuroma Amputation\"], \"Interventions\": [\"Other: Observational\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"OBSERVATIONAL\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nBackground: The formation of neuromas, a fusiform swelling of a nerve or nerve ending, is a well documented response to limb amputation. Likewise, Residual Limb Pain (RLP), pain felt from the remaining portion of the amputated limb, is common among amputees. Neuromas are found in more than 90% of lower extremity amputations, of which 30-50% are pain-generating for the patient . And while surgical techniques reveal the commonly held belief that neuroma formation is one of the causal drivers behind RLP, there has been no study to demonstrate that the two events - namely the magnitude of neuroma formation and the magnitude of pain experienced by amputees - are correlated. If this correlation, or lack thereof, were elucidated with the use of ultrasonography, this would provide the preliminary data which could lead to further studies in neuroma minimization and/or proliferation.\\\\n\\\\nObjective: This study seeks to use ultrasonography (US) to quantify the degree to which neuroma size and the nature of surrounding tissue correlate with the experience of RLP in trans-femoral amputees.\\\\n\\\\nSetting and Subjects: This study will enroll 30 trans-femoral amputees, male and female, who are over the age of 18. The study will take place in the OHSU Orthopaedic Outpatient Clinic, and OHSU Imaging Department.\\\\n\\\\nIntervention: None. This is an observational clinical study in which we will characterize the sciatic nerve/neuroma and surrounding tissue using ultrasound.\\\\n\\\\nMeasurements: We will use US to measure the cross sectional area of the neuroma at its widest point and compare this to the cross section of the same neuron at the lesser trochanter. Furthermore, we will describe the morphology of the neuroma. To quantify the subject\\'s pain experience we will utilize the Questionnaire for Persons with Transfemoral Amputation (Q-TFA), Trinity Amputation \\\\\\\\& Prosthetic Experience Scale (TAPES), Visual Analog Scale (VAS), and the Short Form 36 (SF-36).\\\\n\\\\nAnalysis: The statistical analysis will employ a Pearson correlation coefficient and linear regression analysis.\\\\n\\\\nIntervention \\\\n- OTHER : Observational \\\\n\\\\t- Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.\\\\n\\\\nWe will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36).\", \"criteria\": \"Inclusion Criteria:\\\\n\\\\n* greater than 18 years\\\\n* a trans-femoral amputee\\\\n* more than one year post-amputation\\\\n* has worn a prosthesis within the last year\\\\n\\\\nExclusion Criteria:\\\\n\\\\n* subject also diagnosed with diabetes\\\\n* subject also diagnosed with Peripheral Vascular Disease\\\\n* subject also diagnosed with peripheral neuropathy\\\\n* subject with spinal cord, head, or nerve root injury\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n- Maximum Age : 99 Years\\\\n\\\\nAccepts Healthy Volunteers: Yes\\\\n\"}',\n",
       "   '{\"metadata\": {\"NCT_ID\": \"NCT00130962\", \"Brief_Title\": \"ALGRX 4975 in the Treatment of Patients With Morton\\'s Neuroma\", \"Official_title\": \"A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma\", \"Conditions\": [\"Neuroma\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE2\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"DOUBLE\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nSubjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.\\\\n\\\\nDetailed Description \\\\nSubjects will have painful primary or post-operative intermetatarsal neuroma. Each subject will be randomly allocated to receive either ALGRX 4975 or placebo in a 1:1 ratio. Study drug or placebo will be injected into the intermetatarsal space containing a painful neuroma. Subjects will complete weekly assessments for the Average Foot Pain Severity, the 7 Interference Items of the BPI, and the number of analgesic units taken. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.\\\\n\\\\nPlasma concentrations will be assessed pre-dose and post dose at 5, 10, 15, 20, 30, and 45 min and at 1, 1.5, 2, 2.5, 3 and 4 hours.\\\\n\\\\nSafety will be assessed at baseline and during the study with adverse events (all visits), vital signs (Visit 2 pre and post-injection and Visit 3 or at early termination), and laboratory assessments (hematology, chemistry, urinalysis) and ECG (Screening and Visit 3 or at early termination). The injection site will be examined and assessed by a 6-point scale for erythema, edema, and hemorrhage before the injection and at 1, 2 and 4 hours after the injection. A pain on injection NRS will be assessed immediately post- injection at 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after study drug administration. A sensory examination of the foot will be performed before the injection and 4 hours after the injection and at the completion of the study. If a subject has injection pain, the foot may be wrapped in ice for up to 20 minutes, analgesic medication may be provided.\\\\n\\\\nIntervention \\\\n- DRUG : ALGRX 4975 \", \"criteria\": \"Inclusion Criteria:\\\\n\\\\n* Males or females aged >18 years\\\\n* Foot X-ray to rule out alternative pathology, and ultrasound or magnetic resonance imaging (MRI) to confirm the presence of a neuroma within 6 months of study entry\\\\n* Evidence of either a primary or post surgical recurrence neuroma\\\\n* A score of 4 or greater on the Average Foot Pain Severity Numeric Rating Scale (NRS) during the week prior to randomization\\\\n* Failed conservative treatment such as wide shoes, orthotics, arch supports, or oral and/or injected analgesics\\\\n* Signed an Informed Consent form approved by the Institutional Review Board\\\\n* For female subjects: is surgically sterile, at least 2 years postmenopausal, or using a medically acceptable method (as determined by the Principal Investigator) of birth control; if of child-bearing potential is not pregnant (have a documented negative urine pregnancy test prior to enrollment), is not planning to get pregnant (during the time course of the study), or is not lactating\\\\n* Able to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments\\\\n\\\\nExclusion Criteria:\\\\n\\\\n* History of clearly documented allergic reaction to lidocaine or capsaicin.\\\\n* Prior participation in ALGRX 4975 study.\\\\n* Presence of any medical condition or instability that, in the judgment of the Investigator, might adversely impact the conduct of the study and the collection of data, including chronic conditions that are likely to alter the rate of healing or are likely to result in safety complications unrelated to the study medication, such as diabetes mellitus or extensive vascular disease\\\\n* Treatment of neuroma with a narcotic analgesic\\\\n* Other painful foot pathology\\\\n* Active cutaneous, or other disease, at the anticipated site of study drug injection\\\\n* Laboratory results that are both out of normal range and, in the opinion of the Investigator, clinically significant\\\\n* Drug or alcohol abuse within the past 2 years\\\\n* Require regular oral steroid medication, except for stable use (6 months or longer on the same scheduled dose) for mild or moderate asthma\\\\n* Use of an investigational medication in the 30 days prior to the current study or scheduled to receive such an agent while participating in the current study\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n\\\\nAccepts Healthy Volunteers: No\\\\n\"}',\n",
       "   '{\"metadata\": {\"NCT_ID\": \"NCT01632709\", \"Brief_Title\": \"Pathophysiology of Post Amputation Pain\", \"Official_title\": \"Pathophysiology of Post Amputation Pain\", \"Conditions\": [\"Amputation Stumps\", \"Neuroma\"], \"Interventions\": [\"Drug: Bupivacaine\", \"Drug: Placebo\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE4\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"SINGLE\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nThe purpose of this study is to see how Post Amputation Pain (PAP) affects the body and brain by using sensory testing (such as pinprick testing), taking pictures of your brain (using a functional magnetic resonance imaging (fMRI) machine) and biomedical interventions (such as an injection of pain medicine). All medicines and the fMRI machine used during this study are FDA approved. The investigators hope that by learning the causes of PAP, the investigators can help future amputees.\\\\n\\\\nDetailed Description \\\\nYour participation in this study will last for 5 weeks and you will be asked to come to a total of 3 visits. The first visit will be during the first week of the study, the second visit during the second week of the study and the third (final) visit will be during the fifth (and final) week of the study. For your first visit you will have a physical examination with some sensory stimulation tests (such as vibration and pinprick tests), some questionnaires about your health and pain history, hot and cold sensory tests, and we will take thermal pictures of your body before and after receiving a quick electrical stimulus. You will also be trained on how to use the finger-span device to rate your pain during the second visit, and how to use an electronic pain diary to record your pain scores three times a day during the five weeks of the study.\\\\n\\\\nThe second visit will begin with questionnaires from the first visit and thermal images with a quick electrical stimulus. You will then be brought to an fMRI scanner room at Northwestern University. For an hour and fifteen minutes we will take pictures of your brain and these pictures will help us understand the changes in your brain relating to pain. You will then be put into one of four treatment groups randomly.\\\\n\\\\nThe study treatment that you will get will be decided randomly or by chance, like flipping a coin. Injections in this study will use the local anesthetic bupivacaine (a long lasting drug like the numbing agent novocaine used by dentists). This drug causes numbness, blocks pain and other nerve function near the injection site for 6-8 hours. Group 1 will get a sympathetic nerve block of bupivacaine, which changes how your nerves transmit pain, in either the neck or lower back (depending on where the amputation is located), Group 2 will get a placebo injection (no active medicine) in either the neck or lower back (depending on where the amputation is located), Group 3 will get a neuroma injection of bupivacaine (a neuroma is a group of nerves at the end of your residual limb), and Group 4 will get a placebo injection (no active medicine) at the neuroma. Some people get the bupivacaine injection and some people get the placebo injection so that we can compare the groups and see if the bupivacaine brings more, less or the same pain relief as a placebo injection. We scan your brain before the injection so that we can see how your brain responds to pain. We also scan your brain after the injection so that we can see if your brain responds differently to pain after the injection has been done.\\\\n\\\\nYou will know the location of your injection before you receive the treatment (neck, lower back or neuroma on your affected limb), but you will not know if you are getting a pain medication injection or placebo injection. Only the study doctors will know this information, and it can be told to you in case of an emergency. After the injection, you will have a second hour of brain scanning. After the scanning, you will be asked to complete some questionnaires, sensory tests, hot and cold temperature testing and we will take thermal pictures of your body before and after a quick electrical stimulus.\\\\n\\\\nYour third visit will be four weeks after your second visit. For your third visit you will have the same questionnaires as during the first and second visits, sensory tests, hot and cold temperature testing and we will take thermal pictures of your body before and after a quick electrical stimulus.\\\\n\\\\nIntervention \\\\n- DRUG : Bupivacaine \\\\n\\\\t- one injection of 10ml of .25%, - DRUG : Placebo \\\\n\\\\t- Dry needling\\\\n\\\\t- Dry needling\", \"criteria\": \"Inclusion Criteria:\\\\n\\\\n* At least 18 years\\\\n* Able to read and speak English and provide informed consent\\\\n* Single Amputation, upper or lower.\\\\n* Subject has chronic post amputation pain lasting longer than three months\\\\n* Subject has healed amputation wounds\\\\n* Pain must be >=3 on a scale of 0 <= age <= 10, 0 being no pain, 10 being the worse pain imaginable.\\\\n* If subjects pain is non-existent during fMRI scans, the subject needs to be willing to have their pain induced by targeting pain trigger points (for example, study\\'s postdoctoral fellow would massage certain regions of the affected limb to trigger PAP).\\\\n* Subject agrees to 1) Stop taking all aspirin seven days prior to their second visit (Bayer,Ecotrin,Alka Seltzer, etc.) 2) All inflammatory medications 48 hours prior to their second visit (Advil, Motrin, Indocin, Lodine , Ibuprofen, Aleve, Naproxen, etc. 3) Supplements such as Vitamin E and Fish Oil 48 hours prior to their second visit.\\\\n* Subject agrees to continue other prescribed medications.\\\\n* Subject is willing to have hypodermic needle injections and images taken of them (digital, thermal, and fMRI).\\\\n* Able to understand and comply with all data collection methodology including electronic diary.\\\\n* If female, is not pregnant and not currently attempting to conceive; if of childbearing potential, use of a highly effective method of birth control (as determined by Pl).\\\\n\\\\nExclusion Criteria:\\\\n\\\\n* Subject is allergic to Isovue 300 or amide-type local anesthetics such as bupivicaine, lidocaine, or mepivacaine.\\\\n* Subject has a diagnosis of bleeding diathesis or an immune compromise.\\\\n* Subject has pain that is more severe than their post amputation pain.\\\\n* Subject has a clinical diagnosis of fibromyalgia.\\\\n* Subject has metal shavings and or is frequently in an environment where there is metal work being done or significant amounts of metal shavings.\\\\n* Subject has ferrous metal implants, aneurism clips, bioelectric devices, and other implants which can be affected by the magnetic field of the MRI.\\\\n* Subject is claustrophobic.\\\\n* Subject weighs more than 300 pounds.\\\\n* Subject plans to start new pain treatments or therapies during the study (e.g. new pain medication, injections, PT, surgery).\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n\\\\nAccepts Healthy Volunteers: Yes\\\\n\"}',\n",
       "   '{\"metadata\": {\"NCT_ID\": \"NCT02283957\", \"Brief_Title\": \"A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\", \"Official_title\": \"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\", \"Conditions\": [\"Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\"], \"Interventions\": [\"Drug: CNTX-4975\", \"Other: Placebo\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE2\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"DOUBLE\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nStudy 4975-MN-202 is a double-blind, placebo-controlled, parallel group, single-injection study in which subjects will be randomized to receive three doses of CNTX-4975 or placebo injected into the intermetatarsal space around a Morton\\'s neuroma. The injection of study medication will be administered by ultrasound-guided needle placement following ankle block anesthesia. The study staff will telephone subjects at Week 1 postinjection and subjects will return to the clinic postinjection at Weeks 2, 4, 8, and 12 for study assessments.\\\\n\\\\nIntervention \\\\n- DRUG : CNTX-4975 , - OTHER : Placebo \", \"criteria\": \"Inclusion criteria:\\\\n\\\\n* Male or female aged >18 years at the time of the Screening Visit.\\\\n* Pain associated with intermetatarsal neuroma (Morton\\'s neuroma) for a minimum of 3 months prior to Screening.\\\\n* Diagnosis of Morton\\'s neuroma, confirmed by evidence of focal tenderness and pain in the distal third intermetatarsal space, AND either\\\\n\\\\n   * Presence of neuroma on ultrasound, or\\\\n   * Elicitation of Mulder\\'s sign or a positive Gauthier\\'s test.\\\\n* A mean neuroma foot pain score of 4 or greater during the 7 days prior to dosing (NPRS, 0 <= age <= 10) as rated daily at bedtime (9:00 PM \\\\u00b1 3 hours) for average pain with walking in the last 24-hours. At least 5 of 7 scores during the week prior to dosing must be recorded.\\\\n* Tried conservative treatment with analgesics (acetaminophen or nonsteroidal anti-inflammatory drugs) and non-pharmacologic therapy (such as wide shoes, orthotics, and/or arch supports) without complete success.\\\\n* Female not of childbearing potential, defined as post-menopausal for at least 1 year, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing one of the following medically acceptable methods of birth control throughout the study period:\\\\n\\\\n   * Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject\\'s usual menstrual cycle period) before investigational product (IP) administration.\\\\n   * Total abstinence from sexual intercourse since the last menses before IP administration.\\\\n   * Intrauterine device.\\\\n   * Double barrier method (condoms, sponge, diaphragm, with spermicidal jellies or cream).\\\\n* Willing and able to understand the study requirements, abide by the study restrictions, complete the study procedures, pain scales, and daily IWRS/IVRS entries, and to communicate meaningfully with the study personnel.\\\\n* Signed an Informed Consent Form approved by the Institutional Review Board.\\\\n* Subject agrees to take only the rescue medications for neuroma foot pain from the time of screening through study completion, and agrees to discontinue all topical medications for neuroma pain after Screening.\\\\n\\\\nExclusion criteria:\\\\n\\\\n* Clinically significant bursitis in either foot.\\\\n* The subject has more than one painful intermetatarsal neuroma in the affected foot which, in the opinion of the Investigator, would interfere with evaluation of the symptoms and functional limitations that arise from the intermetatarsal neuroma in the affected foot.\\\\n* Radiography within 6 months of the Treatment Visit (Day 1) to exclude musculoskeletal pathology must be performed, to include any osseous abnormality such as stress fracture, osteophyte, tumor, or cyst in the bones or toes adjacent to the third inter-metatarsal space or any significant evidence of arthritis in the joints of the 3rd and 4th metatarsal-phalangeal joints or inter-phalangeal joints of the 3rd and 4th toes.\\\\n* Previous neurectomy in the same nerve.\\\\n* Any painful condition or prior surgery on the affected ankle or foot, which, in the judgment of the investigator, might adversely impact the interpretation of study data.\\\\n* Other painful foot pathology (e.g., bunion, hammertoe, plantar fasciitis etc.) or evidence of clinically meaningful ischemia which, in the judgment of the investigator and the medical monitor, would interfere with evaluation of the symptoms and functional limitations that arise from the intermetatarsal neuroma.\\\\n* Other chronic pain anywhere in the body that is greater than or equal to the intensity of foot pain from intermetatarsal neuroma.\\\\n* Signs of arterial insufficiency in the feet, including clinically meaningful edema.\\\\n* Current use of opioids for any condition.\\\\n* Corticosteroid injection in the affected foot within 30 days of Screening.\\\\n* History of clearly documented allergic reaction to local anesthetics or capsaicin.\\\\n* Prior use of injection with a sclerosing agent, such as alcohol or phenol, in the affected foot for Morton\\'s neuroma.\\\\n* Presence of any medical condition or unstable health status that, in the judgment of the investigator, might adversely impact the conduct of the study or resulting data, including chronic conditions that are likely to alter the rate of healing or are likely to result in safety complications unrelated to the study medication, such as uncontrolled diabetes mellitus or vascular disease.\\\\n* Regular use of anticoagulant blood thinners (except low-dose aspirin or Plavix which are allowed).\\\\n* Active cutaneous disease at the anticipated site of study drug injection that would prevent the safe administration of study drug.\\\\n* Ulcer or open wound anywhere on the affected foot.\\\\n* Clinically significant abnormal laboratory result at the Screening Visit (in the opinion of the investigator).\\\\n* Has diabetic neuropathy or other peripheral neuropathy in the affected foot.\\\\n* Use of an investigational medication in the 30 days prior to the current study or scheduled to receive such an agent while participating in the current study.\\\\n* Prior participation in an ALGRX-4975 or CNTX-4975 study.\\\\n* Has a history of substance use disorder within the previous year as defined by the Diagnostic and Statistical Manual for Mental Health Disorders, fifth edition, has current evidence for a substance use disorder, is receiving medicinal treatment for drug abuse, or tests positive upon urine drug screen for a substance of abuse.\\\\n* Has a positive pregnancy test at the Screening or Treatment Visit.\\\\n* Has any condition or is taking any medication that would be contraindicated for study participation.\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n\\\\nAccepts Healthy Volunteers: No\\\\n\"}']],\n",
       " 'uris': None,\n",
       " 'data': None,\n",
       " 'included': ['metadatas', 'documents', 'distances']}"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query_embedding = model.encode(\"Effect of Kinesiotaping on Edema Management, Pain and Function on Patients With Bilateral Total Knee Arthroplasty [SEP] After being informed about the study and potential risk, all patients undergoing inpatient rehabilitation after bilateral total knee arthroplasty will have Kinesio(R)Tape applied to one randomly selected leg while the other leg serves as a control. Measurement of bilateral leg circumference, knee range of motion, numerical rating scale for pain, and selected questions from the Knee Injury and Osteoarthritis Outcome Score will occur at regular intervals throughout the rehabilitation stay. Patients will receive standard rehabilitation.\").tolist()\n",
    "    \n",
    "results = collection.query(\n",
    "    query_embeddings=[query_embedding],\n",
    "    n_results=5\n",
    ")\n",
    "results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'id': 'NCT03032679', 'distance': 110.8730239868164, 'document': '{\"metadata\": {\"NCT_ID\": \"NCT03032679\", \"Brief_Title\": \"Pain and Impact of Chronic Pain on Function After Total Knee Replacements\", \"Official_title\": \"Postoperative Pain Severity, Incidence Of Chronic Pain And Its Impact On Daily Function Following Total Knee Replacements (TKR) At A Tertiary Cancer Institute\", \"Conditions\": [\"Pain\", \"Postoperative\", \"Pain\", \"Chronic\", \"Osteogenic Sarcoma\", \"Knee Arthropathy\"], \"Interventions\": [\"Other: Non interventional study\"], \"Location_Countries\": [\"India\"], \"Study_Design\": {\"Study_Type\": \"OBSERVATIONAL\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nAfter Institutional Review Board approval, adult patients scheduled for total knee arthroplasty (TKA) will be enrolled into the study after obtaining informed consent over a 24 month period. Interim analyses of cases who have completed the 6 month follow up as on 31st October, 2017 will be analyzed as part of the co- principle investigator\\'s thesis. All consenting patients will be assessed for pain preoperatively, the first 3 post-operative days, at 1, 4 and 6 months from the date of surgery. Pain scores will be assessed using the Numerical Rating Scale during the 3 postoperative days. Pain will be managed by the Acute Pain Service team as per standard protocols.\\\\n\\\\nThe Brief pain inventory (BPI) (short form with translations, obtained with permission from MD Anderson), which assesses pain severity and its impact on daily functions will be administered to the patient in a language familiar to them, preoperatively, at 1, 4 and 6 months postoperatively.\\\\n\\\\nThe Musculoskeletal Tumour Society Score (MSTS) which evaluates the functional condition (impairment) after completed tumour treatment will be estimated at the end of 6 months from the date of surgery The painDETECT questionnaire (PD-Q) a quick, simple and reliable screening tool to identify the likelihood of a neuropathic pain component in patients and validated in various languages including Hindi and Marathi will be administered preoperatively and at 1, 4 and 6 months after surgery.\\\\n\\\\nDetails of postoperative chemotherapy and radiation will also be obtained from patient\\'s notes and the electronic medical record. If the patient cannot follow up at the said intervals, the pain scores would be obtained telephonically and the BPI and PD-Q forms in prepaid envelopes would be given to them at discharge which they would have to duly fill in and post them to the given address at the appropriate intervals if they cannot visit the pain clinic. At the 6th month of follow up, they would be requested to visit the pain clinic for an assessment of MSTS score and completing the BPI and PD-Q.\\\\n\\\\nINCLUSION CRITERIA:-\\\\n\\\\n* Adult patients above 18 years of age, undergoing TKR\\\\n* Literate: able to read and write in at least one of the following languages English, Hindi and Marathi\\\\n* Willing to fill forms and post them and/or answer questions on phone\\\\n\\\\nEXCLUSION CRITERIA:-\\\\n\\\\n* Refusal of consent\\\\n* Cognitively impaired\\\\n* Revision TKRs (including cases with wound wash and nail spacer cementing)\\\\n\\\\nDetailed Description \\\\nINTRODUCTION:- A Total Knee Replacement (TKR) or arthroplasty (TKA) is a complex procedure that requires an Orthopedic Surgeon to make precise measurements and skillfully remove the diseased portions of the bone, in order to shape the remaining bone to accommodate the knee implant. Knee Replacement Surgery is most commonly performed in people with advanced osteoarthritis and should be considered when conservative treatments have been exhausted. Oncologic TKRs are different from the routine TKRs in a way that the former involves a wide local resection of the bone and soft tissues, ranging from 10 to 20 cm, resection of muscles like the head(s) of biceps femoris, the gastrocnemius muscle, the intermuscular septa, the joint capsule, etc. to ensure negative margins along with the complete resection of the tumour, followed by a reconstruction of almost the same length as that resected, to restore function.\\\\n\\\\nThe most common indication for doing oncologic TKR is Osteogenic Sarcoma (OGS) of and around the knee joint. The distal femur and proximal tibia are among the most common sites for primary bone tumor. OGS is the most common bone cancer in the world in children and adolescents, and the eighth-most common form of childhood cancer, accounting for 4% of all childhood cancers worldwide. In India, the incidence varies from 4.7% to 11.6%, where this malignancy is associated with significant morbidity and mortality. Additional treatment involves chemotherapy which further delays the healing and recovery of the patient.\\\\n\\\\nSurgery is a known risk factor for development of Chronic Post Surgical Pain(CPSP) which as per the definition given by Macrae and Davies, is defined by\\\\n\\\\n* Pain developing after a surgical procedure.\\\\n* Pain of at least 2 months\\' duration.\\\\n* Other causes of pain excluded (e.g.- malignancy, infection, etc.).\\\\n* Pain continuing from a pre-existing pain problem excluded.\\\\n\\\\nCPSP is a well known risk factor in many surgeries like (but not exclusive of)-\\\\n\\\\n* Mastectomy (Incidence of chronic pain = 11-57%)\\\\n* Amputation (30-85%)\\\\n* Inguinal hernia(5-63%)\\\\n* Cholecystectomy (3-50%)\\\\n\\\\nCPSP develops after a surgical procedure or increases in intensity after the surgical procedure. Literature on TKR surgeries indicated for osteoarthritis, report that although many patients report a good outcome after their total knee replacement, at a time when recovery should have been achieved, about 10-34% of patients undergoing TKR for osteoarthritis report moderate to severe CPSP. In around 30% of patients with CPSP, the origin of CPSP might be neuropathic. Neuropathic pain is more severe and adversely affects the quality of life of patients. TKR on its own may cause neuropathic pain postoperatively due to local nerve damage, often to the infrapatellar branch of the saphenous nerve or due to local inflammation. Risk factors associated with the operation include increased duration of surgery and tourniquet time, revision surgery, TKA versus unicompartmental arthroplasty and intraoperative nerve damage. Oncologic TKRs are more extensive and include much morbid excisions, and consequently may be presumed to have a similar if not a greater incidence of CPSP. Some of the risk factors for CPSP include the following (but not exclusive of)-\\\\n\\\\n* Pain, moderate to severe, lasting more than 1 month\\\\n* Repeat surgery\\\\n* Younger age (adults)\\\\n* Surgical approach with risk of nerve damage\\\\n* Neurotoxic chemotherapy\\\\n\\\\nPreoperative pain is consistently found to be a predictor for persistent postsurgical pain, which might reflect an independent risk factor but could well be a manifestation of predisposing factors.\\\\n\\\\nTata Memorial Hospital, a tertiary cancer institute is a 629 bedded hospital and conducts approximately 6000 surgeries per year out of which approximately 100 TKRs are performed per year. Analgesia peri-operatively is provided by an epidural infusion of a combination of local anaesthetic and an opioid or intravenous opioids with non-steroidal anti-inflammatory analgesics and paracetamol as appropriate. Postoperatively, if inserted, epidural analgesia is continued for up to 3-4 days to help mobilization \\\\\\\\& physiotherapy. In the absence of an epidural, around the clock analgesics with or without an opioid administered by means of an Intravenous Patient Controlled Analgesia (IVPCA) device is instituted. These patients are visited by the acute pain service team to address pain issues for the first 3 postoperative days or sometimes longer.\\\\n\\\\nSTUDY DESIGN:- Prospective and Observational study\\\\n\\\\nMETHODS and MATERIALS:- After Institutional Review Board approval, adult patients scheduled for TKR surgeries will be enrolled into the study after obtaining their informed consent over a 24 month period. However, interim analyses of all cases who have completed the 6 month follow up as on 31st October, 2017 would be analyzed as part of the co- principle investigator\\'s thesis. All consenting patients will be assessed for their pain preoperatively and for the first 3 post-operative days, and at 1, 4 and 6 months from the date of surgery. Pain scores will be assessed using the Numerical Rating Scale during the 3 days after surgery. Pain will be managed by the Acute Pain Service team as per the standard management protocols.\\\\n\\\\nThe Brief pain inventory (BPI), (short form with translations, obtained with permission from MD Anderson), which assesses the severity of pain and the impact of pain on daily functions will be administered to the patient in the language familiar to them, preoperatively, at 1, 4 and 6 months postoperatively. The BPI is a useful instrument to assess the severity of pain and impact of pain on daily functions in patients with pain from chronic diseases, conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain. The short form comprises of nine questions related to the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week. It has been widely used and validated in several languages the world over.\\\\n\\\\nThe Musculoskeletal Tumour Society Score (MSTS) evaluates the functional condition (impairment) after completed tumour treatment will be estimated at the end of 6 months from the date of surgery. It is calculated on the basis of a standardized physical examination by the physician. This clinical examination assesses six criteria and differs slightly between the upper and lower limb. For the lower limb, the components are pain, function, emotional acceptance of the treatment outcome, need for walking aids, walking and gait. For all criteria, the estimate is made from bad to very good with parallel awarding of points (0 to 5). There is thus a numerical value for each of the six criteria. These six values are added and divided by the maximum possible number of points (30). The percentage value is obtained by multiplying the calculated point value by 100.\\\\n\\\\nThe painDETECT questionnaire (PD-Q) is a quick, simple and reliable screening tool to identify the likelihood of a neuropathic pain component in patients with neuropathic pain. This questionnaire had been prepared by professionals and validated in various languages including Hindi and Marathi. Its sensitivity and specificity is higher than other screening questionnaires for neuropathic pain, including the Douleur Neuropathique 4 (DN4), Leeds Assessment of Neuropathic Symptoms and Signs (LANNS), and the Neuropathic Pain Questionnaire (NPQ) (Freynhagen et al 2006). The PD-Q has been used to identify neuropathic pain in patients with knee osteoarthritis (Ohtori et al 2012) and to identify sensory pro\\\\ufb01les in patients with diabetic neuropathy and postherpetic neuralgia (Baron et al 2009).This questionnaire will be administered tot he patients preoperatively , at 1, 4 and 6 months after surgery.\\\\n\\\\nDetails of postoperative chemotherapy and radiation will also be obtained from patient\\'s notes and the electronic medical record. If the patient cannot follow up at the said intervals, the pain scores would be obtained telephonically and the BPI and PD-Q forms in prepaid envelopes would be given to them at discharge which they would have to duly fill in and post them to the given address at the appropriate intervals if they cannot visit the pain clinic. At the 6th month of follow up, they would be requested to visit the pain clinic for an assessment of MSTS score and completing the BPI and PD-Q.\\\\n\\\\nMEASUREMENTS:-\\\\n\\\\n* All demographic, preoperative, intraoperative and postoperative data would be collected by the investigators.\\\\n* Demographic data includes case no, age, sex, ASA (American Society of Anesthesiologists) grade.\\\\n* Preoperative variables include pain score, preoperative analgesics, duration of use, and the dose.\\\\n* Intraoperative variables include duration of surgery, tourniquet time, any nerve or muscle resection and length of bone resected.\\\\n* Postoperative variables include median average and worst pain score for the first 3 postoperative days , 1, 4 and 6 months after surgery.\\\\n* Analgesics administered postoperatively, dose \\\\\\\\& dosing intervals, impact on daily functions as obtained from the BPI pre-operatively, 1, 4 and 6 months postoperatively.\\\\n* The painDETECT score to identify the neuropathic component of pain if any, preoperatively and at 1, 4 and 6 months after surgery.\\\\n* The MSTS score calculated by the physician and obtained from the patient\\'s record at the 6th month after surgery.\\\\n\\\\nSTATISTICAL ANALYSIS:- The above mentioned data will be presented as mean (sd), median (range), and frequency (percentage). Categorical data will be analyzed using the Chi-square test or Fisher Exact test (for binary data). Continuous variables will be analyzed using paired t test or Wilcoxon signed rank test as per distribution of data. Repeated measure ANOVA will be used for pain score analysis. Pearson correlation coefficients will be used for association. p-value \\\\\\\\<0.05 will be considered statistical significant.\\\\n\\\\nIntervention \\\\n- OTHER : Non interventional study \\\\n\\\\t- No intervention\", \"criteria\": \"Inclusion Criteria:\\\\n\\\\n* Adult patients above 18 years, undergoing TKR\\\\n* Literate: able to read and write in at least one of the following languages English, Hindi and Marathi\\\\n* Willing to fill forms and post them and/or answer questions on phone\\\\n\\\\nExclusion Criteria:\\\\n\\\\n* Refusal of consent\\\\n* Cognitively impaired\\\\n* Revision knee arthroplasty (including cases with wound wash and nail spacer cementing)\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n- Maximum Age : 99 Years\\\\n\\\\nAccepts Healthy Volunteers: No\\\\n\"}'}, {'id': 'NCT00686764', 'distance': 113.80130004882812, 'document': '{\"metadata\": {\"NCT_ID\": \"NCT00686764\", \"Brief_Title\": \"Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above-Knee Amputees\", \"Official_title\": \"Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above Knee Amputees\", \"Conditions\": [\"Neuroma Amputation\"], \"Interventions\": [\"Other: Observational\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"OBSERVATIONAL\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nBackground: The formation of neuromas, a fusiform swelling of a nerve or nerve ending, is a well documented response to limb amputation. Likewise, Residual Limb Pain (RLP), pain felt from the remaining portion of the amputated limb, is common among amputees. Neuromas are found in more than 90% of lower extremity amputations, of which 30-50% are pain-generating for the patient . And while surgical techniques reveal the commonly held belief that neuroma formation is one of the causal drivers behind RLP, there has been no study to demonstrate that the two events - namely the magnitude of neuroma formation and the magnitude of pain experienced by amputees - are correlated. If this correlation, or lack thereof, were elucidated with the use of ultrasonography, this would provide the preliminary data which could lead to further studies in neuroma minimization and/or proliferation.\\\\n\\\\nObjective: This study seeks to use ultrasonography (US) to quantify the degree to which neuroma size and the nature of surrounding tissue correlate with the experience of RLP in trans-femoral amputees.\\\\n\\\\nSetting and Subjects: This study will enroll 30 trans-femoral amputees, male and female, who are over the age of 18. The study will take place in the OHSU Orthopaedic Outpatient Clinic, and OHSU Imaging Department.\\\\n\\\\nIntervention: None. This is an observational clinical study in which we will characterize the sciatic nerve/neuroma and surrounding tissue using ultrasound.\\\\n\\\\nMeasurements: We will use US to measure the cross sectional area of the neuroma at its widest point and compare this to the cross section of the same neuron at the lesser trochanter. Furthermore, we will describe the morphology of the neuroma. To quantify the subject\\'s pain experience we will utilize the Questionnaire for Persons with Transfemoral Amputation (Q-TFA), Trinity Amputation \\\\\\\\& Prosthetic Experience Scale (TAPES), Visual Analog Scale (VAS), and the Short Form 36 (SF-36).\\\\n\\\\nAnalysis: The statistical analysis will employ a Pearson correlation coefficient and linear regression analysis.\\\\n\\\\nIntervention \\\\n- OTHER : Observational \\\\n\\\\t- Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.\\\\n\\\\nWe will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36).\", \"criteria\": \"Inclusion Criteria:\\\\n\\\\n* greater than 18 years\\\\n* a trans-femoral amputee\\\\n* more than one year post-amputation\\\\n* has worn a prosthesis within the last year\\\\n\\\\nExclusion Criteria:\\\\n\\\\n* subject also diagnosed with diabetes\\\\n* subject also diagnosed with Peripheral Vascular Disease\\\\n* subject also diagnosed with peripheral neuropathy\\\\n* subject with spinal cord, head, or nerve root injury\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n- Maximum Age : 99 Years\\\\n\\\\nAccepts Healthy Volunteers: Yes\\\\n\"}'}, {'id': 'NCT00130962', 'distance': 115.11090087890625, 'document': '{\"metadata\": {\"NCT_ID\": \"NCT00130962\", \"Brief_Title\": \"ALGRX 4975 in the Treatment of Patients With Morton\\'s Neuroma\", \"Official_title\": \"A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma\", \"Conditions\": [\"Neuroma\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE2\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"DOUBLE\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nSubjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.\\\\n\\\\nDetailed Description \\\\nSubjects will have painful primary or post-operative intermetatarsal neuroma. Each subject will be randomly allocated to receive either ALGRX 4975 or placebo in a 1:1 ratio. Study drug or placebo will be injected into the intermetatarsal space containing a painful neuroma. Subjects will complete weekly assessments for the Average Foot Pain Severity, the 7 Interference Items of the BPI, and the number of analgesic units taken. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.\\\\n\\\\nPlasma concentrations will be assessed pre-dose and post dose at 5, 10, 15, 20, 30, and 45 min and at 1, 1.5, 2, 2.5, 3 and 4 hours.\\\\n\\\\nSafety will be assessed at baseline and during the study with adverse events (all visits), vital signs (Visit 2 pre and post-injection and Visit 3 or at early termination), and laboratory assessments (hematology, chemistry, urinalysis) and ECG (Screening and Visit 3 or at early termination). The injection site will be examined and assessed by a 6-point scale for erythema, edema, and hemorrhage before the injection and at 1, 2 and 4 hours after the injection. A pain on injection NRS will be assessed immediately post- injection at 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after study drug administration. A sensory examination of the foot will be performed before the injection and 4 hours after the injection and at the completion of the study. If a subject has injection pain, the foot may be wrapped in ice for up to 20 minutes, analgesic medication may be provided.\\\\n\\\\nIntervention \\\\n- DRUG : ALGRX 4975 \", \"criteria\": \"Inclusion Criteria:\\\\n\\\\n* Males or females aged >18 years\\\\n* Foot X-ray to rule out alternative pathology, and ultrasound or magnetic resonance imaging (MRI) to confirm the presence of a neuroma within 6 months of study entry\\\\n* Evidence of either a primary or post surgical recurrence neuroma\\\\n* A score of 4 or greater on the Average Foot Pain Severity Numeric Rating Scale (NRS) during the week prior to randomization\\\\n* Failed conservative treatment such as wide shoes, orthotics, arch supports, or oral and/or injected analgesics\\\\n* Signed an Informed Consent form approved by the Institutional Review Board\\\\n* For female subjects: is surgically sterile, at least 2 years postmenopausal, or using a medically acceptable method (as determined by the Principal Investigator) of birth control; if of child-bearing potential is not pregnant (have a documented negative urine pregnancy test prior to enrollment), is not planning to get pregnant (during the time course of the study), or is not lactating\\\\n* Able to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments\\\\n\\\\nExclusion Criteria:\\\\n\\\\n* History of clearly documented allergic reaction to lidocaine or capsaicin.\\\\n* Prior participation in ALGRX 4975 study.\\\\n* Presence of any medical condition or instability that, in the judgment of the Investigator, might adversely impact the conduct of the study and the collection of data, including chronic conditions that are likely to alter the rate of healing or are likely to result in safety complications unrelated to the study medication, such as diabetes mellitus or extensive vascular disease\\\\n* Treatment of neuroma with a narcotic analgesic\\\\n* Other painful foot pathology\\\\n* Active cutaneous, or other disease, at the anticipated site of study drug injection\\\\n* Laboratory results that are both out of normal range and, in the opinion of the Investigator, clinically significant\\\\n* Drug or alcohol abuse within the past 2 years\\\\n* Require regular oral steroid medication, except for stable use (6 months or longer on the same scheduled dose) for mild or moderate asthma\\\\n* Use of an investigational medication in the 30 days prior to the current study or scheduled to receive such an agent while participating in the current study\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n\\\\nAccepts Healthy Volunteers: No\\\\n\"}'}, {'id': 'NCT01632709', 'distance': 115.89321899414062, 'document': '{\"metadata\": {\"NCT_ID\": \"NCT01632709\", \"Brief_Title\": \"Pathophysiology of Post Amputation Pain\", \"Official_title\": \"Pathophysiology of Post Amputation Pain\", \"Conditions\": [\"Amputation Stumps\", \"Neuroma\"], \"Interventions\": [\"Drug: Bupivacaine\", \"Drug: Placebo\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE4\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"SINGLE\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nThe purpose of this study is to see how Post Amputation Pain (PAP) affects the body and brain by using sensory testing (such as pinprick testing), taking pictures of your brain (using a functional magnetic resonance imaging (fMRI) machine) and biomedical interventions (such as an injection of pain medicine). All medicines and the fMRI machine used during this study are FDA approved. The investigators hope that by learning the causes of PAP, the investigators can help future amputees.\\\\n\\\\nDetailed Description \\\\nYour participation in this study will last for 5 weeks and you will be asked to come to a total of 3 visits. The first visit will be during the first week of the study, the second visit during the second week of the study and the third (final) visit will be during the fifth (and final) week of the study. For your first visit you will have a physical examination with some sensory stimulation tests (such as vibration and pinprick tests), some questionnaires about your health and pain history, hot and cold sensory tests, and we will take thermal pictures of your body before and after receiving a quick electrical stimulus. You will also be trained on how to use the finger-span device to rate your pain during the second visit, and how to use an electronic pain diary to record your pain scores three times a day during the five weeks of the study.\\\\n\\\\nThe second visit will begin with questionnaires from the first visit and thermal images with a quick electrical stimulus. You will then be brought to an fMRI scanner room at Northwestern University. For an hour and fifteen minutes we will take pictures of your brain and these pictures will help us understand the changes in your brain relating to pain. You will then be put into one of four treatment groups randomly.\\\\n\\\\nThe study treatment that you will get will be decided randomly or by chance, like flipping a coin. Injections in this study will use the local anesthetic bupivacaine (a long lasting drug like the numbing agent novocaine used by dentists). This drug causes numbness, blocks pain and other nerve function near the injection site for 6-8 hours. Group 1 will get a sympathetic nerve block of bupivacaine, which changes how your nerves transmit pain, in either the neck or lower back (depending on where the amputation is located), Group 2 will get a placebo injection (no active medicine) in either the neck or lower back (depending on where the amputation is located), Group 3 will get a neuroma injection of bupivacaine (a neuroma is a group of nerves at the end of your residual limb), and Group 4 will get a placebo injection (no active medicine) at the neuroma. Some people get the bupivacaine injection and some people get the placebo injection so that we can compare the groups and see if the bupivacaine brings more, less or the same pain relief as a placebo injection. We scan your brain before the injection so that we can see how your brain responds to pain. We also scan your brain after the injection so that we can see if your brain responds differently to pain after the injection has been done.\\\\n\\\\nYou will know the location of your injection before you receive the treatment (neck, lower back or neuroma on your affected limb), but you will not know if you are getting a pain medication injection or placebo injection. Only the study doctors will know this information, and it can be told to you in case of an emergency. After the injection, you will have a second hour of brain scanning. After the scanning, you will be asked to complete some questionnaires, sensory tests, hot and cold temperature testing and we will take thermal pictures of your body before and after a quick electrical stimulus.\\\\n\\\\nYour third visit will be four weeks after your second visit. For your third visit you will have the same questionnaires as during the first and second visits, sensory tests, hot and cold temperature testing and we will take thermal pictures of your body before and after a quick electrical stimulus.\\\\n\\\\nIntervention \\\\n- DRUG : Bupivacaine \\\\n\\\\t- one injection of 10ml of .25%, - DRUG : Placebo \\\\n\\\\t- Dry needling\\\\n\\\\t- Dry needling\", \"criteria\": \"Inclusion Criteria:\\\\n\\\\n* At least 18 years\\\\n* Able to read and speak English and provide informed consent\\\\n* Single Amputation, upper or lower.\\\\n* Subject has chronic post amputation pain lasting longer than three months\\\\n* Subject has healed amputation wounds\\\\n* Pain must be >=3 on a scale of 0 <= age <= 10, 0 being no pain, 10 being the worse pain imaginable.\\\\n* If subjects pain is non-existent during fMRI scans, the subject needs to be willing to have their pain induced by targeting pain trigger points (for example, study\\'s postdoctoral fellow would massage certain regions of the affected limb to trigger PAP).\\\\n* Subject agrees to 1) Stop taking all aspirin seven days prior to their second visit (Bayer,Ecotrin,Alka Seltzer, etc.) 2) All inflammatory medications 48 hours prior to their second visit (Advil, Motrin, Indocin, Lodine , Ibuprofen, Aleve, Naproxen, etc. 3) Supplements such as Vitamin E and Fish Oil 48 hours prior to their second visit.\\\\n* Subject agrees to continue other prescribed medications.\\\\n* Subject is willing to have hypodermic needle injections and images taken of them (digital, thermal, and fMRI).\\\\n* Able to understand and comply with all data collection methodology including electronic diary.\\\\n* If female, is not pregnant and not currently attempting to conceive; if of childbearing potential, use of a highly effective method of birth control (as determined by Pl).\\\\n\\\\nExclusion Criteria:\\\\n\\\\n* Subject is allergic to Isovue 300 or amide-type local anesthetics such as bupivicaine, lidocaine, or mepivacaine.\\\\n* Subject has a diagnosis of bleeding diathesis or an immune compromise.\\\\n* Subject has pain that is more severe than their post amputation pain.\\\\n* Subject has a clinical diagnosis of fibromyalgia.\\\\n* Subject has metal shavings and or is frequently in an environment where there is metal work being done or significant amounts of metal shavings.\\\\n* Subject has ferrous metal implants, aneurism clips, bioelectric devices, and other implants which can be affected by the magnetic field of the MRI.\\\\n* Subject is claustrophobic.\\\\n* Subject weighs more than 300 pounds.\\\\n* Subject plans to start new pain treatments or therapies during the study (e.g. new pain medication, injections, PT, surgery).\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n\\\\nAccepts Healthy Volunteers: Yes\\\\n\"}'}, {'id': 'NCT02283957', 'distance': 122.37474060058594, 'document': '{\"metadata\": {\"NCT_ID\": \"NCT02283957\", \"Brief_Title\": \"A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\", \"Official_title\": \"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\", \"Conditions\": [\"Painful Intermetatarsal Neuroma (Morton\\'s Neuroma)\"], \"Interventions\": [\"Drug: CNTX-4975\", \"Other: Placebo\"], \"Location_Countries\": [\"United States\"], \"Study_Design\": {\"Study_Type\": \"INTERVENTIONAL\", \"Phase\": [\"PHASE2\"], \"Primary_Purpose\": \"TREATMENT\", \"Allocation\": \"RANDOMIZED\", \"Interventional Model\": \"PARALLEL\", \"Masking\": \"DOUBLE\"}}, \"description\": \"Study Description \\\\nBrief Summary \\\\nStudy 4975-MN-202 is a double-blind, placebo-controlled, parallel group, single-injection study in which subjects will be randomized to receive three doses of CNTX-4975 or placebo injected into the intermetatarsal space around a Morton\\'s neuroma. The injection of study medication will be administered by ultrasound-guided needle placement following ankle block anesthesia. The study staff will telephone subjects at Week 1 postinjection and subjects will return to the clinic postinjection at Weeks 2, 4, 8, and 12 for study assessments.\\\\n\\\\nIntervention \\\\n- DRUG : CNTX-4975 , - OTHER : Placebo \", \"criteria\": \"Inclusion criteria:\\\\n\\\\n* Male or female aged >18 years at the time of the Screening Visit.\\\\n* Pain associated with intermetatarsal neuroma (Morton\\'s neuroma) for a minimum of 3 months prior to Screening.\\\\n* Diagnosis of Morton\\'s neuroma, confirmed by evidence of focal tenderness and pain in the distal third intermetatarsal space, AND either\\\\n\\\\n   * Presence of neuroma on ultrasound, or\\\\n   * Elicitation of Mulder\\'s sign or a positive Gauthier\\'s test.\\\\n* A mean neuroma foot pain score of 4 or greater during the 7 days prior to dosing (NPRS, 0 <= age <= 10) as rated daily at bedtime (9:00 PM \\\\u00b1 3 hours) for average pain with walking in the last 24-hours. At least 5 of 7 scores during the week prior to dosing must be recorded.\\\\n* Tried conservative treatment with analgesics (acetaminophen or nonsteroidal anti-inflammatory drugs) and non-pharmacologic therapy (such as wide shoes, orthotics, and/or arch supports) without complete success.\\\\n* Female not of childbearing potential, defined as post-menopausal for at least 1 year, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing one of the following medically acceptable methods of birth control throughout the study period:\\\\n\\\\n   * Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject\\'s usual menstrual cycle period) before investigational product (IP) administration.\\\\n   * Total abstinence from sexual intercourse since the last menses before IP administration.\\\\n   * Intrauterine device.\\\\n   * Double barrier method (condoms, sponge, diaphragm, with spermicidal jellies or cream).\\\\n* Willing and able to understand the study requirements, abide by the study restrictions, complete the study procedures, pain scales, and daily IWRS/IVRS entries, and to communicate meaningfully with the study personnel.\\\\n* Signed an Informed Consent Form approved by the Institutional Review Board.\\\\n* Subject agrees to take only the rescue medications for neuroma foot pain from the time of screening through study completion, and agrees to discontinue all topical medications for neuroma pain after Screening.\\\\n\\\\nExclusion criteria:\\\\n\\\\n* Clinically significant bursitis in either foot.\\\\n* The subject has more than one painful intermetatarsal neuroma in the affected foot which, in the opinion of the Investigator, would interfere with evaluation of the symptoms and functional limitations that arise from the intermetatarsal neuroma in the affected foot.\\\\n* Radiography within 6 months of the Treatment Visit (Day 1) to exclude musculoskeletal pathology must be performed, to include any osseous abnormality such as stress fracture, osteophyte, tumor, or cyst in the bones or toes adjacent to the third inter-metatarsal space or any significant evidence of arthritis in the joints of the 3rd and 4th metatarsal-phalangeal joints or inter-phalangeal joints of the 3rd and 4th toes.\\\\n* Previous neurectomy in the same nerve.\\\\n* Any painful condition or prior surgery on the affected ankle or foot, which, in the judgment of the investigator, might adversely impact the interpretation of study data.\\\\n* Other painful foot pathology (e.g., bunion, hammertoe, plantar fasciitis etc.) or evidence of clinically meaningful ischemia which, in the judgment of the investigator and the medical monitor, would interfere with evaluation of the symptoms and functional limitations that arise from the intermetatarsal neuroma.\\\\n* Other chronic pain anywhere in the body that is greater than or equal to the intensity of foot pain from intermetatarsal neuroma.\\\\n* Signs of arterial insufficiency in the feet, including clinically meaningful edema.\\\\n* Current use of opioids for any condition.\\\\n* Corticosteroid injection in the affected foot within 30 days of Screening.\\\\n* History of clearly documented allergic reaction to local anesthetics or capsaicin.\\\\n* Prior use of injection with a sclerosing agent, such as alcohol or phenol, in the affected foot for Morton\\'s neuroma.\\\\n* Presence of any medical condition or unstable health status that, in the judgment of the investigator, might adversely impact the conduct of the study or resulting data, including chronic conditions that are likely to alter the rate of healing or are likely to result in safety complications unrelated to the study medication, such as uncontrolled diabetes mellitus or vascular disease.\\\\n* Regular use of anticoagulant blood thinners (except low-dose aspirin or Plavix which are allowed).\\\\n* Active cutaneous disease at the anticipated site of study drug injection that would prevent the safe administration of study drug.\\\\n* Ulcer or open wound anywhere on the affected foot.\\\\n* Clinically significant abnormal laboratory result at the Screening Visit (in the opinion of the investigator).\\\\n* Has diabetic neuropathy or other peripheral neuropathy in the affected foot.\\\\n* Use of an investigational medication in the 30 days prior to the current study or scheduled to receive such an agent while participating in the current study.\\\\n* Prior participation in an ALGRX-4975 or CNTX-4975 study.\\\\n* Has a history of substance use disorder within the previous year as defined by the Diagnostic and Statistical Manual for Mental Health Disorders, fifth edition, has current evidence for a substance use disorder, is receiving medicinal treatment for drug abuse, or tests positive upon urine drug screen for a substance of abuse.\\\\n* Has a positive pregnancy test at the Screening or Treatment Visit.\\\\n* Has any condition or is taking any medication that would be contraindicated for study participation.\\\\\"Sex\\\\\" : ALL\\\\n\\\\\"Ages\\\\\" : \\\\n- Minimum Age : 18 Years\\\\n\\\\nAccepts Healthy Volunteers: No\\\\n\"}'}]\n"
     ]
    }
   ],
   "source": [
    "# retrieve relevent studies from chromadb but exclude the ones that are already is the query\n",
    "def retrieve_relevant_studies(query, existing_study, n_results=5):\n",
    "    query_embedding = model.encode(query).tolist()\n",
    "    \n",
    "    results = collection.query(\n",
    "        query_embeddings=[query_embedding],\n",
    "        n_results=n_results + 1,\n",
    "    )\n",
    "    \n",
    "    filtered_results = []\n",
    "    for id, distance, document in zip(results['ids'][0], results['distances'][0], results['documents'][0]):\n",
    "        if id != existing_study:\n",
    "            filtered_results.append({\n",
    "                \"id\": id,\n",
    "                \"distance\": distance,\n",
    "                \"document\": document,\n",
    "            })\n",
    "        \n",
    "        if len(filtered_results) == n_results:\n",
    "            break\n",
    "    \n",
    "    return filtered_results\n",
    "\n",
    "print(\n",
    "    retrieve_relevant_studies(\"Effect of Kinesiotaping on Edema Management, Pain and Function on Patients With Bilateral Total Knee Arthroplasty [SEP] After being informed about the study and potential risk, all patients undergoing inpatient rehabilitation after bilateral total knee arthroplasty will have Kinesio(R)Tape applied to one randomly selected leg while the other leg serves as a control. Measurement of bilateral leg circumference, knee range of motion, numerical rating scale for pain, and selected questions from the Knee Injury and Osteoarthritis Outcome Score will occur at regular intervals throughout the rehabilitation stay. Patients will receive standard rehabilitation.\", \n",
    "                              \"NCT05013879\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import json_repair\n",
    "def related_studies_template(title: str, description: str, criteria: str):\n",
    "    return f\"\"\"Example Title: {title}\n",
    "Example Description: {description}\n",
    "Example Criteria: {criteria}\n",
    "\"\"\"\n",
    "\n",
    "def craft_context_from_studies_documents(related_studies: list[str]):\n",
    "    json_related_studies = [json.loads(i) for i in related_studies]\n",
    "    context = \"\"\n",
    "    for i in json_related_studies:\n",
    "        title = i.get('metadata', {}).get('Official_title', \"\")\n",
    "        description = i.get('description', \"\")\n",
    "        criteria = i.get('criteria', \"\")\n",
    "        if title and description:\n",
    "            context += f\"\"\"<STUDY>\n",
    "{related_studies_template(title, description, criteria)}\n",
    "</STUDY>\"\"\"\n",
    "    return context\n",
    "\n",
    "def get_messages_for_create_CoT(encoded_related_studies: str, title: str, description: str, desired_criteria: str):\n",
    "    user_prompt_template = \"\"\"<EXAMPLE_STUDIES>{encoded_related_studies}</EXAMPLE_STUDIES>\n",
    "\n",
    "Title: {title}\n",
    "Description: {description}\n",
    "Desired criteria: {desired_criteria}\n",
    "\n",
    "Task Instructions:\n",
    "1. Derive a step-by-step justification starting from the Title and Description provided, gradually building up to support the Desired criteria.\n",
    "2. Could use example studies (in the <EXAMPLE_STUDIES> section) if they support your justifications, but ensure the reasoning is well-explained and relevant to the study's context.\n",
    "4. Avoid mentioning that the criteria were already provided, and please do not cite the given criteria directly in your justification.\n",
    "5. You should give the justification first before giving out the criteria.\n",
    "\n",
    "Response Format:\n",
    "<STEP-BY-STEP-JUSTIFICATION>\n",
    "Your step by step justification here.\n",
    "</STEP-BY-STEP-JUSTIFICATION>\n",
    "<Criteria>\n",
    "The copied desired criteria here.\n",
    "</Criteria>\n",
    "\"\"\"\n",
    "    return [\n",
    "        {\"role\": \"system\", \"content\": \"You are a justifier chatbot designed to generate step-by-step justifications that derived form the Title and Description of a study and then gradually build up to the Desired criteria. Your task is to analyze the title and description of a study and build logical, step-by-step justifications that connect the studyâ€™s key elements to the desired criteria. Reference related example studies if they reinforce your justifications. You must assume the desired criteria are correct (as it was already reviewed by specialists) and develop arguments to support them based on the study context and relevant research insights.\"},\n",
    "        {\"role\": \"user\", \"content\": user_prompt_template.format(encoded_related_studies=encoded_related_studies, title=title, description=description, desired_criteria=desired_criteria)},\n",
    "    ]\n",
    "\n",
    "def get_prompt_from_studies(study_info: dict):\n",
    "    metadata = json_repair.loads(fix_invalid_json(study_info.get('metadata')))\n",
    "    title = metadata.get('Official_title')\n",
    "    description = study_info.get('data')\n",
    "    study_id = metadata.get('NCT_ID')\n",
    "    desired_criteria = study_info.get('criteria')\n",
    "\n",
    "    # Ensure we have the minimum required information\n",
    "    if not title or not description or not desired_criteria or not study_id:\n",
    "        print(f\"Skipping study {study_id}: Missing title or description or desired criteria or study id\")\n",
    "        return None\n",
    "\n",
    "    query = f'{title} [SEP] {description}'\n",
    "    relevant_studies = retrieve_relevant_studies(query, study_id)\n",
    "    encoded_related_studies = craft_context_from_studies_documents([i['document'] for i in relevant_studies])\n",
    "    messages = get_messages_for_create_CoT(encoded_related_studies, title, description, desired_criteria)\n",
    "    return messages\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/31840 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'metadata': '{\\n\"NCT_ID\" : \"NCT00933777\",\\n\"Brief_Title\" : \"SORAVE - Sorafenib and Everolimus in Solid Tumors\",\\n\\n\"Official_title\" : \"SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors\",\\n\\n\"Conditions\" : [Unspecified Adult Solid Tumor, Protocol Specific, Non-Small Cell Lung Cancer],\\n\\n\"Interventions\" : [Drug: Combination of sorafenib and everolimus],\\n\\n\"Location_Countries\" : [Germany],\\n\\n\"Study_Design\" : {\\n\"Study_Type\" : \"INTERVENTIONAL\",\\n\"Phase\" : [PHASE1],\\n\"Primary_Purpose\" : \"TREATMENT\",\\n\"Allocation\" : \"NA\",\\n\"Interventional Model\" : \"SINGLE_GROUP\",\\n\"Masking\" : \"NONE\"\\n }\\n}', 'data': 'Study Description \\nBrief Summary \\nDose finding part: A phase I clinical trial to evaluate the safety of combined sorafenib and everolimus treatment in patients with relapsed solid tumors (finished).\\n\\nExtension part:Treatment of non-small cell lung cancer (NSCLC) with KRAS mutation after â‰¥ 1st relapse (recruiting)\\n\\nDetailed Description \\nDose finding part: Patients will be recruited to receive combination of defined sorafenib dose (2x400mg) with increasing dose of everolimus (2.5mg, 5mg, 7.5mg, 10mg). There will be a run-in phase of 14 days of everolimus followed by combination sorafenib+everolimus starting from day 15. The combination will be continued as long as it is tolerated by the patient and the patient benefits from the treatment according to RECIST criteria. The maximal tolerated dose will be establish in 3+3 design. Patients will be recruited sequentially at least 14 days apart. The next dose level according to 3+3 design will be initiated if all patients on the previous dose level reach day 29.\\n\\nExtension part: Patients will be treated with a dose of 7,5 mg Everolimus for 14 days (run-in phase) and sorafenib 2x 400 mg until progression\\n\\nIntervention \\n- DRUG : Combination of sorafenib and everolimus \\n\\t- Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg\\n\\t- Nexavar, RAD001', 'criteria': 'Inclusion Criteria:\\n\\n* Patients with solid tumors relapsed after and/or refractory to standard therapy (dose finding part), KRAS mutated NSCLC patients after >= 1st relapse for the extension phase\\n* >= 18 years\\n* Performance status ECOG 0 <= age <= 2\\n* Life expectancy of at least 12 weeks\\n* Subjects with at least one measurable (CT or MRI) lesion\\n* Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:\\n\\n  * Hemoglobin >= 9.0 g/dL\\n  * Absolute neutrophil count (ANC) >= 1,500 /mm3\\n  * Platelet count >= 100 000/ÂµL\\n  * Total bilirubin <= 1,5x upper limit of normal (ULN)\\n  * ALT and AST <= 2,5x ULN (<= 5x ULN for patients with liver involvement)\\n  * Alkaline phosphatase < 4x ULN\\n  * Potassium within normal limits (WNL) or correctable with supplements\\n  * Total calcium (corrected for serum albumin) WNL or correctable with supplements\\n  * Magnesium WNL or correctable with supplements\\n  * PT-INR/PTT < 1.5 x ULN [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]\\n  * Serum creatinine <= 1.5 x upper limit of normal or creatinine clearance (CrCl) >= 50 ml/min calculated by either Cockcroft-Gault or by 24 hours urine collection\\n* More than 14 days since previous systemic therapy, radiotherapy and surgery\\n* Negative urine or serum HCG in women of childbearing potential\\n* Signed and dated informed consent before the start of specific protocol procedures\\n\\nExclusion Criteria:\\n\\n* Squamous cell carcinoma histology in non-small cell lung cancer\\n* History of cardiac disease: congestive heart failure > NYHA class 2; active Coronary Arterial Disease (CAD), (MI more than 6 months prior to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (except, when controlled by beta blockers or digoxin) or uncontrolled hypertension; for Extension phase: Long QT-Syndrome\\n* Active skin, mucosa, ocular or GI disorders of grade > 1\\n* Uncontrolled diabetes\\n* >= grade 3 hypercholesterolemia/hypertriglyceridemia or >= grade 2 hypercholesterolemia / hypertriglyceridemia with history of CAD (despite lipid lowering treatment if given)\\n* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus and sorafenib (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)\\n* History of HIV infection or previously sero-positive for the virus\\n* History of Hepatitis B or/and C or previously sero-positive for the Hepatitis B or/and C virus\\n* Leptomeningeal or uncontrolled brain metastases, including patients who continue to require glucocorticoids or intrathecal chemotherapy for brain or leptomeningeal metastases (documented by lumbar puncture)\\n* Treatment with any other investigational drugs within the previous 14 days\\n* Patients with seizure disorder requiring anti-epileptics\\n* History of organ allograft\\n* Patients with evidence or history of bleeding diathesis\\n* Patients undergoing renal dialysis\\n* Previous treatment with mTOR inhibitors and/or known hypersensitivity to mTOR inhibitors\\n* Past or current history of cancer other than the entry diagnosis EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry\\n* Any person being in an institution on assignment of the respective authority\\n* Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information\\n* Women who are pregnant or breast feeding, or women who are able to conceive and unwilling to practice an effective method of birth control (safe hormonal methods or/and barrier contraception) during study and 2 months after the last study drug intake\\n\\nFor Extension part:\\n\\n* Patients with medication that prolongs QTc and cannot be withdrawn (if the QTc prolonging medication is withdrawn - there must be a time interval of at least 7 days before starting treatment with sorafenib, in case of amiodarone the time interval is at least 90 days)\\n* Testing for Hepatitis B is mandatory\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n', '__index_level_0__': 31648}\n",
      "[{'role': 'system', 'content': 'You are a justifier chatbot designed to generate step-by-step justifications that derived form the Title and Description of a study and then gradually build up to the Desired criteria. Your task is to analyze the title and description of a study and build logical, step-by-step justifications that connect the studyâ€™s key elements to the desired criteria. Reference related example studies if they reinforce your justifications. You must assume the desired criteria are correct (as it was already reviewed by specialists) and develop arguments to support them based on the study context and relevant research insights.'}, {'role': 'user', 'content': '<EXAMPLE_STUDIES><STUDY>\\nExample Title: Phase 1 Dose Escalation Study With Sorafenib in Combination With Sirolimus in Patients With Solid Tumor\\nExample Description: Study Description \\nBrief Summary \\nThe purpose of the trial is to identify the recommended dose of sorafenib and sirolimus for combination therapy in subsequent phase 2 trials.\\n\\nIntervention \\n- DRUG : Sorafenib , - DRUG : Sirolimus \\nExample Criteria: Inclusion Criteria:\\n\\n* Patients with histological or cytological confirmed advanced solid tumor, which is refractory to standard therapies or for which no standard therapy exists and for which there is a rationale for the therapeutic use of a combination of sorafenib and sirolimus (especially metastic RCC, malignant melanoma, HCC, NSCLC, pancreatic cancer, hormone refractory prostate cancer).\\n* Men or women of at least 18 years\\n* Patients who have an ECOG status of 0 or 1\\n* Patients who have a life expectancy of at least 12 weeks\\n* Adequate bone marrow, liver and renal function\\n* Negative pregnancy test for female patients of childbearing potential\\n* Women and men enrolled into this trial must use adequate birth control measures during the course of the trial.\\n* Signed informed consent\\n\\nExclusion Criteria:\\n\\n* History of serious cardiac disease\\n* Active clinically serious bacterial, viral or fungal infections (> grade 2).\\n* Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.\\n* Clinically symptomatic brain or meningeal metastasis.\\n* Patients with seizure disorders requiring medication (such as steroids or antiepileptics).\\n* Patients with evidence or history of bleeding diathesis.\\n* Substance abuse, medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results.\\n* Concomitant treatment with strong CYP3A4 inductors (such as rifampicin, St. JohnÂ´s Wort) or CYP3A4 inhibitors (such as ketoconazole, voriconazole, itraconazole, diltiazem, verapamil, erythromycin). Moderate or weak CYP3A4 modifiers should be used concomitantly only after careful assessment of risk-benefit ratio. Concomitant use of carbamazepine, phenobarbital, phenytoin or chronic use of dexamethasone is excluded\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: A Phase I Study to Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVARÂ®) Treatment in Patients With Solid Tumor\\nExample Description: Study Description \\nBrief Summary \\nThe proposed initial trial is a Phase I, open label study to evaluate the safety and explore efficacy of MG005 in combination with sorafenib in patients with solid tumor. The eligible patients will receive 200 mg of sorafenib with 3 pre-defined dose levels of GW5074, escalated from 750 mg to 1500 mg (daily dose), to determine the Maximum Tolerated Dose (MTD) and dose limiting toxicities (DLT) (if any) at Phase I stage.\\n\\nIntervention \\n- DRUG : MG005 \\n\\t- Phase I:\\n\\nEligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy.\\nExample Criteria: Inclusion Criteria:\\n\\n* Patient who is able to understand the nature of this study and accepts to enter the study by signing written informed consent\\n* Patients who are >= 20 years\\n* Patients with histologically confirmed advanced or metastatic disease that is either refractory to or intolerant of existing standard therapy or for which no effective standard therapy that confers clinical benefit is available (patients may have received prior therapy with sorafenib if not intolerable)\\n* Patient has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\\n* Patient able to provide either an archived tumor sample or with accessible tumor for biopsy and willingness to provide it prior to initiation of study treatment\\n* At least 4 weeks post any therapeutic modalities (e.g., surgery, radiotherapy, and therapeutic agents) prior to initial dosing except the palliative radiotherapy performed on non-study-related local lesions\\n* Eastern Cooperative Oncology Group (ECOG) performance score <= 2 8.Patient\\'s life expectancy of at least 3 months\\n\\n*Patient has adequate hematopoietic, hepatic function and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:\\n\\n* Hemoglobin >= 9.0 g/dL\\n* Absolute neutrophil count (ANC) >= 1,500 cells/Î¼L\\n* Total white blood cell (WBC) >= 3,000 cells/Î¼L\\n* Platelet >= 100,000 counts/Î¼L\\n* Total bilirubin <= 1.5Ã— upper limit of normal (ULN) and no sign of jaundice\\n* ALT and AST <= 2.5Ã— ULN (<= 5Ã— ULN for patients with liver involvement)\\n* ALP <= 5Ã— ULN\\n* Creatinine <= 1.5Ã— ULN\\n* Potassium, total calcium and magnesium within normal limits or correctable with supplements 10.Patient is able to take food and drug orally. 11.Patient is able to correctly operate the provided digital sphygmomanometer. 12.Female patient with childbearing potential should be confirmed of not being pregnant or not lactating at the screening and during the study.\\n\\n  13.Patient is willing to comply with protocol-stated requirements, instructions and restrictions.\\n\\nExclusion Criteria:\\n\\n* Patient who has participated in other investigational studies and received any investigational therapy within 4 weeks prior to study dosing\\n* Patient carries history of primary malignancy other than the entry diagnosis except curatively treated non-melanoma skin cancer, cervical carcinoma in situ, or superficial bladder tumors within 5 years prior to study entry.\\n* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of GW5074 and sorafenib (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)\\n* Patient with known leptomeningeal or brain metastasis (including those who require glucocorticoids or intrathecal chemotherapy) by radiologic/histological evidence, or only bone metastasis\\n* Patient with history of significant cardiac disease including superior vena cava, unstable angina, congestive heart failure > class 2 per New York Heart Association (NYHA) classification, cardiac arrhythmias, cardiac ischemia/infarction, long QT-syndrome (i.e., QTc > 450 msec for males and > 470 msec for females), poorly controlled hypertension (systolic blood pressure > 150 mm-Hg and/or diastolic blood pressure > 90 mm-Hg on anti-hypersensitive medications), and valvular heart disease\\n* History of organ or bone marrow transplant\\n* Patient who has not recovered from side/toxic effects of previous therapy (i.e., NCI-CTCAE grade 1 or less) prior to the first dose of study medications\\n* Patients who are receiving or with conditions requiring substances that are potent inducers of CYP3A4 activity (e.g., rifampin, St. John\\'s wort, phenytoin, carbamazepine, phenobarbital, and dexamethasone)\\n* Patients who are receiving or with conditions requiring sensitive substrates of CYP1A2, 1B1, 2C8, 2C19 and 3A4 with narrow therapeutic windows (e.g., theophylline, duloxetine, alosetron, tizanidine, repaglinide, omeprazole, S-mephenytoin, alfentanil, sirolimus, pimozide, and tacrolimus)\\n* History of stroke or transient ischemic attack within 6 months of study entry\\n* Patient with any hemorrhage/bleeding event (e.g., non-healing wound, ulcer, and bone fracture) >= NCI-CTCAE grade 2 within 28 days prior to study treatment, or history of bleeding diathesis or coagulopathy\\n* Patients with poorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months\\n* Patients with HIV, acute HBV, and HCV (except hepatitis carriers) infections\\n* Patient with known or suspected hypersensitivity to any agent given in the course of this trial\\n* Patient with underlying medical, mental or psychological conditions that would impair the treatment compliance, or in the opinion of the investigator would not permit to participate in the study\\n* Male and female patients (with child-bearing potential [between puberty and 2 years after menopause]) who are unwilling to practice an effective method of birth control (safe hormonal methods or/and barrier contraception) during the entire study period and 2 months after the last study drug intake\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 20 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Single Agent Sorafenib in Advanced Solid \"Tumors\": Phase II Evaluation of Dose Re-Escalation Following a Dose Reduction (IST000375)\\nExample Description: Study Description \\nBrief Summary \\nRATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.\\n\\nPURPOSE: This phase II trial is studying the side effects and best dose of sorafenib and to see how well it works in treating patients with advanced malignant solid tumors.\\n\\nDetailed Description \\nOBJECTIVES:\\n\\nPrimary\\n\\n* To evaluate the feasibility of re-escalating the dose of sorafenib tosylate in patients with advanced malignant solid tumors who initially required a dose reduction for toxicity, and dose escalation in those patients who are able to tolerate the initial dose.\\n\\nSecondary\\n\\n* To evaluate the efficacy of this drug in these patients who are able to tolerate a dose escalation initially or after a dose reduction compared to those who are unable to tolerate a dose escalation.\\n\\nTertiary\\n\\n* To evaluate the percentage and demographic characteristics of patients who are able to tolerate 2 dose escalations without a dose reduction.\\n\\nOUTLINE: This is a dose-finding study.\\n\\n* Course 1: Patients receive oral sorafenib tosylate twice daily at dose level 0 on weeks 1-4.\\n* Course 2: Patients experiencing no dose-limiting or intolerable toxicities receive oral sorafenib tosylate at dose level +1 twice daily on weeks 5-8; while patients experiencing dose-limiting or intolerable toxicities receive oral sorafenib tosylate at dose level -1 once daily on weeks 5-8.\\n* Course 3: Depending on whether or not patients are experiencing dose-limiting or intolerable toxicities, they are escalated to dose level 0 or dose level +2 (patients in both dose levels receive oral sorafenib tosylate twice daily) in weeks 9-12, or de-escalated to dose level 0 or dose level -2 (patients in dose level -2 receives oral sorafenib tosylate once every other day) in weeks 9-12.\\n* Maintenance therapy: Patients receive oral sorafenib tosylate at the dose level\\\\* attained at the end of course 3. Treatment continues in the absence of unacceptable toxicity.\\n* Dose level de-escalation for toxicity or dose re-escalation after a toxicity-related dose reduction allowed to a maximum level of the initial dose level of the maintenance therapy.\\n\\nAfter completion of study therapy, patients are followed for up to 1 year.\\n\\nIntervention \\n- DRUG : Sorafenib \\n\\t- Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.\\n\\t- Nexavar\\nExample Criteria: Inclusion Criteria\\n\\n* Histologically or cytologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective or solid tumor for which sorafenib is considered acceptable therapy\\n* Age > 18 years\\n* Performance Status 0 - 2\\n* Measurable or non-measurable disease.\\n* Adequate bone marrow, liver and renal function\\n* Any number of prior chemotherapy regimens are allowed.\\n* Any prior chemotherapy, immunotherapy or targeted therapy must have been completed at least 2 weeks prior to start of this protocol and all side effects resolved to grade 1 or less. Any prior radiation must have been completed at least 2 weeks prior to start of therapy.\\n* Women of childbearing potential must have a negative pregnancy test performed within 7 days prior to the start of treatment\\n* Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Men should use adequate birth control for at least three months after the last administration of sorafenib.\\n* Ability to understand and the willingness to sign a written informed consent.\\n* International normalized ratio < 1.5 or a Prothrombin Time/Partial thromboplastin time within normal limits.\\n\\nExclusion Criteria\\n\\n* Prior therapy with sorafenib or sunitinib.\\n* Cardiac disease: Congestive heart failure > class II New York Heart Association.\\n* Symptomatic or uncontrolled brain metastasis.\\n* No component of squamous carcinoma can be present in any patient with non-small cell lung cancer\\n* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.\\n* Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.\\n* Known HIV infection or chronic Hepatitis B or C.\\n* Active clinically serious infection > CTCAE Grade 2.\\n* Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.\\n* Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug.\\n* Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.\\n* Serious non-healing wound, ulcer, or bone fracture.\\n* Evidence or history of bleeding diathesis or coagulopathy\\n* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug.\\n* Use of St. John\\'s Wort or rifampin\\n* Known or suspected allergy to sorafenib or any agent given in the course of this trial.\\n* Any condition that impairs patient\\'s ability to swallow whole pills.\\n* Any significant malabsorption problem.\\n* Therapy with bevacizumab < 3 months prior to first dose of study drug.\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors\\nExample Description: Study Description \\nBrief Summary \\nThis Phase 1 study will be conducted in an open-label, non-randomized, dose-escalation design in subjects with advanced, metastatic or refractory solid malignancy who are not candidates for standard therapy. The study drugs are sorafenib and eribulin mesylate.\\n\\nUp to 24 subjects with solid tumors will participate in the dose escalation part of the study, and once the maximum tolerated dose is defined, up to 30 subjects with advanced, metastatic or refractory solid tumors will participate in the expansion phase of the study.\\n\\nEribulin (mesylate) will be administered intravenously at a fixed dose of 1.4 mg/m2 on Days 1 and 8 of 21-day Cycles.\\n\\nThe starting sorafenib dose (Dose Level 1) is 200 mg twice daily. Sorafenib is given orally, continuously on days 11 to 21 of Cycle 1, and from Day 1 to Day 21 of all subsequent cycles. If 200 mg sorafenib twice daily is tolerated with eribulin, the sorafenib dose will be escalated sequentially to 200 mg morning dose and 400 mg evening dose (Dose Level 2) in a new cohort. If Dose Level 2 is tolerated, a second dose escalation to 400 mg twice daily (Dose Level 3) will be studied in a new cohort. If the starting dose of sorafenib is not tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg once daily in a new cohort. Subjects will need to receive two cycles of eribulin plus sorafenib therapy and safety data for the first and second cycle needs to be available before the start of the next cohort.\\n\\nIntervention \\n- DRUG : Sorafenib (Nexavar, BAY43-9006) \\n\\t- Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).\\n\\nIf sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort., - DRUG : Eribulin \\n\\t- Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.\\nExample Criteria: Inclusion Criteria:\\n\\n* Subjects with advanced, metastatic or refractory solid malignancy who are not candidates for standard therapy. For subject with metastatic breast cancer, prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.\\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\\n* Adequate bone marrow, cardiac, liver, renal and pancreatic function\\n* Predicted life expectancy of at least 12 weeks\\n\\nExclusion Criteria:\\n\\n* Prolonged corrected QT (QTc), defined as QTcF (QT interval corrected for heart rate according to Fridericia) interval > 450 msec at screening by central reader\\n* Cardiac disease: Congestive heart failure > NYHA Class II; subjects must not have unstable angina (angina symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months; cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\\n* Arterial or venous thrombi, including cerebrovascular accident and myocardial infarction in the past 6 months\\n* Pulmonary hemorrhage event >= CTCAE (common toxicity criteria for adverse events) Grade 2 within 4 weeks\\n* Any other hemorrhage/bleeding event >= CTCAE Grade 3 within 4 weeks\\n* Chemotherapy, hormonal therapy, investigational drugs, or radiotherapy within the last 28 days and/or not recovered (< Grade 1) from prior therapy. Start of study treatment is allowed within less than 28 days of the prior therapy provided that 5 half-lives of the prior treatment drug(s) have elapsed.\\n* Use of medication that may prolong QTc\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-type Specific Expanded Cohorts at the Recommended Phase 2 Dose\\nExample Description: Study Description \\nBrief Summary \\nThis phase I trial studies the side effects and best dose of giving vorinostat and sorafenib tosylate together in treating patients with kidney or non-small cell lung cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may stop the growth of solid tumors by blocking blood flow to the tumor. Giving vorinostat together with sorafenib tosylate may kill more tumor cells.\\n\\nDetailed Description \\nThe main purpose of this study is to:\\n\\n* Evaluate the safety of vorinostat in combination with sorafenib.\\n* Determine the largest dose of vorinostat + sorafenib that can be given safely to humans.\\n* Determine if vorinostat + sorafenib are effective in stopping tumors from growing or in decreasing their size.\\n* Study the side effects of vorinostat + sorafenib.\\n\\nIntervention \\n- DRUG : Sorafenib \\n\\t- Given by mouth\\n\\t- NexAVAR, - DRUG : Vorinostat \\n\\t- Given by mouth\\n\\t- Zolinza\\nExample Criteria: Inclusion Criteria:\\n\\n* Parts A: Histologically or cytologically documented solid tumor malignancy or non-Hodgkin\\'s lymphoma (Part B: renal cell carcinoma, Part C: non-small cell lung carcinoma) with clinical evidence of advanced and/or metastatic disease, which is refractory to established forms of therapy or for which no effective therapy exists, or for which sorafenib alone would be considered by the investigator as an appropriate therapy; patients who have refused available standard therapies would also be deemed eligible\\n* In Part A, evaluable disease by radiology and/or a recognized serum tumor marker is required; in Parts B and C, measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) is required\\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2\\n* Predicted life expectancy >= 12 weeks\\n* Patients may have had prior therapy, providing the following conditions are met:\\n\\n  * Patients must have recovered from any treatment related toxicities (with the exception of alopecia) to <= CTC grade 1 (fatigue, and neurotoxicity at grade 2 are permissible if stable for > 3 months) prior to registration\\n  * Chemotherapy: A minimum of 5 predicted half-lives of the agent must have elapsed between the end of treatment and registration on to the study; when half-lives are not available the principle of 2 weeks for once daily medications and 3 weeks for agents given less frequently will be adopted, but discussion with the principal investigator is recommended\\n  * Hormonal therapy: Patients may have had prior anticancer hormonal therapy provided it is discontinued > 4 weeks prior to registration into the study; however, patients with prostate cancer with evidence of progressive disease may continue on therapy which produces medical castration (eg, goserelin or leuprorelin) provided this was commenced at least three months earlier\\n  * Radiation: Patients may have had prior radiation therapy that has not exceeded 25% of bone marrow reserve provided that they have recovered from the acute, toxic effects of radiotherapy prior to registration; a minimum of 7 days must have elapsed between the end of radiotherapy to non-target lesions and registration into the study (minimum of 28 days for target lesions)\\n  * Surgery: Previous surgery is permitted provided that wound healing has occurred prior to registration\\n* Supportive therapy including bisphosphonates is permissible; previous use of myeloid and erythroid growth factor support is permissible, but not within 2 weeks of commencement of study; primary prophylactic use of myeloid and erythroid growth factors is not permitted within the study, but intervention or secondary prophylaxis is permitted if instituted following the documentation of >= grade 3 neutropenia or >= grade 2 anemia (hemoglobin)\\n* International Normalized Ratio (INR) < 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits; patients receiving anticoagulation treatment with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, the INR should be measured prior to initiation of sorafenib/vorinostat and monitored at least weekly, or as defined by the local standard of care, until INR is stable; vorinostat and sorafenib have both been reported to elevate INR in those on coumadin derivatives\\n* Neutrophil count >= 1.5 x 10^9/L\\n* Platelet count >= 75 x 10^9/L\\n* Bilirubin <= 1.5 x Upper limit of normal (ULN)\\n* Aspartate aminotransferase (AST) and/or alanine transaminase (ALT) <= 2.5 x ULN (ie, <= CTC grade 1) or <= 5 x Upper limit of normal (UNL) if patient has documented liver metastases (ie, <= CTC grade 2)\\n* Serum creatinine <= 1.5 x ULN\\n* Patient must be accessible for repeat dosing and follow-up\\n* Patients - both males and females - with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study; women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration\\n* Patients must provide verbal and written informed consent to participate in the study, including pharmacokinetic sampling\\n\\nExclusion Criteria:\\n\\n* Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient\\'s ongoing participation in the study\\n* History of any psychiatric condition that might impair the patient\\'s ability to understand or to comply with the requirements of the study or to provide informed consent\\n* Concurrent anticancer therapy (with the exception of hormonal therapies as discussed above)\\n* Pregnant or breast-feeding females (documented methods of birth control are required in those with reproductive potential)\\n* Symptomatic brain metastases which are not stable, require steroids, or anti-epileptic medication\\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drugs\\n* History of grade 3 or greater toxicities with vorinostat or sorafenib previously at equivalent daily doses or lower than those planned on being administered within this study\\n* Exposure to other histone deacetylase (HDAC) inhibitors (e.g. sodium valproate) within 30 days of planned commencement of study drugs, other exposures to HDAC inhibitor and sorafenib in combination\\n* Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management\\n* Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C\\n* Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months\\n* Pulmonary hemorrhage/bleeding event >= Common Toxicity Criteria for Adverse EffectS (CTCAE) grade 2 within 4 weeks of first dose of study drug\\n* Any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks of first dose of study drug\\n* Serious non-healing wound, ulcer, or bone fracture\\n* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug\\n* Use of St. John\\'s Wort or rifampin (rifampicin)\\n* Known or suspected allergy to sorafenib, vorinostat or any planned agent given in the course of this trial\\n* Any condition that impairs patient\\'s ability to swallow whole pills\\n* Any clinically significant malabsorption problem\\n* Clinically significant, in the investigator\\'s opinion, pre-existing cardiac dysfunction or myocardial infarction within 6 months prior to planned commencement of study drugs\\n* Any other condition, which in the investigator\\'s opinion, would compromise the safety of the patient or the feasibility of completing the study objectives through the use of this patient\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY></EXAMPLE_STUDIES>\\n\\nTitle: SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors\\nDescription: Study Description \\nBrief Summary \\nDose finding part: A phase I clinical trial to evaluate the safety of combined sorafenib and everolimus treatment in patients with relapsed solid tumors (finished).\\n\\nExtension part:Treatment of non-small cell lung cancer (NSCLC) with KRAS mutation after â‰¥ 1st relapse (recruiting)\\n\\nDetailed Description \\nDose finding part: Patients will be recruited to receive combination of defined sorafenib dose (2x400mg) with increasing dose of everolimus (2.5mg, 5mg, 7.5mg, 10mg). There will be a run-in phase of 14 days of everolimus followed by combination sorafenib+everolimus starting from day 15. The combination will be continued as long as it is tolerated by the patient and the patient benefits from the treatment according to RECIST criteria. The maximal tolerated dose will be establish in 3+3 design. Patients will be recruited sequentially at least 14 days apart. The next dose level according to 3+3 design will be initiated if all patients on the previous dose level reach day 29.\\n\\nExtension part: Patients will be treated with a dose of 7,5 mg Everolimus for 14 days (run-in phase) and sorafenib 2x 400 mg until progression\\n\\nIntervention \\n- DRUG : Combination of sorafenib and everolimus \\n\\t- Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg\\n\\t- Nexavar, RAD001\\nDesired criteria: Inclusion Criteria:\\n\\n* Patients with solid tumors relapsed after and/or refractory to standard therapy (dose finding part), KRAS mutated NSCLC patients after >= 1st relapse for the extension phase\\n* >= 18 years\\n* Performance status ECOG 0 <= age <= 2\\n* Life expectancy of at least 12 weeks\\n* Subjects with at least one measurable (CT or MRI) lesion\\n* Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:\\n\\n  * Hemoglobin >= 9.0 g/dL\\n  * Absolute neutrophil count (ANC) >= 1,500 /mm3\\n  * Platelet count >= 100 000/ÂµL\\n  * Total bilirubin <= 1,5x upper limit of normal (ULN)\\n  * ALT and AST <= 2,5x ULN (<= 5x ULN for patients with liver involvement)\\n  * Alkaline phosphatase < 4x ULN\\n  * Potassium within normal limits (WNL) or correctable with supplements\\n  * Total calcium (corrected for serum albumin) WNL or correctable with supplements\\n  * Magnesium WNL or correctable with supplements\\n  * PT-INR/PTT < 1.5 x ULN [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]\\n  * Serum creatinine <= 1.5 x upper limit of normal or creatinine clearance (CrCl) >= 50 ml/min calculated by either Cockcroft-Gault or by 24 hours urine collection\\n* More than 14 days since previous systemic therapy, radiotherapy and surgery\\n* Negative urine or serum HCG in women of childbearing potential\\n* Signed and dated informed consent before the start of specific protocol procedures\\n\\nExclusion Criteria:\\n\\n* Squamous cell carcinoma histology in non-small cell lung cancer\\n* History of cardiac disease: congestive heart failure > NYHA class 2; active Coronary Arterial Disease (CAD), (MI more than 6 months prior to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (except, when controlled by beta blockers or digoxin) or uncontrolled hypertension; for Extension phase: Long QT-Syndrome\\n* Active skin, mucosa, ocular or GI disorders of grade > 1\\n* Uncontrolled diabetes\\n* >= grade 3 hypercholesterolemia/hypertriglyceridemia or >= grade 2 hypercholesterolemia / hypertriglyceridemia with history of CAD (despite lipid lowering treatment if given)\\n* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus and sorafenib (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)\\n* History of HIV infection or previously sero-positive for the virus\\n* History of Hepatitis B or/and C or previously sero-positive for the Hepatitis B or/and C virus\\n* Leptomeningeal or uncontrolled brain metastases, including patients who continue to require glucocorticoids or intrathecal chemotherapy for brain or leptomeningeal metastases (documented by lumbar puncture)\\n* Treatment with any other investigational drugs within the previous 14 days\\n* Patients with seizure disorder requiring anti-epileptics\\n* History of organ allograft\\n* Patients with evidence or history of bleeding diathesis\\n* Patients undergoing renal dialysis\\n* Previous treatment with mTOR inhibitors and/or known hypersensitivity to mTOR inhibitors\\n* Past or current history of cancer other than the entry diagnosis EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry\\n* Any person being in an institution on assignment of the respective authority\\n* Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information\\n* Women who are pregnant or breast feeding, or women who are able to conceive and unwilling to practice an effective method of birth control (safe hormonal methods or/and barrier contraception) during study and 2 months after the last study drug intake\\n\\nFor Extension part:\\n\\n* Patients with medication that prolongs QTc and cannot be withdrawn (if the QTc prolonging medication is withdrawn - there must be a time interval of at least 7 days before starting treatment with sorafenib, in case of amiodarone the time interval is at least 90 days)\\n* Testing for Hepatitis B is mandatory\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\nTask Instructions:\\n1. Derive a step-by-step justification starting from the Title and Description provided, gradually building up to support the Desired criteria.\\n2. Could use example studies (in the <EXAMPLE_STUDIES> section) if they support your justifications, but ensure the reasoning is well-explained and relevant to the study\\'s context.\\n4. Avoid mentioning that the criteria were already provided, and please do not cite the given criteria directly in your justification.\\n5. You should give the justification first before giving out the criteria.\\n\\nResponse Format:\\n<STEP-BY-STEP-JUSTIFICATION>\\nYour step by step justification here.\\n</STEP-BY-STEP-JUSTIFICATION>\\n<Criteria>\\nThe copied desired criteria here.\\n</Criteria>\\n'}]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Processed prompts: 100%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ| 1/1 [00:20<00:00, 20.64s/it, est. speed input: 386.98 toks/s, output: 62.89 toks/s]\n",
      "  0%|          | 1/31840 [00:20<183:05:34, 20.70s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['<STEP-BY-STEP-JUSTIFICATION>\\n\\nStep 1: The study aims to evaluate the safety of combined sorafenib and everolimus treatment in patients with relapsed solid tumors. This is evident from the title \"SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors.\" The description further supports this objective, stating that the study will be conducted in a dose-finding part to establish the maximal tolerated dose of the combination.\\n\\nStep 2: To achieve this objective, the study will recruit patients with solid tumors that have relapsed after and/or refractory to standard therapy. This is a common approach in phase I clinical trials, where the primary goal is to assess the safety and tolerability of a new treatment combination. As seen in the study \"A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors,\" the inclusion of patients with advanced solid tumors is a common criterion for phase I trials.\\n\\nStep 3: The study will also include patients with KRAS-mutated non-small cell lung cancer (NSCLC) after â‰¥ 1st relapse, as stated in the extension part of the study description. This is a specific subgroup of patients who may benefit from the combination of sorafenib and everolimus, as seen in the study \"A Phase I, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors,\" which also included patients with metastatic breast cancer.\\n\\nStep 4: Patients will be required to have a performance status of ECOG 0 â‰¤ age â‰¤ 2, indicating that they should be in good health and able to tolerate the treatment. This is a common inclusion criterion in clinical trials, as seen in the study \"Single Agent Sorafenib in Advanced Solid \"Tumors\": Phase II Evaluation of Dose Re-Escalation Following a Dose Reduction (IST000375),\" which also required patients to have a performance status of 0 - 2.\\n\\nStep 5: Patients will also need to have a life expectancy of at least 12 weeks, as stated in the study description. This is a common requirement in clinical trials, as seen in the study \"A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors,\" which also required patients to have a life expectancy of at least 12 weeks.\\n\\nStep 6: The study will also require patients to have measurable disease, as stated in the study description. This is a common inclusion criterion in clinical trials, as seen in the study \"A Phase I Study to Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR(R)) Treatment in Patients With Solid Tumor,\" which also required patients to have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\\n\\nStep 7: Patients will also need to have adequate bone marrow, liver, and renal function, as assessed by laboratory requirements. This is a common requirement in clinical trials, as seen in the study \"A Phase I, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors,\" which also required patients to have adequate bone marrow, cardiac, liver, renal, and pancreatic function.\\n\\nStep 8: Finally, patients will need to provide informed consent and meet other inclusion and exclusion criteria, as stated in the study description. This is a common requirement in clinical trials, as seen in the study \"A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors,\" which also required patients to provide informed consent and meet other inclusion and exclusion criteria.\\n\\n</STEP-BY-STEP-JUSTIFICATION>\\n<Criteria>\\n* Patients with solid tumors relapsed after and/or refractory to standard therapy (dose finding part), KRAS mutated NSCLC patients after >= 1st relapse for the extension phase\\n* >= 18 years\\n* Performance status ECOG 0 <= age <= 2\\n* Life expectancy of at least 12 weeks\\n* Subjects with at least one measurable (CT or MRI) lesion\\n* Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:\\n  * Hemoglobin >= 9.0 g/dL\\n  * Absolute neutrophil count (ANC) >= 1,500 /mm3\\n  * Platelet count >= 100 000/ÂµL\\n  * Total bilirubin <= 1,5x upper limit of normal (ULN)\\n  * ALT and AST <= 2,5x ULN (<= 5x ULN for patients with liver involvement)\\n  * Alkaline phosphatase < 4x ULN\\n  * Potassium within normal limits (WNL) or correctable with supplements\\n  * Total calcium (corrected for serum albumin) WNL or correctable with supplements\\n  * Magnesium WNL or correctable with supplements\\n  * PT-INR/PTT < 1.5 x ULN [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]\\n  * Serum creatinine <= 1.5 x upper limit of normal or creatinine clearance (CrCl) >= 50 ml/min calculated by either Cockcroft-Gault or by 24 hours urine collection\\n* More than 14 days since previous systemic therapy, radiotherapy and surgery\\n* Negative urine or serum HCG in women of childbearing potential\\n* Signed and dated informed consent before the start of specific protocol procedures\\n</Criteria>']\n",
      "{'metadata': '{\\n\"NCT_ID\" : \"NCT00337532\",\\n\"Brief_Title\" : \"A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer\",\\n\\n\"Official_title\" : \"A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer\",\\n\\n\"Conditions\" : [Head and Neck Cancer],\\n\\n\"Interventions\" : [Drug: Paclitaxel, Drug: cisplatin],\\n\\n\"Location_Countries\" : [Korea, Republic of],\\n\\n\"Study_Design\" : {\\n\"Study_Type\" : \"INTERVENTIONAL\",\\n\"Phase\" : [PHASE2, PHASE3],\\n\"Primary_Purpose\" : \"TREATMENT\",\\n\"Allocation\" : \"NON_RANDOMIZED\",\\n\"Interventional Model\" : \"SINGLE_GROUP\",\\n\"Masking\" : \"NONE\"\\n }\\n}', 'data': 'Study Description \\nBrief Summary \\nThe purpose of this clinical research study is to learn if a paclitaxel-cisplatin combination regimen given in the neoadjuvant setting is active in locally advanced head and neck cancer. the safety of this treatment will also be studied.\\n\\nIntervention \\n- DRUG : Paclitaxel \\n\\t- Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days Â± 3 days., - DRUG : cisplatin \\n\\t- solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days Â± 3 days.', 'criteria': 'Inclusion Criteria:\\n\\n* Locally advanced, Stage II-IV (except M1), hand and neck cancer\\n* > = 1 measurable lesion\\n* not been previously treated for head and neck cancer\\n\\nExclusion Criteria:\\n\\n* history of another malignancy\\n* organ allografts\\n* pre-exiting neuropathy > = CTC grade 2\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n- Maximum Age : 75 Years\\n\\nAccepts Healthy Volunteers: No\\n', '__index_level_0__': 29559}\n",
      "[{'role': 'system', 'content': 'You are a justifier chatbot designed to generate step-by-step justifications that derived form the Title and Description of a study and then gradually build up to the Desired criteria. Your task is to analyze the title and description of a study and build logical, step-by-step justifications that connect the studyâ€™s key elements to the desired criteria. Reference related example studies if they reinforce your justifications. You must assume the desired criteria are correct (as it was already reviewed by specialists) and develop arguments to support them based on the study context and relevant research insights.'}, {'role': 'user', 'content': '<EXAMPLE_STUDIES><STUDY>\\nExample Title: Induction Chemotherapy (IC) With Paclitaxel and Cisplatin (PC) Followed by Concomitant Chemoradiotherapy (CCRT) in Patient With Advanced Squamous Carcinoma of the Head and Neck (SSCHN).\\nExample Description: Study Description \\nBrief Summary \\nOver the last 30 years, induction chemotherapy (IC) has become important for the management of patients with locally advanced HNSCC (LAHNSCC), particularly since the introduction of taxanes. The results reported in the TAX 323 and TAX 324 trials indicate that the TPF regimen (docetaxel, cisplatin and 5-fluorouracil) improves overall survival comparing with the PF regimen (cisplatin and 5-fluorouracil), and the TPF regimen is globally the most accepted induction regimen for the treatment of LAHNSCC.\\n\\nHowever, the TPF regimen has been associated with high toxicity rates, and patients frequently decline cisplatin during concurrent radiotherapy and require the use of infusion pumps and a central venous catheter.\\n\\nExtensive efforts are ongoing to identify alternative schemes that are less toxic than the TPF regimen but are as effective for LAHNSCC and safely allow the use of definitive concurrent treatment based on cisplatin and radiotherapy.\\n\\nDetailed Description \\nThis non-randomized phase II trial evaluated the safety, feasibility and response rates of concurrent therapy (cisplatin and radiotherapy) after three cycles of an IC regimen based on the combination of cisplatin plus paclitaxel without 5-fluorouracil (5FU) (thereby avoiding infusion pumps and a central venous catheter) in LAHNSCC patients with a high tumor burden.\\n\\nThe patients were stratified by tumor subsite (oropharynx and hypopharynx/larynx) and by tumor resectable status (resectable or irresectable advanced squamous cell).\\n\\nIntervention \\n- DRUG : Induction TP chemotherapy \\n\\t- 3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.\\n\\t- Paclitaxel, Cisplatin, - RADIATION : Chemoradiotherapy (CRT) \\n\\t- Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.\\n\\t- Cisplatin, Radiotherapy, Concurrent chemoradiotherapy based on cisplatin\\nExample Criteria: Inclusion Criteria:\\n\\n* Histologically confirmed locally advanced squamous cell carcinoma of head and neck (stage III and IV) eligible to chemoradiotherapy.\\n* Presence of measurable disease\\n* >= 18 year\\n* ECOG performance status: 0 <= age <= 2\\n* Adequate bone marrow functions evidenced by: absolute neutrophil count >= 1.5 x 109/L; platelet count >= 100 x 109/L and hemoglobin >= 90 g/L\\n* Adequate renal function.\\n* Adequate hepatic function.\\n* Patients or their legal representatives must be able to read, understand and provide written informed consent to participate in the study.\\n\\nExclusion Criteria:\\n\\n* Any previous chemotherapy or radiotherapy\\n* Patients who have known hypersensitivity to paclitaxel or cisplatin\\n* Patients who are receiving concurrent investigational, biological or immune therapies\\n* Concomitant administration of high doses of systemic corticosteroids\\n* Known HIV or Hepatitis B or C (active, previously treated or both; testing is not required)\\n* Uncontrolled CNS disease (e.g., seizures not controlled with standard medical therapy)\\n* Clinically significant cardiovascular disease.\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n- Maximum Age : 76 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer\\nExample Description: Study Description \\nBrief Summary \\nThe purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer\\n\\nIntervention \\n- DRUG : Paclitaxel \\n\\t- Solution, IV, 100 mg/mÂ², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent\\n\\t- Taxol, BMS-181339\\nExample Criteria: Inclusion Criteria:\\n\\n* Patients with locally advanced head and neck cancer pretreated with surgery and/or radiotherapy and not suitable for further radical local treatment or patients with distant metastases who may have received no or one chemotherapy regimen\\n\\nExclusion Criteria:\\n\\n* Patients with serious, uncontrolled medical illness\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 20 Years\\n- Maximum Age : 74 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer\\nExample Description: Study Description \\nBrief Summary \\nThe purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer\\n\\nIntervention \\n- DRUG : Paclitaxel \\n\\t- Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent\\n\\t- Taxol, BMS-181339\\nExample Criteria: Inclusion Criteria:\\n\\n* Give written and voluntary informed consent.\\n* Patients with cytologically or histopathologically confirmed head and neck cancer (except for thyroid cancer)\\n* Patients with locally advanced head and neck cancer pretreated with surgery and/or radiotherapy (plus or minus one chemotherapy regimen) and not suitable for further radical local treatment or patients with distant metastases who may have received no or one chemotherapy regimen\\n* Patients must have measurable disease (lesion(s) with largest diameter of 10 mm or more)\\n* Patients with 4 weeks or longer interval from completion of previous therapy. (2 weeks for anti-metabolites, Biological Response Modifiers (BRM), Bisphosphonates and brain only or bone irradiation /among radiotherapy/). All reversible residual effects of previous therapy should have resolved or stabilized to the best degree, as can be reasonably expected.\\n* Performance Status of 0 - 2\\n* Patients with normal major organ functions (hematologic, hepatic and renal, etc.) and who met listed below requirements at the time of evaluation done within 2 weeks prior to the scheduled first drug administration date\\n* Neutrophil count: <= 2,000/uL\\n* Platelet count: <= 100,000/uL\\n* Hemoglobin: <= 9.0g/dL\\n* AST: < 100 IU/L\\n* ALT:< 100 IU/L\\n* Total bilirubin: <= 1.5 mg/dL\\n* Serum creatinine: <= 1.5 mg/dL\\n* Patients with expected survival period of at least 2 months or more from study initiation.\\n* Men and Women, with age range of 20 years and older to less than 75 years.\\n\\nExclusion Criteria:\\n\\n* Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study\\n* Women who are pregnant or breastfeeding\\n* Women with a positive pregnancy test on enrollment or prior to study drug administration\\n* Sexually active fertile men not using an effective method of birth control for the entire study period and for up to 8 weeks after the study\\n* Patients with CNS metastasis that are associated with clinical symptoms, and/or are associated with surrounding edema on CT scan or MRI, or that require concomitant therapy with steroids or anti-convulsants\\n* Patients with active second cancer (synchronous second cancer or the disease-free interval from the previous second primary cancer to the current cancer is less than 5 years)\\n* Patients with serious, uncontrolled medical illness (i.e., serious cerebrovascular disorders, uncontrolled hypertension or diabetes mellitus, severe infections or active gastric ulcer, etc.), or acute inflammatory disease, etc.\\n* Patients with interstitial pneumonia or pulmonary fibrosis by chest CT-scan or clinical symptoms (e.g., fever, cough, shortness of breath or dyspnea)\\n* Patients with body cavity fluid retention which requires treatment (or an intervention). However, those who show no re-accumulation of pleural effusion for 2 weeks or longer without use of chemotherapy drugs (BRM included) after post thoracentesis or a chest tube drainage are eligible for enrollment. In addition, those with water suction of pericardial effusion shall be ineligible for enrollment\\n* Patients who meet one of the following criteria;\\n* Either myocardial infarction or anginal attack within 6 months prior to this study participation\\n* Medical history of congestive heart failure\\n* Arrhythmia requiring treatment\\n* Conduction abnormality (Left bundle-branch block, Class II and above atrioventricular [AV] block)\\n* Patients with more than grade 1 peripheral neuropathy as graded by the NCI-CTC version 2.0 criteria\\n* Patients with a history of hypersensitivity due to administration of drugs containing polyoxyethylene castor oil (Cremophor EL) (e.g., cyclosporine), or hardened castor oil (e.g., vitamin preparations for injection, etc.)\\n* Patients with previous therapy with taxanes (e.g., paclitaxel, docetaxel)\\n* Patients received investigational agents within 4 weeks prior to this study participation\\n* Patients who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (e.g., infectious disease) illness\\n* Patients who don\\'t accept use of supportive therapies, i.e., blood transfusion for anemia\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 20 Years\\n- Maximum Age : 74 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)\\nExample Description: Study Description \\nBrief Summary \\nThis clinical trial is Phase II trial for evaluating efficacy of induction chemotherapy using Genexol-PM + cisplatin for locally advanced head and neck cancer. The investigators try to evaluate response rate of Genexol-PM + cisplatin chemotherapy, and safety profile.\\n\\nIntervention \\n- DRUG : genexolPM + cisplatin \\nExample Criteria: Inclusion Criteria:\\n\\n* locally advanced head and neck squamous cell carcinoma\\n* oral cavity, oropharynx, hypopharynx, larynx\\n* measurable lesion\\n* unresectable\\n* age 18 or more\\n* ECOG 0 or 1\\n\\nExclusion Criteria:\\n\\n* distant metastasis\\n* pregnancy\\n* prior chemotherapy or radiation therapy\\n* 2ndary malignancy\\n* other unfit medical condition\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n- Maximum Age : 75 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer\\nExample Description: Study Description \\nBrief Summary \\nThe purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects\\n\\nIntervention \\n- DRUG : Paclitaxel \\n\\t- Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent\\n\\t- Taxol, BMS-181339\\nExample Criteria: Inclusion Criteria:\\n\\n* Subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139 <= age <= 388) and should have continued therapy with paclitaxel as the discretion of the investigator\"Sex\" : ALL\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY></EXAMPLE_STUDIES>\\n\\nTitle: A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer\\nDescription: Study Description \\nBrief Summary \\nThe purpose of this clinical research study is to learn if a paclitaxel-cisplatin combination regimen given in the neoadjuvant setting is active in locally advanced head and neck cancer. the safety of this treatment will also be studied.\\n\\nIntervention \\n- DRUG : Paclitaxel \\n\\t- Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days Â± 3 days., - DRUG : cisplatin \\n\\t- solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days Â± 3 days.\\nDesired criteria: Inclusion Criteria:\\n\\n* Locally advanced, Stage II-IV (except M1), hand and neck cancer\\n* > = 1 measurable lesion\\n* not been previously treated for head and neck cancer\\n\\nExclusion Criteria:\\n\\n* history of another malignancy\\n* organ allografts\\n* pre-exiting neuropathy > = CTC grade 2\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n- Maximum Age : 75 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\nTask Instructions:\\n1. Derive a step-by-step justification starting from the Title and Description provided, gradually building up to support the Desired criteria.\\n2. Could use example studies (in the <EXAMPLE_STUDIES> section) if they support your justifications, but ensure the reasoning is well-explained and relevant to the study\\'s context.\\n4. Avoid mentioning that the criteria were already provided, and please do not cite the given criteria directly in your justification.\\n5. You should give the justification first before giving out the criteria.\\n\\nResponse Format:\\n<STEP-BY-STEP-JUSTIFICATION>\\nYour step by step justification here.\\n</STEP-BY-STEP-JUSTIFICATION>\\n<Criteria>\\nThe copied desired criteria here.\\n</Criteria>\\n'}]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Processed prompts: 100%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ| 1/1 [00:13<00:00, 13.55s/it, est. speed input: 261.79 toks/s, output: 72.09 toks/s]\n",
      "  0%|          | 2/31840 [00:34<145:59:17, 16.51s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['<STEP-BY-STEP-JUSTIFICATION>\\nStep 1: The study aims to evaluate the efficacy and safety of a paclitaxel-cisplatin combination regimen in the neoadjuvant setting for locally advanced head and neck cancer. This is evident from the title and description of the study, which mentions the purpose of learning if the combination regimen is active in locally advanced head and neck cancer and studying its safety.\\n\\nStep 2: To achieve this goal, the study will involve administering paclitaxel and cisplatin to patients with locally advanced head and neck cancer. The use of paclitaxel and cisplatin is supported by previous studies, such as the TAX 323 and TAX 324 trials, which demonstrated the efficacy of the TPF regimen (docetaxel, cisplatin, and 5-fluorouracil) in improving overall survival in patients with locally advanced head and neck cancer.\\n\\nStep 3: The study will involve patients with locally advanced, Stage II-IV (except M1), head and neck cancer, with at least one measurable lesion. This patient population is consistent with the inclusion criteria of other studies, such as the Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer, which included patients with locally advanced head and neck cancer pretreated with surgery and/or radiotherapy.\\n\\nStep 4: Patients who have not been previously treated for head and neck cancer will be eligible for the study. This is consistent with the inclusion criteria of the Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC), which included patients with locally advanced head and neck squamous cell carcinoma who had not received prior chemotherapy or radiation therapy.\\n\\nStep 5: Patients with a history of another malignancy, organ allografts, or pre-existing neuropathy greater than or equal to CTC grade 2 will be excluded from the study. This is consistent with the exclusion criteria of the Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer, which excluded patients with a history of another malignancy or pre-existing neuropathy.\\n\\nStep 6: The study will involve administering paclitaxel and cisplatin in a neoadjuvant setting, which is a common approach in the treatment of locally advanced head and neck cancer. This approach is supported by the results of the TAX 323 and TAX 324 trials, which demonstrated the efficacy of the TPF regimen in improving overall survival in patients with locally advanced head and neck cancer.\\n\\nStep 7: The study will involve patients aged 18 years or older, which is consistent with the age range of other studies, such as the Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer, which included patients aged 20-74 years.\\n\\nStep 8: The study will involve patients with a performance status of 0-2, which is consistent with the inclusion criteria of other studies, such as the Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC), which included patients with an ECOG performance status of 0 or 1.\\n\\nStep 9: The study will involve patients with adequate bone marrow functions, renal function, and hepatic function, which is consistent with the inclusion criteria of other studies, such as the Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer, which included patients with normal major organ functions.\\n\\nStep 10: The study will involve patients with a life expectancy of at least 2 months or more from study initiation, which is consistent with the inclusion criteria of other studies, such as the Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC), which included patients with an expected survival period of at least 2 months or more from study initiation.\\n\\n</STEP-BY-STEP-JUSTIFICATION>\\n<Criteria>\\nLocally advanced, Stage II-IV (except M1), head and neck cancer\\n> = 1 measurable lesion\\nnot been previously treated for head and neck cancer\\nhistory of another malignancy\\norgan allografts\\npre-exiting neuropathy > = CTC grade 2\\n</Criteria>']\n",
      "{'metadata': '{\\n\"NCT_ID\" : \"NCT03147989\",\\n\"Brief_Title\" : \"Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients\",\\n\\n\"Official_title\" : \"A Parallel-Group Comparison of Two Doses Of Multihance (0.10 mmol/Kg and 0.05 mmol/Kg) When Used For Magnetic Resonance Imaging (MRI) of The Central Nervous System (CNS)\",\\n\\n\"Conditions\" : [Central Nervous System Diseases, Central Nervous System Neoplasms],\\n\\n\"Interventions\" : [Drug: MultiHance],\\n\\n\"Location_Countries\" : [United States],\\n\\n\"Study_Design\" : {\\n\"Study_Type\" : \"OBSERVATIONAL\",\\n }\\n}', 'data': 'Study Description \\nBrief Summary \\nThis is a retrospective study to collect already existing data and images from patients â‰¥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05 mmol/kg. The MRI images of all included patients will be prospectively reviewed in a blinded read to compare the efficacy of the two doses.\\n\\nDetailed Description \\nThis study is retrospective in design in that the MR images and other patient data, such as demographic data, will be collected from existing data for the selected patients meeting the inclusion criteria defined in this protocol. The study will be a multicenter study comparing interindividually two groups, one group of patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg and the other group a dose of 0.05 mmol/kg for their clinically indicated MRI examination.\\n\\nIn order to minimize selection bias, recruitment will start with the \"Final Date\" of this protocol and, working backward chronologically from all the MR examinations stored in the local site Picture Archiving and Communication Systems (PACS), every patient meeting the inclusion criteria will be recruited for the study until the total number of patients (160) in each group will be reached.\\n\\nThe images of all included patients will be prospectively reviewed in a blinded read.\\n\\nIntervention \\n- DRUG : MultiHance \\n\\t- gadolinium contrast agent\\n\\t- Gadobenate Dimeglumine', 'criteria': 'Inclusion Criteria:\\n\\n* Was at least 2 years at the time of the MRI with MULTIHANCE injection at the dose of either 0.1 or 0.05 mmol/kg (Â±20% in volume administered).\\n* Has available demographic and safety data.\\n* Belongs to one of these 4 sub-groups:\\n\\n  1. Had a documented known extra-axial lesion of the CNS and previously underwent MRI with a 1.5T magnet requiring an injection of 0.1 mmol/kg MULTIHANCE.\\n  2. Had a documented known extra-axial lesion of the CNS and previously underwent MRI with a 1.5T magnet requiring an injection of 0.05 mmol/kg MULTIHANCE.\\n  3. Had a documented known lesion of the CNS (including extra-axial) and previously underwent MRI with 3T magnet requiring an injection of 0.1 mmol/kg MULTIHANCE.\\n  4. Had a documented known lesion of the CNS (including extra-axial) and previously underwent MRI with 3T magnet requiring an injection of 0.05 mmol/kg MULTIHANCE.\\n* Have both pre- and post-dose T1 SE/FSE, and/or GRE, and T2 SE/FSE, and FLAIR MR Images (when available).\\n* Has one of the two documented doses of MULTIHANCE (either 0.05 or 0.1 mmol/kg) administered for their MRI exam and/or the volume (mL) and weight of the patient available to be used to calculate the exact dose (mmol/kg) of MULTIHANCE that was administered.\\n\\nExclusion Criteria:\\n\\n* Any patient who does not fulfill all of the inclusion criteria;\\n* Any patient who has been previously entered into this study. Patients must be enrolled only once into the study. Working backward chronologically from date of the final Protocol, if a patient has already been enrolled and appears in the PACs System again due to an earlier MRI, this patient must be excluded from the study (i.e., only the first qualifying MRI working backward chronologically from the date of the final Protocol should be included into the study).\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 2 Years\\n\\nAccepts Healthy Volunteers: No\\n', '__index_level_0__': 16089}\n",
      "[{'role': 'system', 'content': 'You are a justifier chatbot designed to generate step-by-step justifications that derived form the Title and Description of a study and then gradually build up to the Desired criteria. Your task is to analyze the title and description of a study and build logical, step-by-step justifications that connect the studyâ€™s key elements to the desired criteria. Reference related example studies if they reinforce your justifications. You must assume the desired criteria are correct (as it was already reviewed by specialists) and develop arguments to support them based on the study context and relevant research insights.'}, {'role': 'user', 'content': '<EXAMPLE_STUDIES><STUDY>\\nExample Title: A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T\\nExample Description: Study Description \\nBrief Summary \\nCompare the efficacy of MultiHance and Magnevist\\n\\nDetailed Description \\nThe purpose of this study was to evaluate whether Multihance is superior to Magnevist in terms of qualitative and quantitative assessment of unenhanced MRI and contrast-enhanced MRI for the visualization of brain disease.\\n\\nIntervention \\n- DRUG : Multihance \\n\\t- 0.5 M at a single injection\\n\\t- gadobenate dimeglumine, - DRUG : Arm 2 - Magnevist \\n\\t- 0.5 M Magnevist at a single dose injection\\n\\t- gadopentetate dimeglumine\\nExample Criteria: Inclusion Criteria:\\n\\n* Was >= 18 years\\n* Provided written informed consent\\n* Scheduled for MRI\\n* Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRI exams within 14 days\\n\\nExclusion Criteria:\\n\\n* Pregnant or lactating females\\n* Allergy to one or more of the ingredients in the products or hypersensitivity to any metals\\n* Congestive heart failure, class IV\\n* Previous stroke in the past year\\n* Received another contrast agent within 24 hours pre and post each exam\\n* Investigational product\\n* Contraindications to MRI\\n* Severe claustrophobia\\n* Surgery with 3 weeks prior\\n* Steroid therapy or radiosurgery between two exams\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: The Safety and Efficacy of ProHanceÂ® at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Younger Than 2 Years of Age\\nExample Description: Study Description \\nBrief Summary \\nSafety and Efficacy Study in pediatric subjects \\\\<2 years of age who have undergone Brain or Spine MRI pre and post 0.1 mmol/kg ProHance administration. Imaging conditions will represent those in routine clinical practice. Retrospective enrolment with a prospective blinded read.\\n\\nDetailed Description \\nThe purpose of this study is to retrospectively enroll children younger than 2 years of age who have undergone brain or spine MRI with 0.1 mmol/kg PROHANCE and to gather safety data as well as to collect MR images for a prospective blinded read to evaluate the efficacy of PROHANCE in terms of visualization and enhancing properties.\\n\\nThe study will be conducted in 4-8 sites in the United States and Europe. It is estimated that 120 patients will be enrolled to provide 108 evaluable patients.\\n\\nThree radiologists unaffiliated with enrolling centers (blinded readers), blinded to the patient\\'s identity and clinical profile will independently evaluate the MRI images. The efficacy analysis will be primarily based on the blinded reader evaluations.\\n\\nImaging conditions will represent those in routine clinical practice, inclusive of pre and post-contrast images.\\n\\nIntervention \\n- DRUG : ProHance \\n\\t- 0.1 mmol/kg ProHance intravenous injection\\n\\t- Gadoteridol\\nExample Criteria: Inclusion Criteria:\\n\\n* Is male or female and was younger than 2 years at the time of the MRI with PROHANCE injection at the dose of 0.1 mmol/kg (Â±25% in volume administered).\\n* Has demographic information, reason for the ProHance-enhanced MR examination, relevant medical history, final diagnosis, and safety data available.\\n* Has documented known or highly suspected enhancing disease of CNS (brain/spine) and previously underwent a cranial or spinal MR examination requiring an injection of PROHANCE contrast agent.\\n* Has both predose and postdose T1 SE/FSE and/or GRE and T2 SE/FSE, and FLAIR MR images (when available) for submission to Bracco or designee to be evaluated in a fully blinded read.\\n* Has complete information on the imaging protocol used for the ProHance-enhanced MR exam including type of exam (brain or spine), MR scanner and field strength (1.0, 1.5 or 3.0 Tesla)\\n* Has a documented dose of PROHANCE administered for their MRI exam and/or the volume (mL) and weight of the patient available to be used to calculate the exact dose of PROHANCE that was administered.\\n\\nExclusion Criteria:\\n\\n\\n* Exclude a patient from this study if the patient does not fulfill all of the inclusion criteria.\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 1 Day\\n- Maximum Age : 2 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor\\nExample Description: Study Description \\nBrief Summary \\nTo verify the number of metastatic brain tumors detected in contrast-enhanced MRI, which is the primary variable, increases after an additional dose of Magnevist (SH L 451A) comparing images after an initial dose (0.1 mmol/kg) with those after an additional dose (0.1 mmol/kg, a total dose of 0.2 mmol/kg) intra-individually in patients with metastatic brain tumors. Safety was also to be assessed.\\n\\nIntervention \\n- DRUG : Magnevist (SH L 451A) \\n\\t- Magnevist at a dose of 0.1 mmol/kg, - DRUG : Magnevist (SH L 451A) \\n\\t- Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.\\nExample Criteria: Inclusion Criteria:\\n\\n* Patients who are confirmed to have 1 <= age <= 5 metastatic brain tumor by the latest contrast-enhanced cerebral CT or contrast-enhanced cerebral MRI, and the lesion(s) have not been treated by surgery or by stereotactic radiosurgery.\\n\\nExclusion Criteria:\\n\\n* Patients who are scheduled to receive another contrast medium for MRI (except for oral agents) or iodine contrast medium (except for oral agents), or to undergo surgical procedures during the period from the day before administration of Magnevist (SH L 451A) to examination of safety on the following day.\\n* Patients who underwent or are scheduled to undergo radiotherapy during the period from 14 days before administration of Magnevist (SH L 451A) to examination of safety on the following day.\\n* Patients who were treated or are scheduled to be treated with anti-cancer agents (except for treatment only by the oral agents of the fixed dose continuously from 28 days or more before administration of Magnevist (SH L 451A)) during the period from 28 days before administration of Magnevist (SH L 451A) to examination of safety on the following day.\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 20 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Intra-individual Cross-over Efficacy Evaluation of DotaremÂ®-Enhanced MRI Compared to GadovistÂ®/ GadavistÂ®-Enhanced MRI in the Diagnosis of Brain Tumors\\nExample Description: Study Description \\nBrief Summary \\nThe purpose of this study is to demonstrate non-inferiority of DotaremÂ®-enhanced MRI as compared to GadovistÂ®/ GadavistÂ®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization (off-site assessment).\\n\\n270 patients will be randomized between 2 arms defining the sequence of administration of the contrast agents at the dose of 0.1mmol/kg, with a minimum of 48 hours and a maximum of 14 days in between.\\n\\nEach patient will, therefore, receive two MRI during his/her participation in the study.\\n\\nThe two arms consist in :\\n\\n* DotaremÂ® in the first MRI, then GadovistÂ®/GadavistÂ® in the second MRI.\\n* GadovistÂ®/GadavistÂ® in the first MRI, then DotaremÂ® in the second MRI.\\n\\nContrast-enhanced MRIs will be performed on 1.5 or 3 Tesla systems.\\n\\nMRI examinations will be evaluated centrally by blinded independent readers for the main evaluation criterion.\\n\\nIntervention \\n- DRUG : DotaremÂ® \\n\\t- DotaremÂ® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus., - DRUG : GadovistÂ®/GadavistÂ® \\n\\t- GadovistÂ®/GadavistÂ®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.\\nExample Criteria: Inclusion Criteria:\\n\\n* Female or male adult patient (patient having reached legal majority age)\\n* Patient with known or highly suspected primary intracranial tumors (intra-axial or extra-axial) detected by previous CT or MRI examination who are scheduled to undergo a routine contrast-enhanced MRI\\n* Female patient must have effective contraception throughout the study and must have a negative urine pregnancy test at inclusion, or be surgically sterilized, or post-menopausal (minimum 12 months of amenorrhea)\\n* Patient having provided his/her written informed consent to participate in the trial prior to any study-related procedure being conducted\\n* Patient with national health insurance (according to local regulatory requirements)\\n\\nExclusion Criteria:\\n\\n* Patient with rapidly evolving brain tumor that could change in appearance between the time of the two study MRI examinations.\\n* Patient undergoing current or recent treatment within past 6 weeks or scheduled for any treatment that could results in changes of lesion appearance between the two study examinations. This would include, but not restricted to, the following: current or recent radiation therapy, surgery, starting or recent chemotherapy.\\n* Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe claustrophobia, infusion pumps, cochlear implants metallic or others according to the imaging site standard practice)\\n* Patient with known severely impaired renal function (defined as eGFR MDRD< 30 ml/min/1.73m2)\\n* Patient with known Class III/IV congestive heart failure according to the New York Heart Association classification\\n* Patient with known severe adverse drug reaction or contraindication to Gadolinium-Based Contrast Agent\\n* Patient having received any contrast agent within 48 hours prior to first study contrast agent injection scheduled for the study and patient expected to receive any other contrast agent within 24 hours of the last study contrast agent injection\\n* Patient presenting with any condition which, based on the investigator\\'s clinical judgment, would prevent the patient from completing all trial assessments and visits\\n* Patient under guardianship and/or unable or unwilling to cooperate with the requirements of this trial\\n* Pregnant or breast feeding female patient\\n* Patient already included in this trial\\n* Patient included in another clinical trial involving an IMP within 30 days before the first investigational contrast agent injection.\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Multi-center, Randomized, Controlled, Single-blind, Intra-individual Comparisons of 2 Dose of Gadobutrol 1.0 Molar and Gadoteridol (ProHance) Crossover Studies With Corresponding Blinded Image Evaluation Following Multiple Injections of 0.1 mmol/kg bw of Gadobutrol and Gadoteridol in Patients With Known or Suspected Brain Metastasis\\nExample Description: Study Description \\nBrief Summary \\nThis study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.\\n\\nIntervention \\n- DRUG : Gadobutrol (Gadavist, Gadovist, BAY86-4875) \\n\\t- Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw), - DRUG : Gadobutrol (Gadavist, Gadovist, BAY86-4875) \\n\\t- Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw), - DRUG : ProHance \\n\\t- ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)\\nExample Criteria: Inclusion Criteria:\\n\\n* Japanese patients at least 20 years\\n* Patients with diagnosed primary cancer\\n* Patients with metastatic lesions by CT/MRI\\n\\nExclusion Criteria:\\n\\n* Patients who have contraindication to the MRI examinations\\n* Patients who have severe renal disorder\\n* Patients in extremely serious general condition\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 20 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY></EXAMPLE_STUDIES>\\n\\nTitle: A Parallel-Group Comparison of Two Doses Of Multihance (0.10 mmol/Kg and 0.05 mmol/Kg) When Used For Magnetic Resonance Imaging (MRI) of The Central Nervous System (CNS)\\nDescription: Study Description \\nBrief Summary \\nThis is a retrospective study to collect already existing data and images from patients â‰¥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05 mmol/kg. The MRI images of all included patients will be prospectively reviewed in a blinded read to compare the efficacy of the two doses.\\n\\nDetailed Description \\nThis study is retrospective in design in that the MR images and other patient data, such as demographic data, will be collected from existing data for the selected patients meeting the inclusion criteria defined in this protocol. The study will be a multicenter study comparing interindividually two groups, one group of patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg and the other group a dose of 0.05 mmol/kg for their clinically indicated MRI examination.\\n\\nIn order to minimize selection bias, recruitment will start with the \"Final Date\" of this protocol and, working backward chronologically from all the MR examinations stored in the local site Picture Archiving and Communication Systems (PACS), every patient meeting the inclusion criteria will be recruited for the study until the total number of patients (160) in each group will be reached.\\n\\nThe images of all included patients will be prospectively reviewed in a blinded read.\\n\\nIntervention \\n- DRUG : MultiHance \\n\\t- gadolinium contrast agent\\n\\t- Gadobenate Dimeglumine\\nDesired criteria: Inclusion Criteria:\\n\\n* Was at least 2 years at the time of the MRI with MULTIHANCE injection at the dose of either 0.1 or 0.05 mmol/kg (Â±20% in volume administered).\\n* Has available demographic and safety data.\\n* Belongs to one of these 4 sub-groups:\\n\\n  1. Had a documented known extra-axial lesion of the CNS and previously underwent MRI with a 1.5T magnet requiring an injection of 0.1 mmol/kg MULTIHANCE.\\n  2. Had a documented known extra-axial lesion of the CNS and previously underwent MRI with a 1.5T magnet requiring an injection of 0.05 mmol/kg MULTIHANCE.\\n  3. Had a documented known lesion of the CNS (including extra-axial) and previously underwent MRI with 3T magnet requiring an injection of 0.1 mmol/kg MULTIHANCE.\\n  4. Had a documented known lesion of the CNS (including extra-axial) and previously underwent MRI with 3T magnet requiring an injection of 0.05 mmol/kg MULTIHANCE.\\n* Have both pre- and post-dose T1 SE/FSE, and/or GRE, and T2 SE/FSE, and FLAIR MR Images (when available).\\n* Has one of the two documented doses of MULTIHANCE (either 0.05 or 0.1 mmol/kg) administered for their MRI exam and/or the volume (mL) and weight of the patient available to be used to calculate the exact dose (mmol/kg) of MULTIHANCE that was administered.\\n\\nExclusion Criteria:\\n\\n* Any patient who does not fulfill all of the inclusion criteria;\\n* Any patient who has been previously entered into this study. Patients must be enrolled only once into the study. Working backward chronologically from date of the final Protocol, if a patient has already been enrolled and appears in the PACs System again due to an earlier MRI, this patient must be excluded from the study (i.e., only the first qualifying MRI working backward chronologically from the date of the final Protocol should be included into the study).\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 2 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\nTask Instructions:\\n1. Derive a step-by-step justification starting from the Title and Description provided, gradually building up to support the Desired criteria.\\n2. Could use example studies (in the <EXAMPLE_STUDIES> section) if they support your justifications, but ensure the reasoning is well-explained and relevant to the study\\'s context.\\n4. Avoid mentioning that the criteria were already provided, and please do not cite the given criteria directly in your justification.\\n5. You should give the justification first before giving out the criteria.\\n\\nResponse Format:\\n<STEP-BY-STEP-JUSTIFICATION>\\nYour step by step justification here.\\n</STEP-BY-STEP-JUSTIFICATION>\\n<Criteria>\\nThe copied desired criteria here.\\n</Criteria>\\n'}]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Processed prompts: 100%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ| 1/1 [00:18<00:00, 18.12s/it, est. speed input: 220.44 toks/s, output: 71.99 toks/s]\n",
      "  0%|          | 3/31840 [00:52<152:33:10, 17.25s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['<STEP-BY-STEP-JUSTIFICATION>\\n\\nStep 1: The study aims to compare the efficacy of two doses of Multihance (0.10 mmol/kg and 0.05 mmol/kg) in Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS). This is evident from the title and description of the study, which highlights the comparison of two doses of Multihance for CNS imaging.\\n\\nStep 2: To evaluate the efficacy of the two doses, the study will collect existing data and images from patients who have undergone MRI for CNS diseases with Multihance administration at either the standard dose of 0.10 mmol/kg or the half dose of 0.05 mmol/kg. This approach is similar to the retrospective design of the study \"The Safety and Efficacy of ProHance at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Younger Than 2 Years of Age\", which also collected existing data for a retrospective analysis.\\n\\nStep 3: The study will include patients who are at least 2 years old at the time of the MRI with Multihance injection, have available demographic and safety data, and belong to one of four sub-groups based on the type of lesion and MRI magnet used. This selection criterion is similar to the inclusion criteria of the study \"A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T\", which also required patients to have a specific type of lesion and MRI magnet.\\n\\nStep 4: The study will also require patients to have both pre- and post-dose T1 SE/FSE, and/or GRE, and T2 SE/FSE, and FLAIR MR Images (when available), which is similar to the imaging conditions in the study \"Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor\".\\n\\nStep 5: To minimize selection bias, the study will start with the \"Final Date\" of the protocol and work backward chronologically from all the MR examinations stored in the local site Picture Archiving and Communication Systems (PACS), which is a similar approach to the study \"A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T\".\\n\\nStep 6: The images of all included patients will be prospectively reviewed in a blinded read, which is similar to the study \"The Safety and Efficacy of ProHance at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Younger Than 2 Years of Age\".\\n\\nStep 7: The study will exclude patients who do not fulfill all the inclusion criteria, which is a common exclusion criterion in many studies, including the study \"Intra-individual Cross-over Efficacy Evaluation of Dotarem-Enhanced MRI Compared to Gadovist/Gadavist-Enhanced MRI in the Diagnosis of Brain Tumors\".\\n\\nStep 8: The study will also exclude patients who have been previously entered into this study, which is a common exclusion criterion to prevent duplicate enrollment.\\n\\nStep 9: The study will be conducted in a multicenter setting, which is similar to the study \"Multi-center, Randomized, Controlled, Single-blind, Intra-individual Comparisons of 2 Dose of Gadobutrol 1.0 Molar and Gadoteridol (ProHance) Crossover Studies With Corresponding Blinded Image Evaluation Following Multiple Injections of 0.1 mmol/kg bw of Gadobutrol and Gadoteridol in Patients With Known or Suspected Brain Metastasis\".\\n\\nStep 10: The study will be conducted in patients who are at least 2 years old, which is similar to the study \"The Safety and Efficacy of ProHance at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Younger Than 2 Years of Age\".\\n\\n<Criteria>\\n* Was at least 2 years at the time of the MRI with MULTIHANCE injection at the dose of either 0.1 or 0.05 mmol/kg (Â±20% in volume administered).\\n* Has available demographic and safety data.\\n* Belongs to one of these 4 sub-groups:\\n  1. Had a documented known extra-axial lesion of the CNS and previously underwent MRI with a 1.5T magnet requiring an injection of 0.1 mmol/kg MULTIHANCE.\\n  2. Had a documented known extra-axial lesion of the CNS and previously underwent MRI with a 1.5T magnet requiring an injection of 0.05 mmol/kg MULTIHANCE.\\n  3. Had a documented known lesion of the CNS (including extra-axial) and previously underwent MRI with 3T magnet requiring an injection of 0.1 mmol/kg MULTIHANCE.\\n  4. Had a documented known lesion of the CNS (including extra-axial) and previously underwent MRI with 3T magnet requiring an injection of 0.05 mmol/kg MULTIHANCE.\\n* Have both pre- and post-dose T1 SE/FSE, and/or GRE, and T2 SE/FSE, and FLAIR MR Images (when available).\\n* Has one of the two documented doses of MULTIHANCE (either 0.05 or 0.1 mmol/kg) administered for their MRI exam and/or the volume (mL) and weight of the patient available to be used to calculate the exact dose (mmol/kg) of MULTIHANCE that was administered.\\n</Criteria>']\n",
      "{'metadata': '{\\n\"NCT_ID\" : \"NCT04618874\",\\n\"Brief_Title\" : \"US NAB With ROSE Versus US FNAB With no ROSE\",\\n\\n\"Official_title\" : \"A RANDOMIZED TRIAL COMPARING PERCUTANEOUS ULTRASOUND-GUIDED NEEDLE ASPIRATION/BIOPSY WITH AND WITHOUT RAPID ON SITE EVALUATION IN PATIENTS WITH SUSPECTED SUPERFICIAL METASTASIS FROM LUNG CANCER\",\\n\\n\"Conditions\" : [Lung Cancer],\\n\\n\"Interventions\" : [Diagnostic Test: Rapid on-site evaluation],\\n\\n\"Location_Countries\" : [Italy],\\n\\n\"Study_Design\" : {\\n\"Study_Type\" : \"INTERVENTIONAL\",\\n\"Phase\" : [NA],\\n\"Primary_Purpose\" : \"DIAGNOSTIC\",\\n\"Allocation\" : \"RANDOMIZED\",\\n\"Interventional Model\" : \"PARALLEL\",\\n\"Masking\" : \"NONE\"\\n }\\n}', 'data': 'Study Description \\nBrief Summary \\nThis is an investigator-initiated, single center, controlled, randomized clinical trial with two parallel arms in a 1:1 ratio. The objective of the study is to systematically assess the influence of rapid on-site evaluation (ROSE) on the diagnostic yield for diagnosis and molecular profiling, as well as on the safety, of pulmonologist-performed ultrasound-assisted needle aspiration biopsy (US-NAB) of superficial lesions across different metastatic sites in a series of consecutive patients with suspect locally advanced or advanced lung cancer.\\n\\nIntervention \\n- DIAGNOSTIC_TEST : Rapid on-site evaluation \\n\\t- Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).', 'criteria': 'Inclusion Criteria:\\n\\n* Known/suspected lung cancer\\n* Presence of a suspected \"superficial\" metastasis at imaging studies (CT and/or PET)\\n* Indication to tissue sampling for diagnosis, staging and/or molecular profiling\\n* >= 18 years\\n* Provision of a written informed consent\\n\\nExclusion Criteria:\\n\\n* Inability or unwillingness to consent\\n* Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma (FFP)\\n* Use of antiplatelet (excluded aspirin) or anticoagulant drugs that cannot be discontinued\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n', '__index_level_0__': 2856}\n",
      "[{'role': 'system', 'content': 'You are a justifier chatbot designed to generate step-by-step justifications that derived form the Title and Description of a study and then gradually build up to the Desired criteria. Your task is to analyze the title and description of a study and build logical, step-by-step justifications that connect the studyâ€™s key elements to the desired criteria. Reference related example studies if they reinforce your justifications. You must assume the desired criteria are correct (as it was already reviewed by specialists) and develop arguments to support them based on the study context and relevant research insights.'}, {'role': 'user', 'content': '<EXAMPLE_STUDIES><STUDY>\\nExample Title: TH-112: Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate\\nExample Description: Study Description \\nBrief Summary \\nNeedle biopsy samples are routinely collected to evaluate cytomorphology, immunohistochemical markers and for mutational analysis. With regular use of immunotheraputic interventions, needle biospy has become more frequent and requires bigger samples for an increasing battery of tests. There has been no clear consensus on which biopsy needle yields the best biopsy sample. It is unclear if large 19g needle offers better yield than a 22 g needle. Although previous studies comparing 21, 22 and 19g needles have suggested that larger needles yield larger biopsy sizes, conflictng studies have shown that larger biopsies lead to bloodier samples with potentially smaller fragments of tissue, offering no improvement in diagnostic, yield, adequacy or sample size.\\n\\nThis study compares biopsy samples collected using 19g and 22g needles from patients of non small cell lung cancer (NSCLC) scheduled to undergo endobronchial ultrasound (EBUS) and transbroncial needle aspiration (TBNA).\\n\\nDetailed Description \\nPrimary Objective To compare the diagnostic yield of 22g and 19g EBUS transbronchial needle aspirate (TBNA)\\n\\nSecondary Objectives\\n\\n1. To compare the sample adequacy of 22g and 19g EBUS TBNA\\n2. To compare the sample quality of 22g and 19 g EBUS TBNA\\n\\nIntervention \\n- PROCEDURE : Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA) \\n\\t- Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles\\nExample Criteria: Inclusion Criteria:\\n\\n* Patients undergoing EBUS TBNA for evaluation of lymphadenopathy, lung nodule or mass\\n* Patients must have atypical lymph nodes. Atypical lymph nodes are characterized by >10mm in short axis or lymph nodes 5 <= age <= 10mm in short axis with atypical features.\\n* Age > 18 years.\\n* Patients must have platelets count > 50,000\\n* Ability to understand and willingness to sign a written informed consent and HIPAA consent document\\n* WOCBP must agree not to get pregnant until the day of the procedure\\n\\nExclusion Criteria:\\n\\n* Patients with uncorrectable coagulopathy will be excluded.\\n* Patients with hemodynamic instability will be excluded\\n* Patients with refractory hypoxemia will be excluded\\n* Patients with therapeutic anticoagulant that cannot be held for 2 days before and 1 day after the procedure.\\n* Patients who are unable to tolerate general anesthesia according to the anesthesiologist\\n* Pregnant or breast feeding.\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Mutational Profile of Patients With and Without Neck and Supraclavicular Lymph Nodes Metastasis From Advanced Non-squamous Non-small-cell Lung \"Cancer\": a Prospective Cohort Study\\nExample Description: Study Description \\nBrief Summary \\nDespite the availability of highly effective endoscopy-based and computed tomography (CT)-based biopsy procedures, up to 50% of patients with advanced lung cancer potentially eligible for targeted therapies or immunotherapy do not have access to a diagnosis or to a thorough molecular profiling for different reasons. Enlarged and/or positron emission tomography (PET) positive cervical/supraclavicular lymph nodes (CSLs) are ideal targets for a minimally invasive diagnosis of lung cancer through a percutaneous ultrasound-guided biopsy (US-NAB). However, the prevalence of metastatic involvement of CSLs in patients with advanced lung cancer was never specifically assessed. Furthermore, the possible association of malignant CSLs involvement with molecular status was never investigated, unlike what was done for several other metastatic sites.\\n\\nIntervention \\n- PROCEDURE : Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes \\n\\t- Patients with evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes suspected of being metastasis from lung cancer will be submitted to the biopsy from this location.\\n\\t- Ultrasound guided biopsy, - PROCEDURE : Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes \\n\\t- Patients without evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes will be submitted to the biopsy considered less invasive and effective based on imaging data and clinical health status.\\n\\t- Ultrasound guided biopsy, Forceps biopsy during bronchoscopy, Surgical biopsy\\nExample Criteria: Inclusion Criteria:\\n\\n* Age >18 years at the time of the procedure;\\n* Suspected advanced, treatment naÃ¯ve non-squamous NSCLC ;\\n* Indication to biopsy for diagnosis and/or molecular profiling;\\n* Written informed consent to the study participation.\\n\\nExclusion Criteria:\\n\\n* Patients with known non-squamous NSCLC sent for re-biopsy after first or second line treatment;\\n* Inability to stop anticoagulant or antiplatelet therapy before the procedure (except acetylsalicylic acid 100 mg/day);\\n* Platelet count <50.000 per Î¼L;\\n* Inability or unwillingness to provide a written informed consent.\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: A Pilot Study Evaluating the Performance of 19-gauge Needles in Testing Molecular Markers in Samples Obtained Via Endobronchial Ultrasound Guided Needle Aspiration of Lymph Nodes in Patients With Lung Cancer\\nExample Description: Study Description \\nBrief Summary \\nThe purpose of this study is to test whether the 19-gauge needle can collect more tissue and get better sampling during a bronchoscopy procedure.\\n\\n\\nExample Criteria: Inclusion Criteria:\\n\\n* Subjects with known or suspected lung cancer with mediastinal adenopathy as defined by a mediastinal lymph node >0.5 cm in short axis on EBUS or any lymph node with uptake on FDG-PET scan that is higher than background PET activity.\\n* Participants must lack bleeding disorders\\n\\nExclusion Criteria:\\n\\n* Subjects who lack fitness for flexible bronchoscopy as determined by the physician performing the bronchoscopy before the procedure\\n* Subjects with suspected sarcoidosis, lymphoma, or metastatic cancer from other sites (i.e. those without a known or suspected lung primary)\\n* Subjects on anticoagulation (other than Aspirin) whom cannot have their anticoagulation held for the procedure due to other clinical reasons (i.e. recent cardiac stent placement).\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: Detection of Heterogeneity in Central Lung Cancer - Prospective Randomized Controlled Trial to Evaluate the Diagnostic Value of EBUS-TBNA and ctDNA Analysis Compared to Endobronchial Forceps Biopsy\\nExample Description: Study Description \\nBrief Summary \\nStudy participants will be selected from clinical routine patients with endobronchial infiltration of a central lung cancer and indication for bronchoscopic sampling.\\n\\nConsented patients will undergo bronchoscopy for tumor sampling applying two routine sampling methods during one single procedure (EBUS-TBNA and conventional forceps sampling). The sequence of both sampling methods will be randomized in advance.\\n\\nThe resulting tissue samples will be analyzed by a pathologist using multiplex PCR and FISH. The corresponding analysis results will be compared between sampling methods.\\n\\nAssignment of a subject to a particular therapeutic strategy is not influenced by this protocol. Medicinal products will be used according to current practice and marketing authorisation.\\n\\nIntervention \\n- PROCEDURE : EBUS-TBNA \\n\\t- Endobronchial ultrasound guided transbronchial needle aspiration, - PROCEDURE : Endobronchial forceps biopsy \\n\\t- Conventional endobronchial forceps biopsy\\nExample Criteria: Inclusion criteria:\\n\\nSubjects eligible for enrolment in the study must meet all of the following criteria:\\n\\n* Informed consent: a signed and dated written informed consent prior to study participation.\\n* Type of subject: inpatient\\n* Age: subjects of more than 18 years and less than 85 years.\\n* Central lesion in computed tomography highly suspicious of lung cancer with clinical indication for further diagnostic applying bronchoscopy.\\n* Central lesion has to be accessible by the biopsy techniques under investigation\\n\\nExclusion criteria:\\n\\nSubjects meeting any of the following criteria must not be enrolled in the study:\\n\\n* Females who are pregnant or lactating , who decide not to undergo a bronchoscopy due to the risk for their child\\n* Any contraindication for bronchoscopy and EBUS-TBNA (IBNLT: INR>2, thrombocytopenia <40/nl)\\n* Drug/alcohol abuse impairing cognitive knowledge which is needed for a GCP conform informed consent.\\n* Inability to read or inability of language: in the opinion of the investigator, any subject who is unable to read and/or would not be able to complete study related materials.\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n- Maximum Age : 84 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY><STUDY>\\nExample Title: EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung \"Cancer\": A Feasibility Study\\nExample Description: Study Description \\nBrief Summary \\nThe incorporation of PD-L1 testing into clinical practice has progressed at a rapid pace, and now offers an additional line of therapy for eligible patients with nonsmall cell lung cancer. The assay used to detect circulating levels of PD-L1 currently requires core biopsies, and is not approved to be used for specimens collected through a needle based cytological technique. Though endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) has markedly improved the manner in which patients are diagnosed and staged for lung cancer, alternative means of tissue collection may be mandatory to offer patients access to newer lines of therapy such as PD-L1 inhibition. EBUS-miniforceps biopsy may allow bronchoscopists to obtain core biopsy specimens through the technique of endobronchial ultrasound, so that more invasive approaches such as surgery may be avoided. Feasibility using this approach would indicate that all patients being staged with endobronchial ultrasound procedures would be candidates for PD-L1 testing and potential therapy.\\n\\nThis study is proposed to evaluate the feasibility of using endobronchial ultrasound guided miniforceps biopsy (EBUS-MFB) to acquire tissue that is adequate for PD-L1 testing. Feasibility in this study is defined as the ability to obtain adequate material during EBUS procedures to perform PD-L1 testing.\\n\\nIntervention \\n- DEVICE : CoreDx Pulmonary Mini-Forceps \\n\\t- Manufactured by Boston Scientific\\n\\t- Endobronchial ultrasound guided mini-forceps\\nExample Criteria: Inclusion Criteria:\\n\\n* Patients with central lung lesion 1cm in size or larger identified on chest CT with the intention to undergo bronchoscopic evaluation and biopsy. The decision to pursue biopsy will be made by the treating physician and agreed upon by the patient.\\n* Are at least 18 years\\n* Are able to provide informed consent\\n* Are not pregnant as confirmed by bHCG testing prior to procedure\\n\\nExclusion Criteria:\\n\\n* Patients who refuse to participate\\n* Are less than 18 years\\n* Are pregnant\\n* Are physically unable to tolerate flexible bronchoscopy or moderate sedation as determined by the bronchoscopist\\n* Are unable to provide informed consent\\n* Are on anticoagulant medications and who cannot safely discontinue their medication prior to their procedure at the recommendation of their treating physician\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\n</STUDY></EXAMPLE_STUDIES>\\n\\nTitle: A RANDOMIZED TRIAL COMPARING PERCUTANEOUS ULTRASOUND-GUIDED NEEDLE ASPIRATION/BIOPSY WITH AND WITHOUT RAPID ON SITE EVALUATION IN PATIENTS WITH SUSPECTED SUPERFICIAL METASTASIS FROM LUNG CANCER\\nDescription: Study Description \\nBrief Summary \\nThis is an investigator-initiated, single center, controlled, randomized clinical trial with two parallel arms in a 1:1 ratio. The objective of the study is to systematically assess the influence of rapid on-site evaluation (ROSE) on the diagnostic yield for diagnosis and molecular profiling, as well as on the safety, of pulmonologist-performed ultrasound-assisted needle aspiration biopsy (US-NAB) of superficial lesions across different metastatic sites in a series of consecutive patients with suspect locally advanced or advanced lung cancer.\\n\\nIntervention \\n- DIAGNOSTIC_TEST : Rapid on-site evaluation \\n\\t- Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).\\nDesired criteria: Inclusion Criteria:\\n\\n* Known/suspected lung cancer\\n* Presence of a suspected \"superficial\" metastasis at imaging studies (CT and/or PET)\\n* Indication to tissue sampling for diagnosis, staging and/or molecular profiling\\n* >= 18 years\\n* Provision of a written informed consent\\n\\nExclusion Criteria:\\n\\n* Inability or unwillingness to consent\\n* Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma (FFP)\\n* Use of antiplatelet (excluded aspirin) or anticoagulant drugs that cannot be discontinued\"Sex\" : ALL\\n\"Ages\" : \\n- Minimum Age : 18 Years\\n\\nAccepts Healthy Volunteers: No\\n\\n\\nTask Instructions:\\n1. Derive a step-by-step justification starting from the Title and Description provided, gradually building up to support the Desired criteria.\\n2. Could use example studies (in the <EXAMPLE_STUDIES> section) if they support your justifications, but ensure the reasoning is well-explained and relevant to the study\\'s context.\\n4. Avoid mentioning that the criteria were already provided, and please do not cite the given criteria directly in your justification.\\n5. You should give the justification first before giving out the criteria.\\n\\nResponse Format:\\n<STEP-BY-STEP-JUSTIFICATION>\\nYour step by step justification here.\\n</STEP-BY-STEP-JUSTIFICATION>\\n<Criteria>\\nThe copied desired criteria here.\\n</Criteria>\\n'}]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 3/31840 [00:56<165:48:43, 18.75s/it]\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[7], line 15\u001b[0m\n\u001b[1;32m     13\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m messages \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m     14\u001b[0m     \u001b[38;5;28;01mcontinue\u001b[39;00m\n\u001b[0;32m---> 15\u001b[0m \u001b[38;5;28mprint\u001b[39m(pipe(messages))\n",
      "Cell \u001b[0;32mIn[3], line 14\u001b[0m, in \u001b[0;36mpipe\u001b[0;34m(messages)\u001b[0m\n\u001b[1;32m     12\u001b[0m sampling_params \u001b[38;5;241m=\u001b[39m SamplingParams(temperature\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m0\u001b[39m, top_p\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m0.9\u001b[39m, max_tokens\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m4096\u001b[39m)\n\u001b[1;32m     13\u001b[0m prompts \u001b[38;5;241m=\u001b[39m tokenizer\u001b[38;5;241m.\u001b[39mapply_chat_template(messages, add_generation_prompt\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mTrue\u001b[39;00m, tokenize\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mFalse\u001b[39;00m)\n\u001b[0;32m---> 14\u001b[0m outputs \u001b[38;5;241m=\u001b[39m llm\u001b[38;5;241m.\u001b[39mgenerate(prompts, sampling_params)\n\u001b[1;32m     15\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m [i\u001b[38;5;241m.\u001b[39moutputs[\u001b[38;5;241m0\u001b[39m]\u001b[38;5;241m.\u001b[39mtext \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;129;01min\u001b[39;00m outputs]\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/utils.py:895\u001b[0m, in \u001b[0;36mdeprecate_kwargs.<locals>.wrapper.<locals>.inner\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    888\u001b[0m             msg \u001b[38;5;241m+\u001b[39m\u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m \u001b[39m\u001b[38;5;132;01m{\u001b[39;00madditional_message\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    890\u001b[0m         warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[1;32m    891\u001b[0m             \u001b[38;5;167;01mDeprecationWarning\u001b[39;00m(msg),\n\u001b[1;32m    892\u001b[0m             stacklevel\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m3\u001b[39m,  \u001b[38;5;66;03m# The inner function takes up one level\u001b[39;00m\n\u001b[1;32m    893\u001b[0m         )\n\u001b[0;32m--> 895\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m fn(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/entrypoints/llm.py:330\u001b[0m, in \u001b[0;36mLLM.generate\u001b[0;34m(self, prompts, sampling_params, prompt_token_ids, use_tqdm, lora_request, prompt_adapter_request, guided_options_request)\u001b[0m\n\u001b[1;32m    321\u001b[0m     sampling_params \u001b[38;5;241m=\u001b[39m SamplingParams()\n\u001b[1;32m    323\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_validate_and_add_requests(\n\u001b[1;32m    324\u001b[0m     inputs\u001b[38;5;241m=\u001b[39minputs,\n\u001b[1;32m    325\u001b[0m     params\u001b[38;5;241m=\u001b[39msampling_params,\n\u001b[1;32m    326\u001b[0m     lora_request\u001b[38;5;241m=\u001b[39mlora_request,\n\u001b[1;32m    327\u001b[0m     prompt_adapter_request\u001b[38;5;241m=\u001b[39mprompt_adapter_request,\n\u001b[1;32m    328\u001b[0m     guided_options\u001b[38;5;241m=\u001b[39mguided_options_request)\n\u001b[0;32m--> 330\u001b[0m outputs \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_run_engine(use_tqdm\u001b[38;5;241m=\u001b[39muse_tqdm)\n\u001b[1;32m    331\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m LLMEngine\u001b[38;5;241m.\u001b[39mvalidate_outputs(outputs, RequestOutput)\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/entrypoints/llm.py:611\u001b[0m, in \u001b[0;36mLLM._run_engine\u001b[0;34m(self, use_tqdm)\u001b[0m\n\u001b[1;32m    609\u001b[0m total_out_toks \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[1;32m    610\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mllm_engine\u001b[38;5;241m.\u001b[39mhas_unfinished_requests():\n\u001b[0;32m--> 611\u001b[0m     step_outputs \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mllm_engine\u001b[38;5;241m.\u001b[39mstep()\n\u001b[1;32m    612\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m output \u001b[38;5;129;01min\u001b[39;00m step_outputs:\n\u001b[1;32m    613\u001b[0m         \u001b[38;5;28;01mif\u001b[39;00m output\u001b[38;5;241m.\u001b[39mfinished:\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/engine/llm_engine.py:919\u001b[0m, in \u001b[0;36mLLMEngine.step\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    909\u001b[0m     finished_requests_ids \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mscheduler[\n\u001b[1;32m    910\u001b[0m         \u001b[38;5;241m0\u001b[39m]\u001b[38;5;241m.\u001b[39mget_and_reset_finished_requests_ids()\n\u001b[1;32m    911\u001b[0m     execute_model_req \u001b[38;5;241m=\u001b[39m ExecuteModelRequest(\n\u001b[1;32m    912\u001b[0m         seq_group_metadata_list\u001b[38;5;241m=\u001b[39mseq_group_metadata_list,\n\u001b[1;32m    913\u001b[0m         blocks_to_swap_in\u001b[38;5;241m=\u001b[39mscheduler_outputs\u001b[38;5;241m.\u001b[39mblocks_to_swap_in,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    917\u001b[0m         running_queue_size\u001b[38;5;241m=\u001b[39mscheduler_outputs\u001b[38;5;241m.\u001b[39mrunning_queue_size,\n\u001b[1;32m    918\u001b[0m         finished_requests_ids\u001b[38;5;241m=\u001b[39mfinished_requests_ids)\n\u001b[0;32m--> 919\u001b[0m     output \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mmodel_executor\u001b[38;5;241m.\u001b[39mexecute_model(\n\u001b[1;32m    920\u001b[0m         execute_model_req\u001b[38;5;241m=\u001b[39mexecute_model_req)\n\u001b[1;32m    921\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    922\u001b[0m     output \u001b[38;5;241m=\u001b[39m []\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/executor/gpu_executor.py:110\u001b[0m, in \u001b[0;36mGPUExecutor.execute_model\u001b[0;34m(self, execute_model_req)\u001b[0m\n\u001b[1;32m    107\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mexecute_model\u001b[39m(\n\u001b[1;32m    108\u001b[0m     \u001b[38;5;28mself\u001b[39m, execute_model_req: ExecuteModelRequest\n\u001b[1;32m    109\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Optional[List[Union[SamplerOutput, PoolerOutput]]]:\n\u001b[0;32m--> 110\u001b[0m     output \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mdriver_worker\u001b[38;5;241m.\u001b[39mexecute_model(execute_model_req)\n\u001b[1;32m    111\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m output\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/worker/worker_base.py:273\u001b[0m, in \u001b[0;36mLocalOrDistributedWorkerBase.execute_model\u001b[0;34m(self, execute_model_req)\u001b[0m\n\u001b[1;32m    268\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m get_pp_group()\u001b[38;5;241m.\u001b[39mis_first_rank:\n\u001b[1;32m    269\u001b[0m     intermediate_tensors \u001b[38;5;241m=\u001b[39m IntermediateTensors(\n\u001b[1;32m    270\u001b[0m         get_pp_group()\u001b[38;5;241m.\u001b[39mrecv_tensor_dict(\n\u001b[1;32m    271\u001b[0m             all_gather_group\u001b[38;5;241m=\u001b[39mget_tp_group()))\n\u001b[0;32m--> 273\u001b[0m output \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mmodel_runner\u001b[38;5;241m.\u001b[39mexecute_model(\n\u001b[1;32m    274\u001b[0m     model_input, \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mkv_cache[worker_input\u001b[38;5;241m.\u001b[39mvirtual_engine]\n\u001b[1;32m    275\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mkv_cache \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;28;01melse\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, intermediate_tensors,\n\u001b[1;32m    276\u001b[0m     num_steps)\n\u001b[1;32m    278\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m get_pp_group()\u001b[38;5;241m.\u001b[39mis_last_rank:\n\u001b[1;32m    279\u001b[0m     \u001b[38;5;66;03m# output is IntermediateTensors\u001b[39;00m\n\u001b[1;32m    280\u001b[0m     get_pp_group()\u001b[38;5;241m.\u001b[39msend_tensor_dict(output\u001b[38;5;241m.\u001b[39mtensors,\n\u001b[1;32m    281\u001b[0m                                     all_gather_group\u001b[38;5;241m=\u001b[39mget_tp_group())\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/torch/utils/_contextlib.py:116\u001b[0m, in \u001b[0;36mcontext_decorator.<locals>.decorate_context\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    113\u001b[0m \u001b[38;5;129m@functools\u001b[39m\u001b[38;5;241m.\u001b[39mwraps(func)\n\u001b[1;32m    114\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mdecorate_context\u001b[39m(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs):\n\u001b[1;32m    115\u001b[0m     \u001b[38;5;28;01mwith\u001b[39;00m ctx_factory():\n\u001b[0;32m--> 116\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/worker/model_runner.py:1384\u001b[0m, in \u001b[0;36mModelRunner.execute_model\u001b[0;34m(self, model_input, kv_caches, intermediate_tensors, num_steps)\u001b[0m\n\u001b[1;32m   1381\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m []\n\u001b[1;32m   1383\u001b[0m \u001b[38;5;66;03m# Sample the next token.\u001b[39;00m\n\u001b[0;32m-> 1384\u001b[0m output: SamplerOutput \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mmodel\u001b[38;5;241m.\u001b[39msample(\n\u001b[1;32m   1385\u001b[0m     logits\u001b[38;5;241m=\u001b[39mlogits,\n\u001b[1;32m   1386\u001b[0m     sampling_metadata\u001b[38;5;241m=\u001b[39mmodel_input\u001b[38;5;241m.\u001b[39msampling_metadata,\n\u001b[1;32m   1387\u001b[0m )\n\u001b[1;32m   1389\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mreturn_hidden_states:\n\u001b[1;32m   1390\u001b[0m     \u001b[38;5;66;03m# we only need to pass hidden states of most recent token\u001b[39;00m\n\u001b[1;32m   1391\u001b[0m     \u001b[38;5;28;01massert\u001b[39;00m model_input\u001b[38;5;241m.\u001b[39msampling_metadata \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/model_executor/models/llama.py:437\u001b[0m, in \u001b[0;36mLlamaForCausalLM.sample\u001b[0;34m(self, logits, sampling_metadata)\u001b[0m\n\u001b[1;32m    432\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21msample\u001b[39m(\n\u001b[1;32m    433\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m    434\u001b[0m     logits: torch\u001b[38;5;241m.\u001b[39mTensor,\n\u001b[1;32m    435\u001b[0m     sampling_metadata: SamplingMetadata,\n\u001b[1;32m    436\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Optional[SamplerOutput]:\n\u001b[0;32m--> 437\u001b[0m     next_tokens \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39msampler(logits, sampling_metadata)\n\u001b[1;32m    438\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m next_tokens\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/torch/nn/modules/module.py:1553\u001b[0m, in \u001b[0;36mModule._wrapped_call_impl\u001b[0;34m(self, *args, **kwargs)\u001b[0m\n\u001b[1;32m   1551\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_compiled_call_impl(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)  \u001b[38;5;66;03m# type: ignore[misc]\u001b[39;00m\n\u001b[1;32m   1552\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m-> 1553\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_call_impl(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/torch/nn/modules/module.py:1562\u001b[0m, in \u001b[0;36mModule._call_impl\u001b[0;34m(self, *args, **kwargs)\u001b[0m\n\u001b[1;32m   1557\u001b[0m \u001b[38;5;66;03m# If we don't have any hooks, we want to skip the rest of the logic in\u001b[39;00m\n\u001b[1;32m   1558\u001b[0m \u001b[38;5;66;03m# this function, and just call forward.\u001b[39;00m\n\u001b[1;32m   1559\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m (\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_backward_hooks \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_backward_pre_hooks \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_forward_hooks \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_forward_pre_hooks\n\u001b[1;32m   1560\u001b[0m         \u001b[38;5;129;01mor\u001b[39;00m _global_backward_pre_hooks \u001b[38;5;129;01mor\u001b[39;00m _global_backward_hooks\n\u001b[1;32m   1561\u001b[0m         \u001b[38;5;129;01mor\u001b[39;00m _global_forward_hooks \u001b[38;5;129;01mor\u001b[39;00m _global_forward_pre_hooks):\n\u001b[0;32m-> 1562\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m forward_call(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[1;32m   1564\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m   1565\u001b[0m     result \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/model_executor/layers/sampler.py:138\u001b[0m, in \u001b[0;36mSampler.forward\u001b[0;34m(self, logits, sampling_metadata)\u001b[0m\n\u001b[1;32m    135\u001b[0m logprobs \u001b[38;5;241m=\u001b[39m torch\u001b[38;5;241m.\u001b[39mlog_softmax(logits, dim\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m-\u001b[39m\u001b[38;5;241m1\u001b[39m, dtype\u001b[38;5;241m=\u001b[39mtorch\u001b[38;5;241m.\u001b[39mfloat)\n\u001b[1;32m    137\u001b[0m \u001b[38;5;66;03m# Sample the next tokens.\u001b[39;00m\n\u001b[0;32m--> 138\u001b[0m sample_results, maybe_sampled_tokens_tensor \u001b[38;5;241m=\u001b[39m _sample(\n\u001b[1;32m    139\u001b[0m     probs,\n\u001b[1;32m    140\u001b[0m     logprobs,\n\u001b[1;32m    141\u001b[0m     sampling_metadata,\n\u001b[1;32m    142\u001b[0m     sampling_tensors,\n\u001b[1;32m    143\u001b[0m     include_gpu_probs_tensor\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39minclude_gpu_probs_tensor,\n\u001b[1;32m    144\u001b[0m     modify_greedy_probs\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_should_modify_greedy_probs_inplace,\n\u001b[1;32m    145\u001b[0m )\n\u001b[1;32m    147\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39minclude_gpu_probs_tensor:\n\u001b[1;32m    148\u001b[0m     \u001b[38;5;28;01massert\u001b[39;00m maybe_sampled_tokens_tensor \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/model_executor/layers/sampler.py:711\u001b[0m, in \u001b[0;36m_sample\u001b[0;34m(probs, logprobs, sampling_metadata, sampling_tensors, include_gpu_probs_tensor, modify_greedy_probs)\u001b[0m\n\u001b[1;32m    694\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_sample\u001b[39m(\n\u001b[1;32m    695\u001b[0m     probs: torch\u001b[38;5;241m.\u001b[39mTensor, logprobs: torch\u001b[38;5;241m.\u001b[39mTensor,\n\u001b[1;32m    696\u001b[0m     sampling_metadata: SamplingMetadata, sampling_tensors: SamplingTensors,\n\u001b[1;32m    697\u001b[0m     include_gpu_probs_tensor: \u001b[38;5;28mbool\u001b[39m, modify_greedy_probs: \u001b[38;5;28mbool\u001b[39m\n\u001b[1;32m    698\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Tuple[SampleResultType, Optional[torch\u001b[38;5;241m.\u001b[39mTensor]]:\n\u001b[1;32m    699\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m    700\u001b[0m \u001b[38;5;124;03m    Args:\u001b[39;00m\n\u001b[1;32m    701\u001b[0m \u001b[38;5;124;03m        probs: (num_query_tokens_in_batch, num_vocab)\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    709\u001b[0m \u001b[38;5;124;03m        sampled_token_ids_tensor: A tensor of sampled token ids.\u001b[39;00m\n\u001b[1;32m    710\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[0;32m--> 711\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m _sample_with_torch(\n\u001b[1;32m    712\u001b[0m         probs,\n\u001b[1;32m    713\u001b[0m         logprobs,\n\u001b[1;32m    714\u001b[0m         sampling_metadata,\n\u001b[1;32m    715\u001b[0m         include_gpu_probs_tensor\u001b[38;5;241m=\u001b[39minclude_gpu_probs_tensor,\n\u001b[1;32m    716\u001b[0m         modify_greedy_probs\u001b[38;5;241m=\u001b[39mmodify_greedy_probs,\n\u001b[1;32m    717\u001b[0m     )\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/model_executor/layers/sampler.py:592\u001b[0m, in \u001b[0;36m_sample_with_torch\u001b[0;34m(probs, logprobs, sampling_metadata, include_gpu_probs_tensor, modify_greedy_probs)\u001b[0m\n\u001b[1;32m    590\u001b[0m (seq_group_id, seq_groups) \u001b[38;5;241m=\u001b[39m sample_metadata[sampling_type]\n\u001b[1;32m    591\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m sampling_type \u001b[38;5;241m==\u001b[39m SamplingType\u001b[38;5;241m.\u001b[39mGREEDY:\n\u001b[0;32m--> 592\u001b[0m     sample_results \u001b[38;5;241m=\u001b[39m _greedy_sample(seq_groups, greedy_samples)\n\u001b[1;32m    593\u001b[0m \u001b[38;5;28;01melif\u001b[39;00m sampling_type \u001b[38;5;129;01min\u001b[39;00m (SamplingType\u001b[38;5;241m.\u001b[39mRANDOM,\n\u001b[1;32m    594\u001b[0m                        SamplingType\u001b[38;5;241m.\u001b[39mRANDOM_SEED):\n\u001b[1;32m    595\u001b[0m     sample_results \u001b[38;5;241m=\u001b[39m _random_sample(\n\u001b[1;32m    596\u001b[0m         seq_groups, multinomial_samples[sampling_type])\n",
      "File \u001b[0;32m~/miniconda3/envs/ML/lib/python3.11/site-packages/vllm/model_executor/layers/sampler.py:336\u001b[0m, in \u001b[0;36m_greedy_sample\u001b[0;34m(selected_seq_groups, samples)\u001b[0m\n\u001b[1;32m    320\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_greedy_sample\u001b[39m(\n\u001b[1;32m    321\u001b[0m     selected_seq_groups: List[SequenceGroupToSample],\n\u001b[1;32m    322\u001b[0m     samples: torch\u001b[38;5;241m.\u001b[39mTensor,\n\u001b[1;32m    323\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m SampleResultType:\n\u001b[1;32m    324\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"Run greedy sampling on a given samples.\u001b[39;00m\n\u001b[1;32m    325\u001b[0m \n\u001b[1;32m    326\u001b[0m \u001b[38;5;124;03m    Args:\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    334\u001b[0m \u001b[38;5;124;03m        seq_group has do_sample=False, tuple contains ([], [])\u001b[39;00m\n\u001b[1;32m    335\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[0;32m--> 336\u001b[0m     samples_lst \u001b[38;5;241m=\u001b[39m samples\u001b[38;5;241m.\u001b[39mtolist()\n\u001b[1;32m    337\u001b[0m     sample_idx \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[1;32m    338\u001b[0m     results: SampleResultType \u001b[38;5;241m=\u001b[39m []\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from datasets import load_dataset\n",
    "from tqdm import tqdm\n",
    "# Load the JSON data\n",
    "\n",
    "ravis_dataset = load_dataset(\"ravistech/clinical-trial-llm-cancer-restructure\")\n",
    "\n",
    "## use the function to get the CoT for the first 10 studies\n",
    "for i in tqdm(ravis_dataset['train']):\n",
    "    print(i)\n",
    "    messages = get_prompt_from_studies(i)\n",
    "    print(messages)\n",
    "    print(pipe(messages))\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "ML",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
